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Chapter 1 
Background 
Cachexia is a frequent problem in cancer patients which is characterized by weight 
loss, impaired perfonnance and futigue.75,127 In general, administration of nutritional 
support does not improve tlle condition 155 nor is any other adequate treatment 
available. 127 The mechanisms wxlerlying cancer cachexia are poorly llliderstood.79 
Factors that may playa role in the etiology of weight loss include increased lipolysis from 
adipose tissue,212,213 and increased proteolysis in muscle. 130 The potential role of elevated 
lipolysis in the occurrence of weight loss in cancer is supported by the recent isolation of a 
lipid-mobilizing fuctor (LMF) from urine of weight-losing cancer patients,97,219 and by 
the observation of increased whole-body lipolysis observed in cancer patients. 124, 192 
Animal studies have shown that weight loss in twnor-bearing mice was effectively 
attenuated by n-3 fatty acids derived from fish oil,214 of which eicosapentaenoic acid 
(EPA; 20:5n-3) proved to be the active component.213 Since EPA was found to inhibit 
lipolysis and proteolysis in vifro,21,212,213 inhibition of lipolysis andlor proteolysis were 
assmne<t to play a role in dlese beneficial effects in vivo. Furdlennore, EPA inhibited 
nunor groWdl in dlese anituals.21 ,213 Recen! lmcontrolled clinical studies suggest tlrat EPA 
supplementation tuay reverse weight loss in patients with pancreatic cancer as well. 17,230 
It is, however, not yet known whetller inhibition of lipolysis andlor proteolysis plays a role 
in the effects of EPA in cancer. In the present dlesis, the results of several studies on the 
effects of EPA on lipid metabolism in cancer patients and heaWlY subjects will be 
presented. 
In this introductory clrapter, background infonuation is provided. In dIe first part of 
this chapler, Ule nomenclature of lipidS is explained, and the types of lipids, the process of 
intestinal absorption of fat, dIe tramport of lipids dlroUghout the body, and mechanisms 
regulating lipolysis are reviewed. In the second part, literature findings regarding u-3 futty 
acids in epidemiological studies are briefly reviewed, metabolic padlways of 11-3 and n-6 
fatty acids are explained, and dIe effects of n-3 futty acids on lipid metabolism and the 
inf1annnatory response are reviewed. In dIe third and last part of this chapter, different 
aspects of cancer cachexia are discussed such as changes in body composition, wKlerlying 
mechanisms of weight loss widl special reference to metabolic abnonnalities, and potential 
treatments of cancer cachexia. Finally, the aims of the cutTent studies and the outline of 
dlis dlesis are presented. 
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Lipid metabolism in healthy subjects 
Lipids139 
Although lipids fitlfill multiple fiUlctiollS in Ule body, two main fimctions can be 
recognized. At first, lipids are an important component of cellular membranes, which are 
layers Widl highly selective pelmeability that regwate the passage of materials into and out 
of Ule cell. The second impOliant fimction is the storage of body lipids in adipose tissue, as 
an energy somce via oxidation pathways. Lipids exist in many different fonns, and are 
characterized by their a-polar character. A subgroup of tllis large group of cOlllpOmlds is 
fonned by lipids containing fatty acids, often in combination Widl one or two oUler 
molecules such as glycerol or cholesterol. Fatty acids consist of a polar, hydropllilic acid 
group and a hydrophobic tail which may be saturated, or unsaturated with double bonels. 
The specific characteristics of fatty acids are detenniued by the length of Ule carbon chain, 
the mnnber of double bonds, and Ule location of the first double bonel within Ule chain. 
The nomenciatlU'e of fatty aciels is based on these characteristics: dIe number before the 
colon indicates Ule total nmnber of carbon atolllS, whereas Ule munber after the colon 
represents the mnnber of double bonds. The munber behind the 'n' indicates the position 
of Ule first double bond seen from Ule methyl end of the chain. According to this notation, 
palnlitic acid is indicated as 16:0, Witll 16 carbon atoms and no double bonds. 
Eicosapentaenoic acid (EPA) is indicated as 20:5n-3 due to Ule 20 carbon atoms, 5 double 
bonds, and Ule first double bond starting at carbon 3 fi'om the methyl end of dIe chain 
(Figme 1.1). AnoUler meUlOd to indicate tlle location of the double bond, is tlle so-called 
'L'<.'-notation. In this notation, tlle location is determined fi'om Ule carboxyl-end instead of 
the meUIYI end of the chain. 
Besides the saturated fatty acids which are mainly present in mammals, three main 
families of lmsaturated fatty acids exist: the n-9 fatty acids wllich are fulUld in maunnals as 
o 
" HO -c ~CHJ Palmitic acid (16:0) 
o 
" HO -C ~CHJ Oleic acid (1B:1n-9) 
o 
" HO - C~CH3 Eicosapentaenoic acid (20:5n-3) 
Figure 1.1 
Molecular structure ofpalOlitic acid (16:0), oleic acid (l8:tn-9) and eicosapentacnoic acid (20:5n-3). 
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well as in plants, the n-6 fatty acids which are mainly fmUld in vegetables and plants, and 
tIle n-3 fatty acids which are mainly fmUld in marine oils derived from fatty fish and algae. 
During life, fatty acids can be obtained from the diet, or they can be synthesized 
within the body. Since human enzyme systems are not able to introduce new double bonds 
beyond 119, fatty acids from tIle n-9, n-6 and n-3 tiunilies are not metabolically 
interconvertible in manunals. Consequently, tIle futty acids 18:2n·6 (linoleic acid) and 
18:3n-3 (a-linolenic acid) are called essential fatty acids and must therefore be provided by 
the diet. Within tIle body, elongation and desattu'ation of fatty acids takes place to form 
various long-chain polytulsaturated latty acids for specific ftUlCtiOn.~. 
Dijferellf types of Iipids139,187 
WitIrin the htunan body, different types of lipids have distinct physiological 
ftUlCtiOns (Figure 1.2). Triacylglycerols (TAG) consist of tIuee fatty acids esterified to a 
glycerol backbone and are lnainly used lor fat storage within tIle adipose tissue. After 
hydrolization of TAG, free futty acids (FFA) are released into the circulation which can 
serve as an energy Ollbstrate for most cells. Phospholipids (PL), which are also called 
glycerophospholipids, consist of a glycerol backbone containing two fatty acids and one 
phosphoric acid group linked to a polar 1Il0lecule. PL are, together WitIl cholesterol, the 
major lipid components of cell membranes. Cholestelyl esters (CE) are fdtty acids 
esterified to cholesterol. CE are lnainly IOtuld in lipoproteins in blood which provide for 
tIle transport of cholesterol tIlroughout the hody. Whether futty acids are incorporated into 
TAG, PL or CE, depends on local lipid concentrations and enzyme activities, but also on 
chain length and degree of saturation. Cellular membranes are lnainly composed of long-
chain polynusaturated latty acids to elmlre membmne fluidity, whereas fut stored in 
adipose tissue contains relatively high proportions of sanuated latty acids. A type of fatty 
acid esterification tImt does not naturally occm but which is used in oral supplements to 
supply specific fatty acids in relatively lrigher doses, are the etIlYI esters (EE). These 
syntIletic preparations exist of fatty acids esterified to an etIlyl group. Some advantages of 
BE over naturally occurring TAG urixtmes are tImt specific fatty acids can be administered 
in high concentrations witIlCut interrerence WitIl otIler components or fatty acids, and that 
the amOtult of oil to be taken can be reduced. 
llllestilla/lipid abSOIpfioll2, 187 
After ingestion of dietary fut, large lipid droplets witIlin the intestine are emulsified 
by bile salts, which results in lipid droplets of about 1 lun in diameter. Lipids on tIle 
surface of these micelles are hydrolyzed by pancreatic lipase, resulting in free futty acids, 
2-monoacylglycerides, and glycerol. CE are broken down by pancreatic hydrolase into free 
cholesterol and futty acids. After fonnation of so-called mixed uricelles (strucnues of 50 to 
13 
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100 1l1ll in diameter), the !i-ee futty acids, glycerol and 2-monoacylglyceddes diffuse 
through tile cell membranes into tile epidlelial cells. Witllin tile epithelial cells, TAG, CE 
and PL are resynthesized and incOlporated into droplets called chylomicrons. The core of 
tllese chylomicrons consists of TAG, CE and cholesterol, whereas PL and apolipoproteins 
are fotUld on the outside. Chylomicrons are released from tile cell into tile extracellular 
fluid, and are subsequently transported to tile systemic venous circulation via tile lymph 
vessels and tile main Iympbatic duct. Short-chain latty acids are not reesterified witllin tile 
enterocyte, but are eitller transported via the portal vein to he reesterified into TAG witllin 
the liver, or directly oxidized. A siniliar pathway is observed for futty acids derived from 
EE, which are also directly transported to tile liver as albmnin-hotllld free acids instead of 
being reesterified within tile cell. As a consequence, only a minor part of the fatty acids 
derived !i'mn EE is incolporated into chylomicrons. In contrast Witll fatty acids supplied as 
TAG, cbain length does not appear to atrect tile route of absorption for futty acids from 
EE. 
Transpon of lipids l87 
TAG-wntaining chylomicrons within the circulation are taken up by tile liver. After 
metabolizatioll amI reesterification, TAG constitute the basic components of vely-Iow-
density lipoproteins (VLDL) together Witll TAG formed fi'om free acids. VLDL is released 
into tile circulation to deliver TAG to tile peripheral tissues. At the surfuce of peripheral 
endothelial cells, VLDL-TAG are hydrolyzed by lipoprotein lipase into glycerol and free 
fatty acids which are taken up by tbe cells. After fatty acid uptake by adipocytes, 
reesterification of fatty acids to TAG takes place. Also other lipoproteins such as low-
density lipoprotein (LDL) and high-density lipoprotein (HDL) play an important role in the 
transport of cholesterol and TAG throughout the bndy. 
Regulation of /ipo(ysis 
Lipids and carbohydrates are tile main substrates for energy prnduction. In tile 
postprandial state, glucose is the most impoliant energy substrate fur most organs. In the 
post-absorptive state, however, energy prnduction from glucose is gradually shifted 
towards processes tbat use fatty acids as substrate lor oxidation. In order to provide tllis 
substrate, lipolysis -the processes in which TAG are hydrolyzed to futty acids and glycerol-
increases, and !i'ee futty acids are released from adipose tissue into the circulation. In this 
condition, lipolysis is mainly mediated by adipose tissue honnone-sensitive lipase (HSL) 
(Figure 1.3). HSL is activated by hormones such as glucagon, epinephrine, growth 
hormone, adrenocorticotropic honnone (ACTH), Utyroid hormone and cortisol, whereas 
iusulin is tile most important irUlibitOlY honllone. However, lipolysis does not only take 
place witllin adipose tissue, but also in the liver and on the surface of peripheral 
14 
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endothelial cells. During tile post-absorptive state, these lipases (i.e. lipoprotein lipase and 
hepatic lipase) play only a relatively minor role in whole-body lipolysis. Within this tilesis, 
tile tenn 'whole-body lipolysis' will rerer to the total release of glycerol into the plasma 
compartment as a result of all lipolytic processes within tile body. The tenn 'pahnitic acid 
release' will refer only to tilDse lipolytic processes where fatty acids are released into tile 
circulation, i.e. HSL-mediated lipolysis wiUlin tile adipose tissue. 
~ 
Adipose 
tissue 
VLDL 
Figure 1.3 
To muscle, liver, etc. To liver 
IDL i i 
Fatty acids Glycerol 
Fatty acids Glycerol 
J 
Acyl-GoA 
Triacylglycerols 
Glycerol-P 
After a meal, triacylglycerols from very-low density lipoprotein (VLDL) arc hydrolyzed by lipoprotein 
lipase (LPL), and VLDL is converted into intermediate density lipoprotein (IDL). Fatty acids diffuse into 
the adipose tissue, and are stored as triacylglyccrols aller reestcrification. During the poslabsorptive state, 
triacylglycerols are degraded into glyc(Jrol and fatty acids by homlone-sensilive lipase (I-ISL). Glycerol 
diffuses out of the cell and is taken up by the liver. Fatty acids also diffuse into the blood to be oxidized, 
stored or metabolized in muscle, liver or other tissues, or fatty acids are rccsterified within the tissue. 
After fatty acids have heen taken up by peripheral tissues such as muscle, oxidation 
via mitochondrial fl-oxidation takes place. In each cycle of fl-oxidation, a futty acid is 
shortened by two carbolLl, yielding reduction equivalents lor adenosine triphosphate (ATP) 
production via tile respiratOlY chain. Besides p-oxidation, latty acids can also he degraded 
by peroxisomal oxidation. This patllway can handle velY long chain futty acids (2:20 
carbons) which are poor substrates for mitochondrial fl-oxidation. In contrast with tile 
mitochondrial fl-oxidation, tile peroxisomal oxidation does not generate ATP since it is not 
coupled to the respiratory chain. The process of fatty acid oxidation is not directly 
regulated but is proportional to FFA concentrations in plasma and in tile specific organ or 
cell. This implicates tllat futty acid oxidation is mainly regulated at the level of adipose 
tissue HSL which provides the substrate for Ihis this process. 
15 
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n-3 Fatty acid metabolism 
11-3 Fatty acids ill epidemiological studies 
In the 1970s, it was reported that Eskimos had low rates of coronary heart disease 
(CHD) and cancer despite Uleir high-Iitt diet. 11, 12,55 EPA appeared to playa role in dlese 
effects, since EPA was fmOld to have anti-thrombotic effects by reducing platelet 
aggregation. 56 In 1985, Ule 20-year follow-up study from the Dutch town of Zutphen 
renewed tlle interest in dIe 'fish oil hypotllesis' by reporting that mortality from CHD was 
reduced by more dum 50% in those subjects who had eaten tlle equivalent of 30g of fish 
per day.121 In the following years, some sUKlies confirmed Ule potentially beneficial 
effects of the conslllnption of fatty fish31,199 or a Mediterranean alpha-linolenic acid-rich 
diet46 on CHD, but other studies did not detect any significant efrects of fish conslllnption 
on coronary heart disease8 or of fish oil supplementation on coronary atherosclerosis. 184 
AWlOUgh it is now generally accepted Umt n-3 fatty acids have beneficial effects in 
preventing CHD, tlle potential benefit of n-3 fatty acids in other diseases such as cancer, 
chronic inflauumtory diseases and diabetes is c\lfrently !Older investigation. 
Effects ofll-3 fally acids Oil lipid metabolism 
Epidemiological studies have suggested tlmt cardiovascular disease lO,78,111,149,202 
and non-insulin-dependent diabetes mellitus (NIDDM)67,165 are associated with elevated 
levels of TAG and/or FPA in blood. lInmy tllerefore be beneficial to reduce plasma lipid 
concentrations in subjects at risk.4 Supplementation of EPA and/or docosallexaenoic acid 
(DRA; 22:6n-3) was shown to reduce postabsorptive71 ,81, 109, 175 as well as postpran-
dial226 serum TAG concentrations and FFA45 levels, but the effects of n-3 Iittty acids on 
senIm cholesterol concentrations are inconsistent.27,71,94,99,224 Despite extensive 
research, there is still much uncertainty about tlle mechanism by which n-3 fatty acids 
reduce plasma lipid concentrations. The decrease in senun TAG concentrations appears to 
be caused by a reduction in hepatic TAG synthesis. 88,183 This reduction lmy in part be 
related to low substrate availability due to decreased plasma FFA concentra-
tions45,89,109,182,198 as a consequence of eitller reduced peripheral lipolysis,213 or 
enhanced FA oxidation. 1,70,231 
Studies have shown tllat stimulation of lipolysis by a tumor-derived lipid'mobilizing 
factor (LMF) ill vitro is effectively aUenuated by EPA. 170,212,213 Hormonal stimulation of 
adenylate cyclase, and thus the formation of cyclic AMP, is also inhibited by EPA,I10,211 
This effect appears to be mediated by an inhibitory effect of a gllalline nucleotide-
regulatory protein. 170,211 This effect of EPA on lipid metabolism is aSS\1flled to playa role 
in the potentially beneficial efrects of EPA in cachectic cancer patients.230 
16 
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Metabolism ofll-3 alld n-6fatty acids139,197 
As already mentioned, the futty acids of the n-6 and the n-3 series are essential fatty 
acids, since tiley are necessary for proper physiological fImctioning and cannot be 
synthesized witllin the hwnan hody. After 18:2n-6 (linoleic acid) and 18:3n-3 (a-linolenic 
acid) have been absorbed frollI tile diet, they are elongated to fatty acids witll 20 and 22 
carbon atollIS. In this pathway, n-O and n-3 fatty acids compete, since they are desaturated 
and elongated by tlle same enzymes (Figure 1.4). AltllOUgh botll M- and i16-desaturases 
prerer n-3 fatty acids over n-6 fatty acids,197 20:4n-6 is the 1Ilajor long-chain 
polyunsaturated fatty acid withln the hody since the intake of n-6 fatty acids is usually 
substantially bigber tlIan tilal of n-3 futty acids. However, when the intake of n-3 futty 
acids increases, tile contribution of 20:5n-3 and 22:6n-3 will increase at the expense of 
20:4n-6.227 S1Ilall amounts of n-3 futty acids in the diet may tllerefiJre substantially aftect 
metabolic pathways witllin the Inunan hody. 
n-6 series n-3 series 
18:20·6 18:30·3 
'" 
116-Desaturase 
'" 18:30·6 18:40-3 
'" 
li{ollgase 
'" 20:30-6 20:40-3 
'" 
M-Desaturase 
'" 20:40-6 20:50-3 
'" 
Efollgase 
'" 22:40-6 22:50-3 
'" 
114-lJesalurase 
'" 22:50-6 22:60-3 
Figure 1.4 
Essential fatty acid metabolism: elongation and desaturation of n-6 and n-3 fatty acids. 
Effects of 11-3 fatty acids Oil tlie illjlaIl1I11QtOl)' respollse 
Competition between n-6 and n-3 futty acids also appears to play a role in the 
regulation of tlle pathways of eicosanoid synthesis.227 Eicosanoids are important 
compounds in tile regnlation of tile inllanunatOlY respollSe and blood clotting. 32 They are 
synthesized from C20 polYllllsaturated futty acids (Figure 1.5) and can be divided iuto Un-ee 
groups: prostaglandins (pGs), thromboxanes (TXs) and leukotrienes (LTs). FGs and TXs 
are products from the cyclooxygenase pathway and contain a cyclopentane ring or a six-
membered oxygen-contaiIling ring, respectively. LTs are produced via the Iipoxygenase 
pathway. 
17 
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The major biologically active members of dIe eicosanoid fumily are dIOse derived 
from arachidonic acid (AA; 20:4n-6), i.e. the PGs and TXs of !he 2-series (i.e. PGE, and 
TXA,) and dIe LTs of the 4-series (LTB.). These compOllllds stimulate dIe inflanllllatory 
response as well as platelet aggregation.32 hI contrast, eicosanoids derived from EPA, i.e. 
!he PGs and TXs of the 3-series (i.e. PGE3 and TXA3) and dIe LTs of !he 5-series (LTBs), 
are biologically less active !han !he eicosanoids derived from AA, with anti-aggregating 
and lllllllUllosuppressive etrects as a result. 52 Most lunnan studies regarding dIe etrects of 
n-3 fatty acids on cytokine production showed a decrease in dIe production of one or more 
proinfIamlUatory cytokines such as interleukin-l, interleukin-6 and tumor necrosis factor-
a.26,44,60,147,148 The inhibitory effects of EPA on !he inflammatOlY response may play an 
inlportant role in the potentially beneficial effects of EPA in inflannnatory bowel 
disease,9,24 rheumatoid arthritis, 119, 191 psoriasis80,140 and cancer cachexia.230 
COOH 
20:4n-6 CX:X:X;CH
J 
[
20:5n-3 ;=v=vvCOOHJ ~CHJ 
Iljl~\\ 
r.l'1-~COOH 
\i~CHJ 
OH 
Thromboxane A, 
Figure 1.5 
/COOH 
~CHJ 
OH 
Prostacyclin (PGI,) 
OH OH 
~COOH 
Leuko~iene (LTB.,) 
Examples of molecular structures of thromboxanes, prostaglandins and leukotrienes synthesized from 
arachidonic acid (AA; 20:4n~6) or eicosapentaenoic acid (EPA; 20:5n-3). 
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Cancer cachexia: etiology and potential treatment 
Many patients WiOl cancer suffer hom invohUltalY weight loss which is called 
cancer cachexia. The tenn 'cachexia' is derived from the Greek words 'KaKos' meaning 
'bad', and "llStS' meaning 'condition'. The occurrence of weight loss is related to the type 
of tlllnor alld fallges from 30% in patients with fuvorable non-Hodgkin's lymphoma to 
nearly 90 % in patients widl gastric Callcer. 50 Patients widl cachexia have a decreased 
survival time50,164 and an impaired respolLle to chemodlerapy,49,50 and they suffer from 
futigue75 and a reduced quality-of-life. 162 Weight loss in cancer can parUy be explained by 
reduced food intake due to fuctors such as abdominal nUlness, taste change, constipation, 
moudl dlyness, nausea and vomiting,83 or by impaired food uptake due to intestinal 
malabsorption. 146, 168,225 However, weight loss in Callcer patients differs from that during 
sinlple starvation. During starvation, fut hOUl adipose tissue is usually used as dIe lnain 
fuel whereas muscle mass is conserved. In contrast, in cancer cachexia, substantial loss of 
muscle lnass is observed in addition to loss of fut mass.65,96 These changes in body 
composition suggest dlat factors odler dian reduced food intake playa role in the loss of 
body mass in cancer. This assumption is supported by die obselvation dlat increased 
energy intake in cancer patients does not reverse the cachexia syndrome. 38,161 Nutritional 
support increased only body fut but not total body nitrogen,40,193 and total parenteral 
nutrition did not stimulate overall protein syndlesis in lnahlourished cancer patients. 104 
Metabolic alteratiol/s 
Although dIe mecllanisms llllderlying cachexia have not been fully clarified, 
metabolic alterariOlLl appear to play an important role in dIe OCClU'rence of weight loss in 
cancer. Tn healthy subjects, reduced food intake usually reslUts in reduced resting energy 
expenditure (REE) whereas in many cancer patients, REB is increased despite nonnal or 
even reduced energy intake.5,103,204 This is illustrated by REE data of a patient with 
progressive pancreatic cancer hom our study during long-tenn follow-up, showing that an 
increase in REB preceded the decrease in body weight (Figure 1.6). Tn general, tmnor type 
appears to play an important role in detennining whedler REE is elevated or no!. In Imlg 
cancer69,204 as well as in pancreatic CallCer,62 REE was higher than in healtlly subjects, 
whereas in gastric or calorecta! cancer, REE was not altered.68 
Furtllel1llore, alterations in lipid, protein and carbohydrate metabolism have been 
reported in cancer. Widl regard to lipid metabolism, an elevated turnover of glycerol alld 
fatty acids has been obselved in cancer patients, 124,192 although one study did not reveal 
ally differences in lipolytic rates between tile groups. lOS CallCer patients with weight loss 
were shown to have all increased turnover of both glycerol and fatty acids when compared 
with patients without weight losS.'92 Tn allother study, however, it was concloded that the 
observed increase in lipolysis alld triglyceride-fatty acid cycling in cachectic patients with 
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esophageal cancer was due to alterations in their nutritional status radler than die presence 
of tmnor itself.116 Besides alterations in lipolysis, concentrations of specific fdtty acids 
may also be affected by tumor presence and tumor type: in colorectal cancer,18 18:2n-6 
and 18:3n-3 were reduced and 18: In-9 was increased in red blood cells, whereas in 
platelets of lung cancer patients,l72 18:2n-6 and die n-3 futty acids were reduced. In 
patients widl bladder cancer, 142 totaln-3 and n-6 fatty acids were reduced in plasma PL. 
Alterations in protein metabolism in cancer cachexia are clearly illustrated by the 
IUldesired loss of muscle mass. % In metabolic studies, muscle protein syntilesis was 
significantly reduced in mahlOmished patients widl advanced gastric carcinoma54 and in 
weight-losing cancer patients of different tmnor typeS,58 whereas protein breakdown was 
elevated in patients with hepatocellular carcinoma. 159 In muscle biopsy specimens from 43 
newly diagnosed cancer patients widl weight loss, botll reduced protein synUlesis and 
elevated protein degradation were detected,l32 Furdlennore, plasma alllino acid profiles 
may be altered in patients Widl cancer cachexia, as suggested by a low plasma 
glutallline:cystine ratio,85 high plasma glutalllate levels86 and reduced serum tryptophan 
levels. 107 
Changes iu glucose metabolism also occur in cancer.51 The rate of endogenous 
glucose production is increased, and the magnitude of this increase appears to be related 
willi fuctors such as Imnor stage, nunor histology and cachexia.5! Increased 
gluconeogenesis, i.e. hepatic production of glucose fi'om lactate, alanine and glycerol, is 
one of die most important alterations in glncose metabolism in cancer.5! The rate of Cori 
cycling, the energy·consmning process in which lactate is released as a result of glycolysis 
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in peripheral tissues and resyntllesized to glucose by the liver, is also increased in cancer 
cachexia.51 
Ullderlying meeilanisllls 
The mechanisms llllderlying tile metabolic alterations in cancer have not yet been 
clarified. Besides alterations in food intake, many metabolic fuctors appear to playa role in 
cancer cachexia, such as the recently identified lipid-mobilizing fuctor (LMF)219 and 
proteolysis-inducing factor (plF}.130 Recent studies have stressed the important role of the 
acute-phase response associated Witll high levels of tumor necrosis fuctor-a, interleukin-l 
and interleukin-6, and interleron_y.25,62,64,I%,203 Otller fuctors such as hOlmonal 
alterations and metabolic competition between tlUnor and host may also playa role in the 
metabolic alterations in cancer cachexia.79 
Polenliallreallllellls 
An adequate trea~nent for cancer cachexia is not available. Corticosteroids alld 
progestational dmgs have been shown to improve appetite, food intake and the sensation of 
well-being, but tile beneficial effects on muscle mass are minimal.73 AltllOUgll hydrazine 
sulfate has received much attention, tllis compolUld was shown to be ineffective in 
improving the symptoms of tile patient with cancer cachexia.73 Megestrol acetate had 
beneficial therapeutic effects on appetite, body weight and quality-of-lire, t34 but these 
beneficial efrects appeared to be related to conservation of fat mass rather tlllUl of muscle 
mass. 30 Melatonin may be effective in tile treatment of CalICer cachexia by decreasing TNF 
blood concentrations, 128 and medroxyprogesterone acetate may contribute to 
downregl~ation of the acute-phase response. 134 In conclusion, tile n-3 futty acid EPA may 
have beneficial efrects in cancer cachexia by inhibiting proteolysisl3O and lipolysis, 170 alld 
by modulation of the acute-phase response.229 
Aims of the study 
The main aims of this tllesis were the following: 
To detennine whether lipid metabolism is altered in cancer patients 
To detennine whetller supplementation of EPA reduces lipolysis and lipid oxidation 
in healtlly subjects and in weight-losing cancer patients 
To obtain pilot infonnation on tile long-tenn efrects of EPA supplementation on 
body weigllt in weight-losing cancer patients 
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Outline of the thesis 
Differences in lipolysis and lipid oxidation between weight-losing cancer patients 
and healthy subjects are presented in Chapter 2. Since it was not known wheiller whole-
body lipolysis and lipolytic activity ill vitro are related, Chapter 3 describes ille 
measmements of lipolytic activity in the plasma samples of our cancer patients. In Chapter 
4, we report difrerences in plasma n-3 fatty acid concentrations between patients wiill 
pancreatic cancer, hlllg cancer and esophageal cancer in comparison with healthy subjects. 
The level of incorporation of EPA and DBA in difrerent plasma lipid fractions dming 
short-tenn n-3 fatty acid eillYl ester supplementation in healthy subjects is reported in 
Chapter 5. The efrects ofshort-tenn EPA ethyl ester supplementation on lipolysis and lipid 
oxidation in heaW1Y subjects and weight-losing cancer patients are presented in Chapter 6 
alld 7, respectively. hI Chapter 8, the short-term metabolic effects of different n-3 fatty 
acid supplements are compared, and Chapter 9 describes our pilot study on ille effects of 
long-term EPA ethyl ester supplementation on body weight, body composition and 
biochemical parameters in weight-losing cancer patients. Finally, ille main results of illis 
Ulesis are discussed in Chapter 10, and a SlUnmaty of results is presented in Chapter II. 
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Abstract 
Increased lipolysis has been suggested as one of Ule possible mechanisms 
lUlderlying cancer cachexia. The aim of our study was to assess wheUler lipolysis is 
increased in weight-losing cancer patients taking differences in food intake and body 
composition into accoUllt. 
Sixteen heaWlY subjects and 18 cancer patients WiOl different tumor types and 
weight loss of:>5 % in the previous six months were included in the study. Food intake was 
recorded for fuur days. After an ovemight fast, [1,1 ,2,3,3-'H5]glycerol was infilsed to 
detennine Ule rate of appearance (Ro) of glycerol as a measure of whole-body lipolysis, 
and [1-"C]palmitic acid was infilsed to determine the R, of palmitate as a measure of 
pailllitic acid release. Palmitate oxidation was detennined by measuring "CO, enricilinent 
in breath samples and body composition was measured by bioelectrical impedance 
analysis. 
After adjnstment for energy intake, whole-body lipolysis was significantly higher in 
cancer patients than in heaWlY subjects (6.46 ± 0.63 and 4.67 ± 0.46 flmol/kg.min, 
respectively; P < 0.05). The difference in palmitic acid release did not reach statistical 
significance. The rate of palInitate oxidation was also significantly higher in patients Uum 
in heaWlY subjects (1.15 ± 0.10 and 0.93 ± 0.07 fll1lol/kg.min, respectively; P < 0.05). 
No differences in body composition were observed between groups. 
In conclusion, whole-body lipolysis as measured by the R, of glycerol, and 
palInitate oxidation are elevated in weight-losing cancer patients, but pailllitic acid release 
was not significantly different. 
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Introduction 
Cancer cachexia is a syndrome of involl1l1tatY weight loss, impaired physical 
performance and fatigue, and is frequently seen in patients with malignant tmllors. 75,127 
Different studies have shown tlmt weight loss is associated with increased morbidity, 
attenuated response to tllerapy, decreased quality of WelO and reduced slU'vival. 48 The 
beneficial effect of dietaty supplementation is modest, and phannacological agents have 
failed to improve the condition.38 Therefore, better knowledge of the mechanisms 
mlderlying CatlCer cachexia is importatlt in order to develop new treabnent strategies. 
One of the fuctors contributing to tlle development of weight loss is reduced fuod 
intake, which may be caused by decreased appetite or ul1I1or treatment, 146, 168 by 
mechanical obstl1lction of the gastrointestiJJaI tract,48 or by intestiJJaI malabsorption. 146 In 
addition, metabolic aberrations may contribute to cachexia in cancer patients. 103,204 The 
combination of reduced energy intake and increased energy expendittne in CatlCer panents 
will result in substatltial weight loss. It Ims been shown that weight loss in cancer patients 
comprises botll muscle Inass and fat mass (pM).96 One of the mechanisms tllat may be 
involved in tile reduction of PM is increased lipolysis. In literature, several studies have 
reported elevated lipolysis in CatlCer patients, 116, 124, 192 aWlOugh one study did not detect 
any difference in lipolysis between CatlCer patients and heaWlY subjects. 108 
The mechanisms responsible for elevated lipolysis in cancer patients are poorly 
lUlderstood. Lipolysis lllay be ,tinudated by reduced energy intake, weight loss or by tile 
presence of catreer as such. In urine of weight-losing cancer patients, a probably turoor-
derived lipolytic matetial has been detected219 which stinlldated lipolysis lOl and 
proteolysis ill vitro,130,216 and induced weight loss in atlimals.218 Pmthennore, 
inflaIlllnation mediated by cytokines such as interlenkin-6 Inay affect lipolysis in CatlCer 
patients.79,84 Studies in healthy subjects have demonstrated tlmt lipolytic rate depends on 
energy intake34,114 and die size of fat-li"ee lllass (FpM).34,1I8 To 01U" knowledge, 
however, no data have been published on lipolysis in cancer patients after adjustment for 
energy intake or body composition. Therefore, the aim of tile present study WdS to assess 
whetller whole-body lipolysis, palmitic acid release atld palmitate oxidation are increased 
in weight-losing CatlCer patients taking differences in lood intake and body composition 
into aCcOlUlt. 
Methods 
Subjects 
Eighteen patients with histologically proven cancer and weight loss ~ 5 % in the 
previolls 6 months, and 16 healthy subjects with stable weight were included in this study. 
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The study was approved by tlle Medical Etllics Committee of tlle Erasmus University 
Medical Center Rotterdam, and written infOlmed consent was obtained from all 
participants prior to start of tlle study. The following exclusion criteria were used: 
treatment witlh chemotlherapy or radiation tlherapy in tlhe 2 weeks preceding tlhe study, 
surgelY in tlhe previous 2 montlhs, concurrent corticosteroid treatment, insulin-dependent 
diabetes mellitus, wlcontrolled hyper- or hypotllyroidism, edema or fever. Clinical 
characteristics of cancer patients are smwnarized in Table 2.1. 
Table 2.1 
Clinical characteristics ofwcight-iosing cancer patients," 
Age Sex Tumor type Time since Metastases Prior Weight loss 
diagnosis (mo) Treabnent' (%/6mo) 
Gastrointestinal tumors: 
50 M Adenocarc. of the oesophagus None None 6.9 
60 M Adenocarc. of the oesophagus 48 Liver, lung S,C 7.3 
69 M Squamous cell care. of Ihe oesophagus 8 Lymph nodes C 18.1 
59 M Squamous cell care. of the oesophagus 22 None C,R 14.8 
49 M Squamous cell care. of the oropharynx 14 None C,R 10.7 
59 M Care. of the reclum 24 Liver S,R 18.0 
63 M Pancreatic cancer ~ocoregional relapse) 19 None 8,R 14.3 
75 M Pancreatic cancer (Iocoregional relapse) 7 None S 7.3 
59 M Gall bladder care. 2 Liver None 25.0 
Olher tumors: 
74 M Adenocarc. of the lung 12 Liver 8 10.8 
55 M Undifferentiated large cell carc.of the lung 16 Mediastinum R 5.3 
65 M Mesothelioma of the lung 3 None None 14.0 
73 F Adenocarc. of the mamma 180 Lung,bone 8,H,R 14.4 
74 F Adenocarc. of Ihe mamma 1 Bone, H 7.2 
lymph nodes 
65 F Care. of cervix (iocoregional relapse) 24 None 8,R 5.3 
66 F Carcinoid 96 Liver, None 17.1 
omentum, 
lymph nodes 
65 M Adenocarc. of Ihe kidney 15 Lung 8,1 13.1 
65 M Adenocarc. of unknown primary 1 Liver None 11.1 
• Care.: carcinoma 
b S = Surgery; R = Radiotherapy; C = chemotherapy; H = Hormonal treatment; 
I = Interferon treatment 
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Study protocol 
After an overnight fast of ",12 hours, subjects attended dle outpatient department 
between 8 and 9 a.m. for measurements of whole-body lipolysis and lipid oxidation, 
resting energy expenditure (REE) and body composition. After fifteen minutes of absolute 
rest at dIe department, teflon catheters were inserted into dle antecubital vein of one arm 
for the infhsion of isotopes and into tlle contralateral dorsal hand vein or foreann vein of 
die other ann for blood sampling. Baseline blootl samples were collected in heparinized 
vacmnn tubes. Four baseline breath samples were collected by exhaling tln'ough a straw 
into lOmL Exetainer tubes. Blood samples were centrifuged immediately at 1200g for 
IOmin at 4"C, and plasma was stored at -80'C under nitrogen until analysis. 
After baseline sampling, a plasma protein solution (40g protein/L; albUlllin <0 85 %; 
CLB, Amsterdam, The Nedlerlands) was infilsed containing die stable isotope labeled 
tracers [1,1,2,3,3-'H5]glycerol (MassTrace, Woburn, USA) and [l)3Clpalntitic acid 
(MassTrace). Labeled glycerol was infilSed at a rate of -0.08~llllOVkg.min (prime 
1.2Jlmollkg) to detennine the rate of appearance (R,) of glycerol as an index of whole-
body Iipolysis233 using a Perfilsor® Secura pmnp (B.Brallll, Melsllllgen, Gennany). 
Labeled pahnitate was infused at a rate of - 0.04~moVkg.min to detennine dIe R, of 
palmitate as an index of fatty acid release.233 The plasma bicarbonate pool was primed 
with NaH13C03 (-1.7~unollkg) dissolved in saline. The exact amount of tracers infilsed 
during the study was detennined afterwards by measuring the isotope concentration in the 
infilsate. 
During the isotope infilsion, REE was measmed for 30 minutes by indirect 
calorimetry using a ventilated hood system (Deltatrac"! MBM-lOO, 
DATEXlInstnunentarium Corp., Helsinki, Finland). The amOlUlts of 0, consumed and 
CO, produced during the last 20 minutes of the measurement were used to calculate REE 
and total respiratory quotient (RQ). At 50, 60, 70, 80 aud 90 Irtiuutes after statt of tlle 
isotope infusion, arterialized venous blood samples239 were taken in heparinized tubes to 
meaS\ll'e r'H,]glycerol and IIYClpainlitate enrichment. Breadl samples were taken to 
measme "CO, em'iclllnent in order to calculate [l-"Clpalntitate oxidation. All blood 
samples were placed on ice immediately, and centrifilged and stored at dIe end of die 
infilsion perind. In order to prevent obstruction, the venflon sampling device was flushed 
with 2 mL saline containing heparin in Jow concentration. Heparin-released lipoprotein 
lipase activity was verified to be less dllm 3 % of tlle measured values for total whole-body 
lipolysis. 
Body composition was detel1llined by bioelectrical impedance analysis (BTA; 
HUMAN-1M SCAN, Dietosystem, Milan, Italy), using the equation of Deurenberg et 
a!.. 47 Body weight (BW) and height were measured. Subjects recorded tlleir dietary intake 
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for fom days preceding tile measurements of lipolysis. Dietary intake was calculated using 
tile nutritional package 'Komeet' (B.ware Nutrition Software, Ambem, the Netherlands). 
Al/a(ysis of blood samples 
To isolate plasma glycerol, 0.2mL plasma was deproteinized by subsequently 
adding and mixing O.5mL H20, 0.2mL 0.15M CuSO. and 0.2mL 0.15 M Na,W04. After 
centrifugation at 15000g and 15'C lor 8 minutes, the supernatant was passed through a 
mixed ionexchange colmnn (AG50W-X8, AGI-X8, 200-400 mesh, 0.2 g each; Biarad, 
Richmond, USA). The column was washed Witll 4mL H,O and tlle effluent containing 
glycerol was collected and dried 'mder nitrogen. Derivatives of glycerol were fonned 
during incubation Witll 0.030mL pyridine and 0.015mL N-methyl-N-(tert-
butyldimetllylsilyl)-trifluoroacetamide (MTBSTFA, Pierce, Ornnilabo, Breda, The 
Netllerlands) for one hour at 60'C. 
To measure [I-"C]pahnitate enrichment, lipids were extracted from 250f'L plasma 
using chlorofonn/metllanol (2:1, by vol.; Merck; Danmtadt, Gennany) according to Falch 
et al.66 in the presence of butylated hydroxy toluene (BHT; Img/mL) as an antioxidant. 
Plasma fi'ee futty acids (FFA) were isolated by thin layer chromatography (silica plates; 
Merck, 5721) using hexane/diisopropyletller/acetic acid (60:40:3, by vol.; Merck) as a 
developer. Spots were scraped off, extracted using cWorofOlmlmethanol (2:1), dried under 
nitrogen and converted to tlleir derivatives by MTBSTFA. 
Plasma enrichment of free ]2H5]glycerol and [l-BC)pahrtitic acid were analyzed on 
a Carlo Erba GC8000 gaschromatograph coupled to a Fisons MD800 mass spectrometer 
(Interscience BV, Breda, The Netllerlands) in electron impact ionization mode Witll an 
interface temperature of 280'C and a source temperature of 200'C, All measurements of 
isotopic enrichment were carried out by injecting If'L Witll a split ratio of 50: I on a filSed 
silica capillaly cohunn of 25m x 0.22mm, coated Widl O.lIm HT5 (SGE, Victoria, 
Australia). Natural glycerol alld ['H5)glycerol (mass 387 and 381), alIt! naturdl pahrtitic 
acid alJd [t-t'C]palmitic acid (mass 313 arJd 314) were measmed by selected ion 
monitoring. For both ['H,jglycerol and ]l-BC]pahrtitic acid, the coefficient of variation 
was 0.2Mol% and no concentration etrect was observed for the Mol% enrichment. "CO, 
in breath SaJllples was measured on an isotope ratio mass spectrometer (ABCA; Europa 
Scientific, Van Loenen Ill$tnnnents, Leidell, The Netherlands) with a standard deviation of 
O.0002Atom%"C01. 
Blood hemoglobin, albtUnin, prealbmnin arJd C-reactive protein (CRP) were 
meastU'ed according to starJdal'd clinical chemical metllods. Thyroid honnones T3, T4 allt! 
1'1', were measured according to the method of Bauer et al.. 20 Plasma insulin was 
measured by radioimmtUloassay (BiosotU'ce, Fleun", BelgitUll). 
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Calculatiolls 
Calculations of the rate of appearance (R,) of glycerol and palmitate were made 
according to Klein et aI., 116 using file equation described by Steele:205 
R, (~mol/kg.min) ~ (IR/IE,- I) * F 
where F is the isotope infusion rate (runol/kg.min), IEl is dIe isotopic enrichment of 
file infusate (atom percent excess) and IE, is the isotopic emiclllnent in plasma (atom 
percent excess) during steady state conditions. The R, of total free futty acids (R, FFA) 
was calculated from the R, of palmitate asswniug that dIe palmitate concentration was 23 % 
of total plasma FFA concentrations.1 10 An index of dIe relative rates of lipolysis and 
reesterification was calculated as file ratio of R, FFA / R, of glycerol. 233 
Palmitate oxidation was calctdated according to dIe following equation: 
Palmitate oxidation (~mol/kg.min) ~ (IEc02 * VCO,) / (IE, * BW * k) 
where IEco, is file isotopic enrichment of tile expired CO, (atom percent excess), 
VCO, is dIe CO, production (runol/min), BW is body weight (kg) and k is the bicarbonate 
correction factor for incomplete recovery of "C (k ~ 0.75) according to Wolfe et al.. 234 
Statistical {/lIa(l'sis 
Data are expressed as mean ± SEM. Statistical differences between cancer patients 
and heaWlY subjects were assessed using linear regression analysis including as covariates: 
1. a dmnmy variable to indicate tmllor presence and 2. energy intake. Pearson correlation 
coefficients were calculated. Due to dIe skewed distribution of CRP data, a 
logtransformation was applied for plasma CRP concentratioll$. P-V'dlues less than 0.05 
were considered statistically significant. Analyses were performed Widl SPSS software 
(SPSS for Windows version 6.1.3, SPSS Inc., Chicago). 
Results 
The characteristics of cancer patients and healtllY subjects are smnmarized in Table 
2.2. The mean age of cancer patients was significantly higher than filat of healthy subjects 
altllOugh the age range was comparable, i.e. 49-75 year in patients and 40-75 year in 
heaWlY subjects. BW, body mass index (BMl; kg/m~, percentage of ideal BW (%IBW), 
ann circmnference and smn of fom' skinfolds were significantly lower in cancer patients 
than in healthy subjects. Absolute values of FFM anI PM were reduced in cancer patients, 
but file percentage of FFM (%PFM) was not difterent between cancer patients and healthy 
subjects. Since %FFM was also comparable in patients with gastrointestinal (GJ) cancer 
and patients Widl odler types of tlUnors (non-GJ), %PFM was not included as a covariate 
in the statistical allalyses. 
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Table 2.2 
Characteristics of study population. 
, 
Cancer patients 
Gastrointestinal other Total group 
(n = 9) (n = 9) (n = 18) 
Age (y) 60 ± 3 67 ± 2' 64 ± 2' 
Sex 9M 5M;4 F 14 M; 4 F 
Weight (kg) 67.2 ± 3.4 63.8 ± 3.1b 65.5 ± 2.3b 
Weight loss (%) 13.6 ± 2.1 b 10.9 ± l.4b 12.3 ± 1.2b 
8MI (Kg/m') 21.5 ± 1.1' 23 ± 1 22.2 ± 0.7' 
%18w' 97.8 ± 4.9b 108 ± 5.1 102.9 ± 3.6' 
Ann circumference (cm) 27.5 ± 1.3b 28.5 ± 1.0' 28 ± 0.8b 
Sum of four skinfolds (mm) 33.3 ± 4.6b 45 ± 7.7' 39.1 ± 4.6b 
Fat·free mass (kg) 47.6 ± 2.2 44.3 ± 2.5' 45.9 ± 1.7' 
Fat mass (kg) 20.4 ± 2.4 19.5 ± 1.8 19.9 ± 1.4 
Fat-free mass (%) 71 ± 3 70 ± 2 70 ± 2 
"mean ± SEM 
b,CSignificantly different from healthy subjects (I-test): "p < 0.01, bp < 0.05, 
d Percentage of ideal body weight 
Healthy subjects 
(n = 16) 
54 ± 2 
10 M; 6 F 
77 ± 3.4 
o ± 0 
25.3 ± 1 
118.2 ± 4.6 
31.9 ± 0.8 
69.2 ± 7.4 
54.1 ± 2.9 
23.6 ± 2.2 
70 ± 2 
Total energy intake (kJ/day) was significantly lower in cancer patients than in 
healthy subjects, especially in patients Witll non-Gl tlUnors (Table 2.3). When expressed 
per kg BW, energy intake in patients Witll non-G! tumors remained 25 % lower tllllO in 
heaWlY controls (P == 0.055). Because of the differences in energy intake between groups, 
furtller statistical al1lllyses were adjusted lor energy intake. No significamt differences in 
energy percenlage of mt, protein or carbohydmte intake were observed between amy of tlle 
groups. 
Blood hemoglobin, alblUnin and prealblUnin were fOlmtl to be significantly 
decreased in cancer patients, whereas CRP was significantly increased (Table 2.4). Wid, 
regard to tlryroid honnones, T, was signilicantly lower and rT, significantly higher in 
cancer patients tl1lln in heaWlY subjects, whereas T4 did not show any significant difference 
between the groups. Urimuy creatinine excretion was significantly lower in cancer patients 
tl1lln in healthy subjects. Again, no significant difference in any biochemical parameter was 
detected between cancer patients Witll GI tumors and patients with other types of tlUnors. 
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Table 2.3 
Dietary intake in weight-losing cancer patients and healthy subjects3 
Cancer patients 
Gasuointestinal Other Total group 
(n = 9) (n = 9) (n = 18) 
- total (kJld) 8348 ± 902 5903 ± 568' 7054 ± 588' 
- per kg body weight 128 ± 15 92 ± 8 109 ± 13 
(kJ/kg.d) 
- Protein (E%)d 17.8 ± 1 17A ± 1 17.6 ± 0.7 
_ Fat (E%)d 34.9 ± 2 33.9 ± 1.1 34A ± 1.1 
- Carbohydrate (E%)d 45 ± 3 50 ± 2 47 ± 2 
"X' ± SEM 
b,c Significantly different from healthy SUbjects: b P < 0.01 j C P < 0.05 
d E %: energy percent 
Table 2.4 
Biochemical parameters in weight-losing cancer patients and healthy subjects" 
Cancer patients 
Gasuointestinal Other Total group 
(n = 9) (n = 9) (n = 18) 
Blood: 
Hemoglobin (mmoUL) 7.7 ± OA' 7.1 ± 0.3b 7A ± 0.3b 
Albumin (gil) 39 ± 2b 39 ± 1b 39 ± 1b 
Prealbumin (giL) 0.19 ± 0.02b 0.17 ± O.Olb 0.18 ± O.Olb 
T3 (nmolJL) 1.22 ± 0.15 b 1.52 ± 0.13' 1.39 ± O.l1b 
T, (nmoIIL) 93 ± 8 112 ± 9 102 ± 6 
rT3 (nmollL)d 0.54 ± 0.14' 0.36 ± 0.11' OA8 ± 0.09b 
C-Reactive Protein (mgIL)d 25 ± 13' 17 ± 15' 21 ± lOb 
Urine: 
Creatinine excretion (gl24h) 0.14 ± 0.01' 0.13 ± 0.02 0.14 ± 0.01' 
" Mean ± SEM unless otherwise slated 
b,c Significantly different from healthy subjects (I-test): bp < 0.01; tp < 0.05 
d Median ± SEM 
Heatthy subjects 
(n = 16) 
9081 ± 621 
122 ± 10 
16.9 ± 0.8 
36.2 ± 1.5 
47 ± 1 
Healthy subjects 
(n = 16) 
8.6 ± 0.2 
48 ± 1 
0.28 ± 0.01 
1.89 ± 0.1 
90 ± 4 
0.25 ± 0.02 
1 ± 
0.17 ± 0.01 
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Table 2.5 
Rate of appearance (l~) of glycerol and palmitate and the ratio of R.. of total free faUy acids 
(FFA) / R.. of glycerol in plasma, rate of palmitate oxidation and resting energy expenditure 
(REE) in weight-losing cancer patients and healthy subjects.a 
R, of glycerol (~moVkg.mln) 
R, of palmitate (~ollkg.min) 
Ratio R, FFAI R, glycerol 
Palmitate oxidation (~ollkg,min) 
REE (kJ/kg.24h) 
~ Mean ± SEM 
Cancer patients 
Gastrointestinal Other 
(n=9) (n=9) 
5.88 ± 0.6 7.04 ± 1.]2" 
4.23 ± 0.41 4.38 ± 0.55 
3.23 ± 0.25 2.82 ± 0.17 
1.14 ± 0.16 
97 ± 4' 
1.16 ± 0.j4b 
96 ± 4' 
Total group 
(n = 18) 
6.46 ± 0.63' 
4.3 ± 0.33 
3.03 ±0.16 
1.15 ±0.1O" 
97 ± 3' 
b--d Significantly different from healthy subjects after adjustment for energy intake: 
bp = 0.05; 0p < 0.05; dp < 0.02 
Healthy subjects 
(n = 16) 
4.67 ± 0.46 
3.59 ± 0.23 
3.75 ± 0.37 
0.93 ± 0.07 
84 ± 2.40 
Whole-body lipolysis, as measured by tile R, of glycerol, was 38% higher after 
correction for energy intake in cancer patients than in healthy subjects (Table 2,5; P < 
0.05). When the two subgroups of cancer patients were considered separately, a 50% 
elevation of R, of glycerol was observed in patients with non-GI cancer (P < 0.05), 
whereas the elevation of R, of glycerol did not reach statistical significance in the GI 
patients. Although pahnitic acid release, as measured by tile R, of palmitate, also tended to 
be higher in cancer patients than in healthy subjects, this difference failed to reach 
statistical significance (P < 0.10). Reesterilication, as indicated by tile ratio R, FFA / R, 
glycerol, did not differ significantly between cancer patients and healtllY subjects, altllOugh 
values tended to be lower in cancer patients than in healtllY subjects. Pahnitate oxidation 
was significantly elevated in tile total group of cancer patients (P < 0.05) as well as in the 
subgroup of non-GI cancer patients (P < 0.05). REE per kg BW WaS significantly 
elevated in both patients with GI cancer <UKI with otIler tmnor types (P < 0.01). 
Pahnitate oxidation (R = 0.52; P < 0.05) and REE (R = 0.65; P < 0.01), but not 
lipolysis or fatty acid were significantly correlated WitIl the 10g<U'ithm of plasma CRP 
concentrations. 
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Discussion 
Increased lipolysis is one of the factors dlat may contribute to development of 
weight loss in cancer cachexia.97 It is not known, however, whether liJXllysis is increased 
in cancer patients when alterations in energy intake and body composition are taken into 
accOlml. In the present study, we investigated whedler lipolysis was higher in weight-
losing cancer patients duUl in healtlly subjects taking differences in food intake and body 
composition into accOlUlt. Since no differences in %FFM were observed, this factor was 
not included in the statistical analyses. Energy intake, however, showed substantial 
differences between groups, and was theretore included in the statistical analyses as a 
covariate. Whole-body lipolysis was assessed using infilsion of 'Hs-labeled glycerol, 
whereas palmitic acid release was measlU"ed using J3C-labeled pahnitate. Whole-body 
lipolysis and palmitate oxidation were signitkantly higher in cancer patients tllan in healthy 
subjects, but the difterence in latty acid release between tile two groups failed to reacb 
statistical significauce. 
Lipolysis is the hydrotysis of triglycerides into free glycerol and fatty acids. For 
every triacylglycerol molecule hydrolyzed, one molecl~e of glycerol is released into tile 
plasma. The R, of glycerol is tllerefore a direct reflection of the rate of lipolysis. 233 Tn 
contrast, the R, of palmitate may be affected by other factors such as reesterification within 
tile tissue233 and differential mobilization of different latty acids from adipose tissue. 43 
The index for reesterification, calculated as tile ratio of R, FFA I R, glycerol, did not 
differ significantly between groups in tile present study. 
Several studies llave shown that lipolysis expressed per kg BW does not differ 
significantly between YOlmger and older subjects. 35, 117,221 Based on tllOse observatiOlm 
and tile fact tllat age did not correlate witll lipolysis in the present study, we conclude that 
the slight difference in age between cancer patients and healthy subjects in tile present 
study has not affected study outcome. 
Previous studies have shown t1lat REE is higher in cancer patients WiOl an acute-
phase respolme than in patients without this response.62.203 This finding was confinned in 
the present study, where REE was significantly conelated with plasn11 CRP 
concentratiOlm. Whole-body lipolysis was, however, not correlated Witll plasma CRP in 
cancer patients, aWlough it has been snggested tl11t cytokines and inflallln11tion nlaY 
mediate c1langes in lipid metabolism. 84 RaUler, the presence of a lipolytic factor 101 ,219 or 
lipolytic hormones may llave stimulated whole-body lipolysis in cancer patients. 
It may be noted that our values of tlle R, of glycerol and pahnitate in cancer 
patients as well as in healthy subjects were higher tllan tllOse reported in comparable 
studies,lOB,116,124,192 Although tllere is no simple explanation for tlils, it should be 
emphasized tllat the differences between OW" values and those reported in literature did not 
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affect the comparison between patients and heaWlY subjects within our study, since 
identicalmetllOdology was applied for all subjects. 
We conclude that lipolysis and palmitate oxidation are elevated in weight-losing 
cancer patients when energy intake is taken into account. Body composition did not differ 
between patients aod healthy subjects, so tlmt adjustment for this potential confolmder was 
not needed. Differences in palmitic acid release and reesterification between caocer 
patients and heaWlY subjects did not reach statistical significance. Prospective studies are 
needed to assess the role of increased lipolysis and tat oxidation in the etiology of weight 
loss of cancer patients. 
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Abstract 
In urine of cachectic caucer patients, a lipid-mobilizing factor (LMF) has recently 
been identified which may be responsible for the increased breakdown of adipose tissue in 
these patients, It is not known wheUler the presence of Ulis LMF in plasma, which cau be 
measmed as plasma lipolytic activity, is associated with increased lipolysis ill vivo, The 
aim of the present study was to assess wheUler whole-body lipolysis aud plasma lipolytic 
activity are correlated in weight-losing cancer patients and healtllY control subjects. 
In 18 weight-losing cancer patients of different tmnor types and in 16 healthy 
subjects, Ule rate of appearance of glycerol was detennined as a measme of whole-body 
lipolysis using 'Hs-Iabeled glycerol. III vitro lipolytic activity of plasma was determined by 
measming glycerol release from incubated adipocytes. 
III vitro lipolytic activity towards isolated fat cells was significantly higher in 
plasma from weight-losing cancer patients dIan in plasma of healthy subjects (P < 0.0 I), as 
was dIe rate of whole-body lipolysis (P < 0.05). However, no significant correlation was 
detected between lipolytic activity ill vitro and whole-body lipolysis ill vivo in the total 
study group, nor in healtlly subjects or cancer patients separately. 
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Introduction 
Many cancer patients suffer fi'om involtuUary weight loss which is caused bOUl by 
reduced food intake and by metabolic alteratiol1~.127 Recent studies have identified a lipid-
mobilizing factor (LMF), which shows homology with Ule plasma protell' Zn-C(2-
glycoprotein. 97 LMF was shown to induce lipolytic activity in lllcuhated adipocytes l43,219 
and to stimulate lipid mobilization and catabolism III mice. 97 Theretore, LMF may play an 
important role III Ule excessive breakdown of adipose tissue in cancer. In a recent study in 
weight-losing cancer patients of different tlunor types and healthy subjects, we showed Ulat 
whole-body lipolysis, as measlll'ed by stable isotope steady state kinetics, was increased in 
cancer patients (Chapter 2). We decided to measure lipolytic activity in Ule plasma samples 
of Ulese patients to assess whether whole-body lipolysis ill vivo and lipolytic activity ill 
vitro in weight-Ioslllg cancer patients and healthy control subjects are correlated. 
Subjects and methods 
Eighteen patients WiOl histologically proven cancer of different ttunar types and 
weight loss C5% III Ule previous six monUls, and 16 healtllY subjects WiOl stable weight 
were lllcluded in the study. Whole-body lipolysis was detenninC(I by measlll'ing the rate of 
appearance of glycerol. 116 After baseline blood sampling, [1,1,2,J,J-'H,]glycerol (Mas-
sTrace, Woburn, USA) was infilSed by approximately 0.08~mol/kg.min (priming dose 
1.2~mol/kg). After 50, 60, 70, 80 and 90 minutes of infilsion, blood samples were taken 
for determination of plasma ['H,]glycerol enricbment as described previously (Chapfer 2). 
Plasma lipolytic activity was determined via a modified meUlod of Beck amI 
Tisdale,22 measuring glycerol release from lllcubated adipose cells. Adipocytes fi'om 
recenUy sacrificed NMRI mice were separated and incubated WiOl plasma lor 2 hours. The 
release of glycerol was detennined spectrophotomehically accarding to Ule method of 
Wieland.228 
Differences between patients and controls were tested USlllg the Mann-Whitney U 
test. Speamlan's rank correlation coeftlcient was calculated between plasma lipolytic 
activity and whole-body Ro of glycerol. Diflerences were considered statistically significant 
when P < 0.05. 
Results 
Results showed Ulat lipolytic activity ill vitro was significantly higher III weight-
losing cancer llatients (median 0.007 tunol/IO' adipocytes.2h; range 0.000 - 0.195) UUUl in 
bealtlly subjects (median 0.000 tlmol/IO' adipocytes.2h; 0.000 - 0.031; P ~ 0.006). 
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Lipolysis ill vivo was also higher in cancer patients (6,46±0.63 ftmollkg.min; Mean±SEM) 
than in heaWlY subjects (4.67±0,46 Ilmollkg.min; P < 0.05). No significant correlations 
were detected between lipolytic activity ill vitro and lipolysis ill vivo (Figure 3.1). 
o 
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Plasma lipolyUc acUvily in vitro 
No significant correlation between whole-hody lipolysis (Rate of appearance of 
glycerol; J.!moUkg.min) and plasma lipolytic activity in vitro (mmoles glycerol I 
10 5 adipocytes 12h) in weight-losing cancer patients and in healthy subjects. 
Discussion 
The presence of LMF is asslUned to be one of dIe factors drat stimldate lipolysis in 
cancer patients. 97 Our results conlinn that both lipolysis ill vivo and lipolytic activity ill 
vitro are increased in cancer patients. However, as dlere was no correlation between the 
two measures, mctors adler than LMF probably play a role in whole-body lipolysis in 
cancer patients. Such factors may include prointlammatory cytokines such as tmnor 
necrosis factor-alpha, interleukine-I, interleukin-6 and interferon-gamnra. 6,84 Also 
hormonal alieratiOllS lrave been reported in cancer patients, such as decreased plasma 
insulin, increased glucagon levels l9 and alieratiOlLs in glucocorticoids.6 We conclude drat 
bodl lipolysis ill vivo and lipolytic activity ill vitro are elevated in weight-losing cancer 
patients. No con'elation was detected, however, between these two measures. Flll'ther 
studies are needed to study dIe mechanisms lUlderlying elevated lipolysis in cancer 
patients. 
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Abstract 
Despite the general notion of impaired nutritional status in cancer patients, studies 
on fatty acid status in cancer patients are limited. Plasma n-3 fatty acid concentrations may 
be reduced due to reduced uptake or intake, or due to enhanced metabolic demands. The 
aim of the present study was to investigate whedler plasma n-3 fdtty acids concentrations 
are reduced in patients with different tlUnOJ' types. 
We measured fatty acid composition in plasma phospholipids (PLs) and cholestelyl 
esters (CBs) in 45 healtllY subjects and 71 newly diagnosed, 1m treated cancer patients of 
duee lIunor types: esophageal or cardia cancer (n=35), non-small cell lung cancer (n=22) 
and pancreatic cancer (n=15). 
In pancreatic cancer, plasma n-3 fatty acids showed a substantial reduction in both 
plasma PLs and CBs. Although n-3 fatty acids in IIUlg cancer also tended to be reduced, 
dlis difference titiled to reach statistical significance. In esophageal cancer, n-3 latty acid 
concentratiollS were comparable to diose in healtlly subjects. n-3 Fatty acid levels were 
lower in weight-losing tllall in weight-stable patients widl hmg cancer, whereas pancreatic 
cancer patients Witil diabetes had significantly higher levels of n-3 latty acids dtan dIOse 
pancreatic cancer patients widlOut diabetes. For all tmllor types combined, total n-3 latty 
acids were also significantly reduced in patients with plasma C-reactive protein 
concentration); > 10 mgfL. 
We conclude dtat plasma n-3 fatty acid levels are reduced in pancreatic cancer, 
llOssibly reduced in Ilmg cancer, but not altered in esophageal cancer. Further studies are 
needed to assess die mecltaniSlllS underlying the observed changes in n-3 latty acid 
concentrations. 
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Introduction 
Many cancer patients sulrer from substantial weight loss due to reduced food 
intake, impaired intestinal absorption, metabolic alterations or a combination of dlese 
factors, widl consequent increased risk of developing nutritional insufficiencies. The risk 
of essential fatty acid deficiency, including deficiency of n-3 fatty acids, is especially 
elevated in conditions of decreased intake, intestinal malabsorption, and inflammation. 
Little is known, however, on the plasma concentratiolL~ of n-3 futty acids in specific 
groups of cancer patients. In patients with hladder caucer, plasma n-3 and n-6 futty acid 
levels were reduced in plasma phospholipids (PLs).142 A small study in cancer patients 
with different tumor types reported reduced concentrations of eicosapentaenoic acid 
(20:5n-3; EPA) and docosahexaenoic acid (22:6n-3; DHA) in total plasma lipids in 
comparison widl healthy subjects.2oo In ltulg cancer patients, reduced levels of EPA, DHA 
and linoleic acid (18:2n-6) in platelet phosphatidylcholine have been reported. 172 Mosconi 
et al. 152 described reduced levels of polyunsaturated fatty acids in malnourished cancer 
patients, but did not report any specific data regarding n-3 futty acids. In colorectal cancer 
patients, no significant alterations in plasma n-3 futty acid levels were detected. 18 Most 
studies are small, however, and to our knowledge, direct comparisons between different 
ttullOr types have not been made. 
Recent studies have reported potentially beneficial effects of n-3 fatty acid 
supplementation in cancer such as inhibition of weight IOS8 15 ,17,230 and a prolonged 
survivalJ6 Although the mechanislns IUlderlying dleSe eftects are not known, they may be 
related with impaired n-3 futty acid status in cancer patients. 
The aim of dIe present study was to investigate whether plasma n-3 fatty acid 
concentrations are reduced in patients with pancreatic cancer, itmg cancer and esophageal 
cancer when compared with healthy subjects. 
Subjects and Methods 
Subjects 
The sltKly protocol was approved by the Medical Ethical COlmnittee of the Erasmus 
University Medical Center Rotterdam. Written infonned consent was obtained fi'Om evelY 
subject before inclusion into this study. Fifteen patients widl pancreatic cancer, 22 patients 
with non-small cell llllig carcinoma and 35 patients widl esophageal or carrlia carcinoma 
were included in the study. All patients were newly diagnosed and Imtreated, and were 
recnuted in consultation with clinicians of the Departments of SurgelY, Pulmonary 
Diseases, Oncology and Thoracic SurgelY of dIe University Hospital Rotterdam, The 
Nedlerlands. Exclusion criteria were a previous histOlY of malignant disease and previous 
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anti-ttuuor treatment. Forty-five healtllY subjects were included as a control. Exclusion 
criteria for the healtllY subjects were a histOlY of maliguant disease and clle presence of 
diabetes, which was defined as treatment Widl insulin, oral antidiabetics or a special diet. 
Mean alcohol consumption, smoking behavior and weight loss over the previous six 
monUlS were recorded using a questionnaire, as were diseases other than cancer. Age, sex, 
weight, height and medication were also noted. 
Determinanon of plasma fatty acid composition 
A heparinized blood sample was collected from every subject after an overnight 
fast, and was centrifilged at 1600 g at 4"C for 10 minutes. Plasma samples were frozen 
lmder nitrogen at -80 "C lmtil analysis. Fatty acid composition of plaslna PLs _ and 
cholestelyl esters (CBs) was determined as described in Chapter 5. Briefly, plasma 
samples were extracted using a cWorofonn-methanol mixture (2:1 by vol.) according to 
Folclr et al.. 66 Lipid fi'actions were separated by thin-layer chromatography, CE and PL 
fi'actions were scraped off and fdtty acids were transmecllylated by an acetylchloride-
meclJanolmixttlre (1:20 by vol.) according to Lillington et al.. '25 Fatty acid compositions 
were mJalyzed by Gas Liquid ChronJatography (GLC; Carlo Erba HRGC 5160) using a 
FID detector mKl a CP-sil 88 collUnn (Chrompack; lengUI SOm, diameter 0.2Smm) using 
'on collUlln' injection. The carrier gas was helilUn (pressure: ISO kPa). Tire temperattn'e 
program started at 90"C, mId Ulen increased to 170"C by 10' per minute, continuing to 
220"C Widl 2" per minute, alKl to clle final temperattlre of 225'C by I" per minute, IUltil the 
end of analysis. In Ule chromatograms of Ule PL fi'actions, Ule following fatty acids were 
identified: pahnitic acid (16:0), stearic acid (18:0), linoleic acid (18:2n-6), dihomo-y-
linolenic acid (20:3n-6), arachidonic acid (20:4n-6), BPA (20:5n-3), docosapenlaenoic acid 
(22:Sn-3), docosahexaenoic acid (22:6n-3) and Ule total sum of vaccenic acid (18: 1n-7) atud 
oleic acid (18: In-9). Since 18:1n-7 and 18: I n-9 could not be appropriately separated in all 
chromatograms, the SlUn of 18:1n-7 mId 18:1n-9 was used for data mJalysis (referred to as 
18:1). 18:1n-7 accollllted lbr approxilnately 16% of total 18:1 in plaslna PLs. Total n-3 
fatty acids in PLs were calculated as the SlUn of20:Sn-3, 22:Sn-3 atud 22:6n-3. In CE, the 
fatty acids 16:0, pahnitoleic acid (l6:ln-7), 18:0, 18:1, 18:2n-6, <x-linolenic acid (18:3n-
3), y-linolenic acid (l8:3n-6), 20:3n-o, 20:4n-6, 20:Sn-3 mId 22:6n-3 were identified. In 
plasma CE, 18: In-7 accOlUlted for about 5 % of total 18: 1. Total n-3 fatty acids in CEs 
were calcldaled as Ule S\iln of 18:3n-3, 20:5n-3 and 22:6n-3. The weight percentage of 
each fatty acid was calculated by defining the stun of all nominated futty acids as 100 
percent. Three desattn'ation itulices were calculated as lbllows (based on tlle PL data): 
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L>6-desattu'ation index ~ [(20:4n-6 + 20:3n-6 + 18:3n-6) I 18:2n-6] 
M-desattll'ation index ~ [(20:4n-61 (20:3n-6 + 18:3n-6 + 18:2n-6)] 
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Table 4.1 
Characteristics of healthy subjects and cancer patients.a 
Healthy Pancreatic 
subjects cancer 
(n=45) (n=15) 
Age (y)b 59 (50-83) 64 (45-78) 
Sex 26 M; 19 F 6 M;9 F 
Body weight (kg) 74.3 ± 2.0 67.4 ± 4.1 H 
Body mass index (kg/m') 24.0 ± 0.7 24.6 ± 1.1 
Weight loss (kg)' 0.1 ± 0.1 7.1 ± 1.2* 
Weight loss (%)' 0.05 ± 0.13 10.1 ± 1.81 
Alcohol use (units/week) 6.7 ± 1.1 2.1 ±1.1 
Smoking (cig/day) 1.3 ± 0.6 3.7 ± 1.1 
Prevalence of NIDDM' n=O (0%) n=6 (40%)1tI 
3 Mean ± SEM 
t. Median (range) 
C Wcight loss in the preceding six months 
d NIDDM: Non-Insulin Dependent Diabetes Mellitus 
* Significantly differcnt rrom healthy subjects (P < 0.05) 
/I Signilicantly different from pancreatic cancer (P < 0.05) 
§ Signilicantly different from lung cancer (P < 0.05) 
f Significantly different frolll esophageal cancer (P < 0,05) 
Lung Esophageal 
cancer cancer 
(n=22) (n=35) 
66 (45-83) 63 (32-79) 
15 M; 7 F 28 M; 7 F 
76.6 ± 3.1 75.5 ± 1.8 
26.0 ± 1.0 24.5 ± 0.5 
3.8 ± 1.71 4.9 ± O.S=!: 
4.8 ± 2.01 5.7 ± 0.91 
8.1 ± 2.6 15.4 ± 2.4#§1 
7.9 ± 1.61 7.8 ± 2.2* 
n=2 (9.5%) n=3 (8.6%) 
C-reactive protein (CRP) was measured in plasma of cancer patients using a 
standard assay based on the principle of imIllUllological agglutination (Boehringer 
Mauuheim GmbH, Mannhei1l1, Germany). 129 
Statistical al1(1(l'sis 
Results are expressed as meau ± SEM tUlless odtenvise stated. Differences between 
dle four groups were assessed using one-way analysis of variance, followed by the post-
hoc least-significant difference methoo. Differences between two gronps were assessed 
using the Student's t-test, and Pearson's correlation coefficients were calculated between 
fatty acid concentrations aud odler factors. For statistical analyses on CRP concentratiol1s, 
analysis of variance including IIllnor type as a covariate lVas llsed and log-transfomration 
was applied because of skewed distribution. An inflarmnatOlY response lVas asslUlled to be 
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present when CRP > 10 mg/L,210 CRP levels were not measured in healtllY subjects, since 
tlley were assmlled to be nonnal in this group « 10 mg/L). 3 Statistical analyses were 
perlbnned by SPSS for Windows 6.1.3 (SPSS Inc., Chicago). Differences were considered 
significant when P <; O. OS. 
Table 4.2 
Fatty acid composition of plasma phospholipids (PL) in healthy subjects and in cancer 
patients. Figures arc expressed as weight percentage oftolal llL. a,b 
Fatty acids Healthy Pancreatic Lung 
in PL subjects cancer cancer 
(n=45) (n=15) (n=22) 
16:0 29.1 ± 0.2 30.4 ± 0.5 I 30.1 ± 0.5 + 
18:0 14.8 ± 0.2 14.3 ± 0.5 15.0 ± 0.4 
18:1' 10.6 ± 0.2 12.0 ± 0.6 II 10.8 ± 0.4 
18:211·6 24.7 ± 0.5 22.3 ± 0.9 §! 24.6 ± 0.8 Nt 
20:3n-6 3.2 ± 0.1 3.0 ± 0.3 3.4 ± 0.2 
20:411-6 11.2 ± 0.4 12.3 ± 0.9 § 10.5 ± 0.7 
20:5n-3 1.2 ± 0.1 0.7 ± 0.1 tl 0.9 ± 0.1 t 
22:5n-3 1.1 ± 0.1 0.9 ± 0.1 tl 1.0 ± 0.1 
22:6n-3 4.1 ± 0.2 4.2 ± 0.4 3.9 ± 0.4 
Indices: 
total n-3 6.5 ± 0.4 5.7 ± 0.5 5.7 ± 0.5 
total n-6 39.0 ± 0.5 37.6 ± 0.5 38.5 ± 0.5 
a Mean ± SEM 
b Statistical differences arc assessed by one-way ANOVA with post-hoc LSD method 
c 18:1 refers to the sum of 18:10-7 and 18:10-9 
t Significantly different from healthy subjects (P < 0.05) 
/I Significantly different fcom pancreatic cancer (P < 0,05) 
t Significantly different from lung cancer (P < 0.05) 
f Significantly different from esophageal cancer (P < 0.05) 
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Esophageal 
cancer 
(n=35) 
30.2 ± 0.4 I 
14.4 ± 0.3 
10.8 ± 0.3 
21.8 ± 0.6 II 
3.5 ± 0.2 
11.9 ± 0.4 
1.3 ± 0.2 
1.1 ± 0.1 
5.0 ± 0.2 II 
7.5 ± 0.4 §# 
37.2 ± 0.5 t 
Plasma fatty acid composition ill cancer 
Results 
Baseline cliaracteristics 
Characteristics of the healthy subjects and cancer patients are slllnmarized in Table 
4.1. No differences in age were obselved between any of the groups. Body weight was 
significantly reduced in pancreatic cancer patients when compared with all other groups. 
Mean weight loss in the previous six montiLs was significantly different between all patient 
groups and healtlw subjects, and mnged fium 4.8±2.0% in itmg cancer to 1O.l±1.8% in 
pancreatic cancer. Alcohol use was significantly higher in esophageal cancer than in otiler 
groups, and patients witil esophageal and lung cancer smoked significantly more cigarettes 
per day tltan healthy subjects. None of the patients had insulin·dependent diabetes, but 
non·insulin-dependent diabetes mellitus (NIDDM) was observed in 40 % of tile pancreatic 
cancer patients which was significantly more tltan in the other patient groups. Plasllta futty 
acid composition of tile dift"rent patient groups is presented in Tables 4.2 and 4.3. Fatty 
acid ratios and de saturation indices are reported in Table 4.4. 
Plasma fOlly acid concellfrations 
Pancreatic cancer: Compared to healtllY subjects, patients Witll pancreatic cancer 
showed considerable reductions in total n·3 tatty acid concentrations in plasnta PLs as well 
as CBs (Tables 4.2 and 4.3), but this reduction only reached statistical significance in 
plasllta CBs (P < 0.05). The fatty acids 20:5n·3 and 22:5n·3 showed significant 
reductiotLs bOtil in PLs and CBs in pancreatic cancer (P < 0.05), as did 18:3n·3, 18:2n·6, 
18:3n·6 and totaln·6 tatty acids in CBs (P < 0.05). Most saturated and monOlmsaturated 
fatty acids were higher in pancreatic cancer patients tllan in healthy subjects. The ratio of 
total polYlUlsaturated fdtty acids to total satmated futty acids (PIS ratio) was reduced in 
pancreatic cancer (Table 4.4; P < 0.05), whereas no significant difference in n·3/n·6 ratio 
was detected between patients and controls. The /';9· and f.,S·desatmation indices in PLs 
were elevated in pancreatic cancer (P < 0.05). Pancreatic cancer patients wi til NIDDM 
showed higher concentrations of 20:5n·3, 22:5n·3, 22:6n·3 as well as totaln·3 futty acids 
than patients without diabetes, both in plasma PLs and CBs (Table 4.5; P < 0.05). Only 
l8:3n·3 ill plasma CBs did not differ between tile two groups. 
L/il/g cancel': Although levels of n·3 fatty acid concentratiot1S in plasma PLs and 
CBs tended to be reduced in llUlg cancer, these reductions failed to reacll statistical 
significance (Tables 4.2 and 4.3). Tile observed l~ductiot" in totaln·3 futty acids in PLs 
aud CBs were not statistically significant, nor were Ole chauges in 20:5n·3 and 22:6n·3. 
18:3n·3 was significantly reduced in plasnta CBs (P < 0.05), whereas 16:0 and 18:0 were 
significantly elevated in plasma PLs and CBs (P < 0.05). No significant differences in 
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Table 4.3 
Fatty acid composition of plasma cholesteryl esters (CE) in healthy subjects and in 
cancer patients. Figures are expressed as weight percentage oftolal CE.3 ,b 
Fatty acids Healthy Pancreatic Lung Esophageal 
inGE subjects cancer cancer cancer 
(n=45) (n=15) (n=22) (n=35) 
16:0 11.8 ± 0.2 13.4 ± 0.4 !tl 11.5 ± 0.3 12.3 ± 0.3 §# 
16:1n·7 2.8 ± 0.2 3.1 ± 0.2 2.6 ± 0.3 2.8 ± 0.3 
18:0 1.6 ± 0.0 2.2 ± 0.3 t! 2.1 ± 0.1 ! 1.9 ± 0.1 
18:1' 18.9 ± 0.4 21.3 ± 0.8 II 19.0 ± 0.6 20.4 ± 0.5 ! 
18:2n·6 54.6 ± 0.8 49.6 ± 1.1 It 54.9 ± 1.1 51.5 ± 1.1 I! 
18:3n·6 0.8 ± 0.1 0.5 ± 0.1 tl 0.8 ± 0.1 0.8 ± 0.1 
20:3n·6 0.7 ± 0.0 0.9 ± 0.1 ! 0.8 ± 0.1 0.9 ± O.P 
20:4n·6 6.9 ± 0.3 7.7 ± 0.8 6.6 ± 0.5 7.3 ± 0.4 
18:3n·3 0.5 ± 0.0 0.3 ± 0.0 §tl 0.4 ± 0.0 ! 0.4 ± 0.0 ! 
20:5n·3 1.0 ± 0.1 0.5 ± 0.1 t! 0.8 ± 0.1 1.1 ± 0.1 
22:6n·3 0.6 ± 0.0 0.6 ± 0.1 0.6 ± 0.1 0.7 ± 0.1 
Indices: 
total n·3 2.0 ± 0.1 1.3 ± 0.1 I! 1.7 ± 0.2 2.2 ± 0.2 
tolal n·6 63.0 ± 0.7 58.7 ± 1.1 II 63.1 ± 0.9 60.5 ± 0.9 II 
a Mean ± SEM 
t> Statistical differences are assessed by one-way ANOVA with post-hoc LSD method 
c 18:1 refers 10 the sumof18:1n-7 and 18:10-9 
* SigniHcanUy different from healthy subjects (P < 0.05) 
1/ Significantly different from pancreatic cancer (P < 0.05) 
§ Significantly different from lung cancer (P < 0.05) 
t Significantly different from esophageal cancer (P < 0.05) 
fatty acid ratios or desaturation indices were detected between llUlg cancer patients and 
healdlY subjects, except for a 6% reduction in PIS ratio (Table 4.4; P < 0.05). 
Esophageal cancer: Plasma n-3 tatty acid concentrations in PLs and CBs in 
esophageal cancer showed a tendency for higher values than in healthy subjects, although 
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Table 4.4 
Desaturation indexes in plasma phospholipids in healthy subjects and in cancer patients") 
Index Healthy Pancreatic Lung Esophageal 
subjects cancer cancer 
(n=45) (n=15) (n=22) 
PIS ratio' 1.0 ± 0.0 1.0 ± 0.0 j 1.0 ± 0.0 ! 
n-3/n-6 ratio 0.2 ± 0.0 0.2 ± 0.0 0.1 ± 0.0 
20:4n-6/18:2n-6 0.5 ± 0.0 0.6 ± 0.1 ! 0.5 ± 0.0 
L19-desaturation index 
, 0.7 ± 0.0 0.9 ± 0.1 ! 0.7 ± 0.0 
L16-desaturation indexe 0.6 ± 0.0 0.7 ± 0.1 0.6 ± 0.1 
L15-desaturation index r 0.4 ± 0.0 0.5 ± 0.1 §I 0.4 ± 0.0 
"Mean ± SEM 
b Statistical differences are assessed by one-way ANOVA with post-hoc LSD method) 
C PIS ralio; ratio tolal polyunsaturated fatly acids 1 tolal saturated fatly aeids 
d .6.9-desaturation index: 18:1/18:0 
c .6.6-desaturation index: [(20:4n-6 + 20:3n-6 + 18:3n-6) 118:2n-6] 
f .6.5-desaturation index: [20:4n-6 I (20:3n-6 + 18:2n-6 + 18:3n-6)J 
* Significantly different from healthy subjects (I' < 0.05) 
H Significantly different from pancreatic cancer (I' < 0.05) 
§ Significantly different from lung cancer (P < O.OS) 
f Signific11fltly different from esophageal cancer (P < 0.05) 
cancer 
(n=35) 
1.0 ± 0.0 I 
0.2 ± 0.0 §ff 
0.6 ± 0.0 II 
0.8 ± 0.0 
0.7 ± 0.0 II 
0.5 ± 0.0 §j 
the difference did not reach statistical significance (Tables 4.2 and 4.3). The slight increase 
in n-3 fatty acid levels was mainly dIe result of elevated concentrations of 22:6n-3, 
especially in plasma PLs. As in the other patients groups, 18:3n-3 showed a significant 
reduction in plasma CBs (P < 0.05). Totaln-6 fatty acid concentrati011S were significantly 
reduced in both plasma PLs and CBs (P < 0.05). The L16- and L15-desaturation indices 
were elevated by 23 % and 20%, respectively (Table 4.4; P < 0.05). 
Relation witll weight loss 
In PLs and CBs of lung cancer patients widl weight loss, concentrations of 20:5n-3 
and total n-3 futty acids were significantly lower dum those patients without weight loss 
(Table 4.6; P < 0.05). In esophageal cancer, the n-3 futty acid content was not different 
between weight-losing and weight-stable patients. The efrect of weight loss could not be 
assessed in pancreatic cancer since all patients of this tmnor type had lost weight in dIe 
previous six months. 
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Table 4.5 
0-3 Patty acids in plasma phospholipids (PL) and cholesteryl esters (eE) in pancreatic canc 
patients with and without non-insulin dependent diabetes mellitus (NIDDM). 
Figures arc expressed as weight percentage of total PL and cE,",b,e 
Fraction Fatty acid No NIDDM With NIDDM P·value 
(n0 9) (noS) 
Plasma PL 20:5n·3 0.5 ± 0.1 1.0 ± 0.1 0.001 
22:5n·3 0.8 ± 0.1 1.2 ± 0.1 0.002 
22:6n·3 3.5 ± 0.2 6.0 ± 0.5 0.000 
total n·3 4.8 ± 0.3 8.2 ± 0.5 0.000 
Plasma CE 18:3n·3 0.3 ± 0.3 0.2 ± 0.0 0.307 
20:5n·3 0.4 ± 0.1 0.8 ± 0.1 0.003 
22:6n·3 0.5 ± 0.1 0.8 ± 0.1 0.012 
total n·3 1.1 ± 0.1 1.8 ± 0.2 0.004 
a Mean ± SEM 
b Statistical differences are assessed by the Student's I-test 
C Presence or absence of DM unknown in one patient 
Relation lVitil inflammation 
Plasma CRP concentrations in pancreatic cancer were 20 (1 . 385) mg/L (median 
and range), in IlUlg cancer 21 (0 - 205) mg/L, and in esophageal cancer 5 (0 - 214) mg/L. 
Plasma CRP concentratiolL' were higher than 10 mg/L in 14 hmg cancer patients (63.6%), 
in 9 esophageal cancer patients (25.7%) and in 10 pancreatic cancer patients (66.7%). In 
patients widl IlUlg and pancreatic cancer, plasma CRP concentratiolL' were significantly 
higher than in patients witll esophageal cancer (P < 0.05). After correction for ttunor 
type, patients with CRP concentrations higher than 10 mg/L showed significantly reduced 
levels of total n·3 fatty acids (P = 0.04) and 22:5n·3 (P = 0.02) in PLs, and of 18:3n·3 in 
CBs (P = 0.003), when compared with patients with CRP concentrations < 10 mg/L. 
Total n·3 fdtty acid concenO'atiml' also tended to be reduced in plasma CBs of patients 
Witll CRP > 10 mg/L, although this difference did not reacb statistical significance (P = 
0.06). The PIS ratio and tlle n·3/n·6 ratio were also lower in patients witll CRP values 
> 10 mg/L (P = 0.02 and P = 0.07, respectively). 
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Table 4.6 
n-3 Patty acids in plasma phospholipids (PL) and cholcsteryl esters 
(CE) in weight-losing and weight-stable lung cancer patients. 
Figures are expressed as weight percentage of total PL and en,s,to.c,d 
Fraclion Fatly acid Weight-losing Weight-stable 
(n=10) (n=ll) 
Plasma PL 20:5n-3 0.6 ± 0.1 1.1 ± 0.1 
22:5n-3 1.0 ± 0.1 1.0 ± 0.1 
22:6n-3 3.2 ± 0.3 4.4 ± 0.7 
tolal n-3 4.8 ± 0.4 6.5 ± 0.8 
Plasma CE 18:3n-3 0.3 ± 0.1 0.4 ± 0.1 
20:5n-3 0.5 ± 0.1 1.0 ± 0.2 
22:6n-3 0.6 ± 0.1 0.7 ± 0.1 
total n-3 1.4 ± 0.1 2.1 ± 0.3 
a Weight-losing: when weight loss in previous six months> 5 % 
to Presence or absence of weight loss unknown in one patient 
c Mean ± SEM 
d Statistical differences are assessed by the Student's Hest 
Relation with other jactors 
p-yalue 
0.01 
0.17 
0.12 
0.06 
0.19 
0.02 
0.62 
0.03 
No significant correlatioll5 were detected between plasma n-3 fatty acid 
concentratioll5 and mctors such as body weight, BMI, alcohol intake, or smoking behavior. 
Discussion 
In the present study, we investigated whether plasma n-3 fatty acids were reduced 
in different types of cancer. Resldts showed tllat differences in fatty acid pattern exist 
between difterent tlUnor types. In pancreatic cancer, plasma total n-3 fatty acids were 
significantly reduced in plasma CBs. In hlllg cancer, total n-3 fatty acids tended to be 
reduced as well, but these difterences failed to reach statistical significance. In esophageal 
cancer, the totaln-3 fatty acid concentrations in plasma PLs and CBs were comparable to 
or even higher tllan tllose in heaWlY subjects. Totaln-3 tatty acid levels were lower in IlUlg 
callc;er patients with weight loss than in those without weight loss, and pancreatic cancer 
patients WiOl diabetes showed significantly higher levels of total n-3 fatty acids thaUi dIOse 
patients Witllout diabetes. For all !tunor types combined, total n-3 fatty acid levels were 
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Table 4.7 
Fatty acids in plasma phospholipids (PL) and cholesteryl esters 
(CE) in cancer patients with and without an inflammatory response, as 
defined by C-reactive protein (eRP) concentrations> 10 mg/L. 
Figures are expressed as weight percentage of lola I PL and CE,",b 
Fraction Fatly acid CRP <;10 mglL CRP> 10 mglL 
(n=39) (n=33) 
Plasma PL 20:5n-3 1.2 ± 0.1 0.9 ± 0.1 
22:5n-3 1.1 ± 0.1 0.9 ± 0.1 
22:6n-3 4.8 ± 0.3 4.1 ± 0.3 
total n-3 7.1 ± 0.4 6.0 ± 0.4 
n-3/n-6 ratio 0.19 ± 0.01 0.16 ± 0.01 
PIS ratio' 1.00 ± 0.01 0.97 ± 0.01 
Plasma CE 18:3n-3 0.4 ± 0.0 0.3 ± 0.0 
20:5n-3 1.0 ± 0.1 0.7 ± 0.1 
22:6n-3 0.7 ± 0.1 0.6 ± 0.1 
total n-3 2.0 ± 0.2 1.6 ± 0.1 
3 Mean ± SEM 
b Statistical differences are assessed by analysis of variance with correction for tumor type 
C PIS ratio; ratio total polyunsaturated fatty acids I total saturated fatty acids 
P-valu. 
0.14 
0.02 
0.10 
0.04 
0.Q7 
0.02 
0.00 
0.14 
0.38 
0.06 
reduced in plasma PL and CB in patients with CRP plasma levels > 10 mg/L in 
comparison with patients Witll CRP levels < 10 mg/L. 
Fatty acids in plasma are present mainly as componenls of o·iacylglycerols (TAGs), 
CBs and PLs. We measured futty acid composition in plasma PLs and CBs, since tllese 
fractions are good indicators of tlle resultant of dietalY fut intake133 and probably also of 
metabolic demands, and the day-to-day variation of tlleir futty acid composition is smaller 
than in TAGs. lSI Furtl,ermore, fatty acid composition of the plasma PL fraction is closely 
related to that ofPLs in platelet and e,ytlu-ocyte membranes.28,169 
The patient groups included in the present study all represent cancer patients at risk 
to develop nutritional deficiencies. The lUlderlyil1g mechanism .. ,,> may, however, differ 
between tlle different groups, since contributing fuctors such as decreased food intake, 
reduced uptake and increased metabolic demands may differ between tumor types. The 
observed presence of an acute-phase respome has previously been reporled in patients with 
Illllg cancer209,232 and pancreatic cancer. 13,62,64 and appears to be related with plasma 
levels of n-3 tatty acids in tl,e present study. Previous studies ill non-cancer patients with 
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an evident inflammatOlY response reported tbat plasma n-3 futty acid levels were inversely 
correlated widl inflammation.61 ,163 Plasma n-3 futty acids were also significantly lower in 
patients widl rhelUnatoid ardlJ'itis dum in healtllY subjects.20B An inflammatOlY response in 
luunans is also attenuated by supplementation of n-3 fatty acids.26,33 These findings may 
indicate tbat reduced plasma n-3 futty acid levels in patients could contribute to an 
inflatmnatory state. Anodler possible explanation of reduced plasma n-3 fatty acid levels 
might be atl increased metabolic demand for n-3 fatty acids during inflammation, since n-3 
ami n-6 fdtty acids are dIe preclU'sor molecules tor inflammatOlY substances such as 
prostaglatKlins and Ieukotrienes. 
Yet another factor that might have contributed to the difference in futty acid pattern 
between 111l1g cancer patients and healthy subjects is smoking, since smoking has been 
reported to be inversely associated widl 22:6n-3 and 20:4n-6 in sel1lm PLs and CEs. 194 
However, we were not able to detect a significant correlation between smoking behavior 
and plasma n-3 fatty acids in the present study. 
Plasma n-3 fatty acid levels in pancreatic cancer were even lower tllan those in lung 
cancer. Patients Widl pancreatic cancer often suffer from intestinal malabsorption due to 
impaired excretion of pancreatic enzymes.225 Reduced abS011Jtion of polytll1satmated fdtty 
acids lnay subsequently result in essential fatty acid deficiency .112 The observation that n-3 
fatty acid levels in pancreatic cancer patients witll NIDDM are not reduced but are instead 
comparable to those in healthy subjects, is difficult to explain. Some studies in non-catlcer 
NIDDM patients reported reduced plasma levels of polytll1satmated futty acids in 
comparison to healthy subjects, 173, 176, 190 whereas one study in newly diagnosed NIDDM 
patients reported increased levels of elongated PolyulLsaturated fatty acids. 167 Furtiler 
studies are needed to identifY the Imderlying mechanism of tile relation between the 
presence of NIDDM and plaslna n-3 fatty acid levels in pancreatic cancer. 
In esophageal cancer, alcohol intake was higher than in tile other patient groups, 
which may explain tile elevated n-3 fatty acids plasma levels obselved in our study. 
Previous studies showed that plasma n-3 latty acid levels were higher in moderate drinkers 
thatl in nondrinkers. 195 and tlmt 22:6n-3 and 18:3n-3 were elevated in esoplmgeal tissue of 
rats administered ethanol, especially after tumor induction. 153 Furtllennore, weight loss 
may have played a role in tile changes in plasma lipid composition. In contrast witil lnany 
other tumor types, weight loss in esophageal cancer is thought to be the result of decreased 
food intake due to iJmbility to swallolY, mtller tlum of metabolic a1temtions.63 When 
energy intake is reduced, fatty acids are mobilized fi'om tile adipose tissue to meet energy 
reqltirements. Since tile rate of mobilization is higher for n-3 fatty acids thatl for saturated 
fatty acids,37,41,180 the proportion of n-3 futty acids in blood may increase. Thus, a study 
in obese women showed timt total n-3 fatty acids increased during weight reduction,39 and 
it may partly explain the relatively high concentrations of n-3 fatty acids in esophageal 
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cancer patients in the present study. However, this is not consistent Witll tlle fact that we 
did not detect any difterence inn-3 fatty acids between esophageal cancer patients with and 
without weight loss. 
We conclude that differences in plasma fatty acid composition exist between 
different tlUnor types. When compared Witll healthy subjects, totaln-3 futty acids in plasma 
CEs are significantly reduced in pancreatic cancer, tend to be reduced in plasma PLs and 
CBs in lung cancer, but are unchanged in esophageal cancer. FlU'Uler studies are warranted 
to clarifY Ule mechanisms llllderlying the observed differences in n-3 futty acid 
concentratiol1~ in cancer. This knowledge may contribute to better lUlderstanding of 
potential benefits of n-3 fulty acid supplementation in different types of cancer. 
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Chapter 5 
Abstract 
The aim of om study was to quantifY the incorporation of EPA and DHA in plasma 
lipids after oral administration of n-3 fatty acid eillyl esters, since little is known about the 
rate and pattern of incorporation into plasma lipid fractions. In addition, we aimed to 
obtain pilot information regarding EPA half-life, wltich is needed to establish a optimal 
dosing schedule. 
Five healtlly VOltUlteers ingested 2 x 8.5g n-3 fatty acid edryl esters per day for 7 
days, supplying 6.0g EPA and 5.3g DHA per day. The futty acid compositions of plasma 
phospholipids (PL), cholestelyl esters (CE) and triacylglycerols (TAG) were detenrtined 
during supplementation and during a washout period of 7 days. Half-lives of EPA and 
DHA were calculated. 
The proportion of EPA in PL showed a IS-fold increase after 7 days (P < 0.00]), 
while DHA showed a smalier increase (P < 0.01). In CE, EPA also increased (P < 
0.05), wllile DHA did not increase at all. Remarkably, incorporation of DHA into TAG 
was even higher than that of EPA. Half-life of EPA in PL ranged fi'om1.63 to 2.31 days 
(1.97 ± 0.15 days; mean ± SEM), whereas mean half-life of EPA in CE was 3.27 ± 0.56 
days. In dlree subjects, washout of EPA and DHA fi'om TAG seemed to follow a bi-
exponential pattem, wiill a shOlt half-life « I day) in ille utitial phase and a half-lire of 
several days in ille second phase. In conclusion, EPA ethyl esters are rapidly ulcorporated 
into plasma lipids, especially into PL. The relatively long half-life of EPA Ul plasma would 
pennit a dosing schedule with intelvals of;o:l2homs in supplementation studies. 
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Introduction 
Beneficial healtll effects of n-3 futty acids in fish oil have been described in several 
diseases. n-3 Fatty acids, especially eicosapentaenoic acid (20:5n-3; EPA) and 
docosahexaenoic acid (22:6n-3; DHA), are known to reduce plasma triacylglycerol (TAG) 
concentrations and may be beneficial in atherosclerosis and inflrumnatory diseases.52,197 
Since fish oil contains a mixtme of TAGs Witll various futty acids, tile 
concentration of n-3 fatty acids is relatively low. A higher concentration of EPA ruKI DHA 
Crul be achieved by using a supplement of lmesterified futty acids. Ingestion of free frltty 
acids (FFA), however, causes gastrointestinal complaints ruld lnay be toxic.23 
In contrast to FFA, no side effects are induced by n-3 futty acid etllyl esters (EE), 
and EE would t1lerelare be appropriate for supplementation of n-3 fatty acids. However, 
the abSOl]ltion of EPA and DHA as EE may be lower than of EPA and DHA as TAG or 
PPA, since previous studies reported tIlat the plasma incorporation of EPA- and DHA-EE 
was lower tilan the inCOl]loration of EPA- ruld DHA-TAG afier a single dose23,57,122 as 
well as during prolonged supplementation of n-3 fatty acids as EE.92 However, other 
studies did not find any differences in incorporation between supplements. 120, 156,177 The 
diversity of results nlaY partly be explained by the lact tIlat some studies measured EPA 
and DHA only in plasnla TAG and not in plasma phospholipids (PL) or cholestelyl esters 
(eE). Before using n-3 fatty acid EE in a clinical setting, it is important to determine tile 
actual level of incOlporation when using n-3 tatty acid EE. 
In addition, inlonnation about tile kinetics of EPA ruld DHA is needed to devise 
proper dosing schedules. However, only limited data ru'e available about the rate of 
incorporation and tile half-lire of EPA and DHA in blood, and the data available are 
mainly restricted to single dose supplementation. A few studies investigating the rate of 
incorporation of EPA afier a single dose of oral EPA-EE reported a lnaxitnal itlcorporation 
of EPA into TAG after 4-6 hours. 57,122,156 In studies Witll prolonged supplementation of 
n-3 fatty acid EE or TAG, EPA was laund to reach its maximurn level Withitl one 
week. 92,98 In conn'ast, tile rise itl DHA contitmed for several weeks.92,98 AltllOugh t1ils 
difference itl incOlporation between EPA and ORA may be due to a difference in EPA or 
ORA concentration in tile supplement, it may also be callsed by a difference in metabolism 
between EPA and ORA. Some studies llave shown that tile decrease in EPA after cessation 
of supplementation is much more rapid than that of DHA, 98 but no illfonnation is available 
abollt the half-life of EPA ruld DRA itl plasma lipidS. 
The first ainl of our study was to detemline tile level of itlcorporation of EPA and 
OHA in different plasma lipid /i'actions during supplementation \Vitll n-3 fulty acid EE. In 
addition, we attempted to quantity tlle half-lire of EPA and DHA in the different plasma 
lipid fractions. 
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Subjects and methods 
Subjects 
Study subjects were five healUlY volunteers, fom females and one male, of nonnal 
weight (body mass index 20·25) and ages between 23 and 30 years. None had a histOlY of 
gastrointestinal complaints or metabolic or other serious diseases. All subjects constuned a 
nonnal Dutch diet, containing not more than one meal of fish per week. From one week 
before start of the protocol lllltil tlle end of tlle study, subjects did not ingest any fish or 
fish products apart Ii-om the supplement. Tllis study was approved by tlle Medical BUlleal 
Committee of the Ulliversity Hospital Dijkzigt, Rotterdam. 
Rlperimemal protocol 
Duration oftlle study was 14 days: 7 days ofn·3 futty acid BE supplementation and 
7 days of washout. On day 0, subjects attended the outpatient department after an 
ovelnight fast. After 15nlin of rest, venous blood samples were taken in EDTA tubes. 
Hereafter, subjects consumed 8.5g of n·3 fatty acid EE as a fhlid (lncromega E2573; 
Croda Oleocheulicals, North Htunberside, England) twice daily Witil breakfust and supper 
respectively, for a period of 7 days. To improve the taste, the n·3 fatty acid EE were 
mixed Witil two drops of peppelmint oil just belore consumption. The supplement 
contained 35.0 w/w% EPA and 31.2 w/w% DHA according to infonnation from the 
supplier, resnlting in an intake of 6g EPA and 5.3g DHAld. The fatty acid composition of 
dIe suppiement is shown in Table 5.1. 
Table 5.1 
Contents of the relevant fally acids in the n-3 fatty acid ethyl ester supplement. 
Fally acid w/w% of lolal fally acids 
18:111·9 4.7 
18:211-6 
18:311-3 
20:311·6 
20:411·6 
20:411-3 
20:511·3 (EPA)' 
22:511-3 
22:611·3 (DHA)' 
Olher fally acids 
Q EPA: eicosapcntaenoic acid 
b DHA: docosahexacnoic acid 
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Plasma incorporation of EPA ethyl esters 
Subsequently, fasting blood samples were taken dm'ing supplementation in tlle 
moming of days 1,2, 3, 4 and 7. To detennine the rate of washout of EPA and DHA, 
blood sampling was continued on days 8, 9, 10, 11 and 14. Blood samples were placed in 
ice innnediately after sampling and centriflIged within 5min. Plasma was stored in -70'C 
lUlder nitrogenlmti1 analysis within 6 weeks. 
Fatty acid composition 
Plasma lipids were extracted using cWorofonnlmetlllll101 (2: I, by vol.; Merck; 
Dannstadt, Gennany) according to Folch et a1. 66 in the presence of butylated 
hydroxy toluene (Img/ml) as antioxidant. Prior to extraction, internal standards were added 
to be able to calculate absolute plasma concentrations of PL, CE and TAG (plU'ity 96 %, 
74% and 95%, respectively). Plasma lipids were separated into PL, TAG and CE by thin 
layer chromatography (silica plates; Merck, 5721) usiog hexane/diisopropylether/acetic 
acid (60:40:3, by vol.; Merck) as a developer. Fatty acids were converted into their 
metllyl ester using a lnixture of acetyl chloride (Merck) and methanol. 125 Fatty acid 
analyses were performed by Gas Liquid Chromatography (GLC; Carlo Erba HRGC 5160) 
using a Fill detector, a Chrompack CP-sil 88 COllUllll (length 50m, dillineter 0.25nlln), llil 
lU1coated methyl deactivated retention gap, helilIDl as a carrier gas and 'on cohunn' 
injection. Concentrations of individual fatty acids are presented as mole per 100 mole and 
not as absolute values, because of the statistically significant decreases in total plasma PL, 
CE and TAG concentrations. 
Biocliemical ana()'ses 
Plasma TAG concentrations were measlU'ed on day 0, 2, 7 and 11 using a siandard 
enzymatic assay fi'Om Boehringer-Mannheim (no. 917; Mannheim, Gennany). Plasma 
FFA concentrations were measured on day 0, 2, 7 llild II using an enzymatic colorimetric 
metllod (NEFA C test kit; Wako Chemicals, Neuss, Germany). Total plasma PL and CE 
were detennrned on all days by adding up tlle GLC peak areas of all fatty acids for tlle 
fraction concerned. 
CalclIlation of EPA and DBA lialf-life 
The Scientist"' software package (MicroMath Scientific Software, Utah) was used 
for least squares fitting of the data during the washout period, using a mono-exponential 
and a bi-exponential model (powell, (970): 
Mono,exponential model: 
Concentration = a*exp«-b)*time) 
Halflire = O.693/b 
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Bi-exponential model: 
Concentration ~ al *exp«-bI)*time) + a2*exp« -b2)*time) 
Half-lire 1 ~ 0.693/bI 
Half-lire 2 ~ 0.693/b2 
The Model Selection Criterion (MSC) was defined by the fOllllula: 
MSC 0 In 1-1 .11>.. t (w, (yOb'l'YObS)'j n n l: w, (yob'l-Ycal,)' io l 
where w; are the weights applied to tile poinls, y,>; is the observed value ofY, y", is the 
calculated value of Y and n is the lllullber of data points. 
The MSC attempts to represent the 'information content' ofa dala set, and indicates 
whether tile model is suitable for tile data or not. To calculate EPA and DHA half-lire, the 
model Witll tile largest MSC is in principle tile best model for the given data, and was used 
for data analysis. A MSC<0.5 was considered to be inadequate to give a good fit of the 
data. When one of tile calculated parameter values was identical to the upper or lower 
limits plllposely set as model cOl"traints, data were cOllsidered invalid and were excluded 
fi'om statistical analyses. 
Statistical al/a()'sis 
Based on an estinrated mean difference of 3 molllOO mol, a standard deviation of 
1.4 moillOO mol and use of tile paired t-tests, power of tile study was 0.94. Results are 
expressed as mean ± SEM. Changes in plasma lipid concentrations were tested by tile 
Student paired t-test, and in tile figures by tile Proc Mixed proce<1111'e for repeated 
measmes of tile SAS statistical software package. P-values less than 0.05 were cOl1sidered 
to be significant. 
Results 
n-3 Fatty acid EE supplementation was well tolerated by all subjects. However, 
when belching occurred, a fishy smell or taste was noted. All subjects completed tile 
study, but in one subject the blood sample of day 4 cO\~d not be taken. Dming 
supplementation, concentratiOl" of individual plasnra lipid fractions showed moderate to 
substantial changes (Table 5.2). Plasma TAG concentrations decreased significantly during 
supplementation (days 2 and 7; p < 0.05), retmuing to near baseline values afier 4 days 
of wash out (day 11). Plasma fi'ee fatty acid (FFA) concentrations also decreased 
significantly within 2 days of supplementation (P ~ 0.01) and remained low during 
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supplementation, aWlOugh the difference from baseline after 7 days failed to reach 
statistical significance (P ~ 0.07). Both plasma PL and CE concentrations showed a 
significant decrease dming n-3 fatty acid EE supplementation. 
Supplementation ofn-3 futty acid EE for one week resulted iu considerable changes 
ill plasma fulty acid comllOsition. In plasma PL, a highly significant iucrease of EPA 
(20:5n-3) was observed, approachiug a plateau level after approximately 4 days (Figme 
5.1). During washout, the EPA concentration decreased rapidly, WiOl an ahnost complete 
retmn to baseline values after 7 days of washout. A significant increase was also fOlllld for 
DHA (22:6n-3) concentratiol1' in plasma PL, aWlOugh tIlis iucrease was much less 
pronOllllced tIlan tItat of EPA. Arachidonic acid (20:4n-6) also showed a slight increase, 
which reached significance only on days 2 and 3 when usiug the paired t-test. In conU'ast, 
levels of 18:2n-6, 18: In-9 and 20:3n-6 in plasnla PL decreased significantly dming 
snpplementation, and retmned to initial leveb by day 14. No significant changes in plasma 
PL were found for 22:5n-3. 
Table 5.2 
Plasma concentrations (mmollL) ofiolal phospholipids (PL), cholesteryl esters (CE), 
triacylglycerols (TAG) and free fatty acids (FFA) before (day 0), during (day 1-7) and 
after (day 8-14) supplementation offish oil ethyl esters. , 
Day PLb., CEb TAG FFA 
0 1.26 ± 0.09 2.29 ± 0.21 0.84 ± 0.15 0.29 ± 0.04 
1 1.21 ± 0.09 2.01 ± 0.13 
2 1.16 ± 0.08 1.85 ± 0.13 0.50 ± 0.13' 0.12 ± 0.02' 
3 1.10 ± 0.09 1.86 ± 0.16 
4 1.11 ± 0.11 1.75 ± 0.14 
7 1.15 ± 0.08 1.85 ± 0.11 0.51 ± 0.04' 0.14 ± 0.05 
8 1.19 ± 0.08 1.89 ± 0.10 
9 1.26 ± 0.08 1.95 ± 0.08 
10 1.25 ± 0.10 1.92 ± 0.09 
11 1.31 ± 0.09 1.98 ± 0.07 0.72 ± 0.09 0.27 ± 0.03 
14 1.29 ± 0.Q7 2.04 ± 0.06 
a Mean ± SEM; n=5. 
b SigniHeant decrease during supplementation (P < 0.05; repeated measures). 
C Signiftcant increase during washout period (P < 0.05; repeated measures). 
d Significantly different from day 0 (P < 0.05; paired I-test). 
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Figure 5.1 
TIle concentration of different ratty acids in plasma phospholipids (PL) during daily intake of 
0-3 fatty acid ethyl esters (17 g/d) and during the washout period (in mole percent of lotal fatty 
acids in the PL fraction), 
• P < 0.05 (repealed measurements analysis) 
.... P < 0.0001 (repeated measurements analysis) 
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In plasma cholestetyl esters (CE), changes in fuuy acid composition were less 
pronOlUlced !han in plasma PL (Figure 5.2). Incorporation of EPA into !lte CE fraction 
was less rapid !han in the PL fi'action, and the EPA concentration did not reach a plateau 
level witltitt 7 days. Subsequently, the decrease of EPA during washout was less rapid !han 
in PL. DHA incotporation into CE was minimal, while !lte proportion of 20:4n-6 
increased significanUy. A small and insignificant increase of 20:3n-6 and 22:5n-3 was 
fmUld. No cbanges were detected in the levels of 18:2n-6 and 18:ln-9 in plasma CE during 
supplementatiou. 
A completely different paUem of incorporation was observed for plasma TAG 
(Figure 5.3): here, DHA was incorporated to an even higher extent !han EPA, in contrast 
to Ute incOllloration into PL and CEo BoUt latly acids showed a rapid decrease during 
wasbouL EPA had completely retlll'ned to baseline on day 14, while DHA was still 
significantly increased by Utis time. While incorporation of 22:5n-3 into PL and CE was 
minimal, a fivefuld increase of 22:5n-3 was detected in TAG, reaching a plateau value 
within 2 days. This was followed by a rapid retlll1l to baseline values during washouL In 
addition, 20:4n-6 showed a significant increase on days 2 and 3 (paired Hesl), wbile 
20:3n-6 was signit1can!ly increased at day I. This was accompanied by a decrease in 
18:ln-9, whicb only reached significance on day 3 (paired Hesl). Again, no significant 
changes in the levels of 18:2n-6 in TAG were fmUld during !lte study. 
Plasma half-life of EPA could be calculated in all plasma lipid fractions, but 
calculation of half-life ofDHA was only possible in plasma TAG, due to Ule high scaUer 
of data in plasma PL and Ute small changes of DHA in plasma CE. Individual washout 
curves are shown in Figure 5.4. 
The washout of EPA from plasma PL was well fitted by a mOllo-exponential 
model, resulting in an EPA halflife ranging fi'om 1.63 to 2.3ldays (1.97 ± 0.15 days; 
Mean ± SEM) (Table 5.3). The higb MSC value showed Ulat !lte model used was suitable 
for !lte clata. In plasma CE, clata were also best fiued mono-exponentially, al!ltougb Ule 
MSC value was lower U,al, in PL due to the higher intra-individual scaUer. Halflife of 
EPA in CE could be calculated in 10m subjects altd ranged finm 1.63 to 4.08 days (3.27 ± 
0.56 days). 
The decrease of EPA in plasma TAG was initially liUed by dte mono-exponential 
model (Table 5.3). Half-life of EPA in TAG could be calculated in four subjects and 
raltged from 0.47 to 1.63 days (mean 1.12 days). However, in Utree of Utem, !lte MSC 
value showed alt increase when fitting the data with a bi-exponential model, whereas in Ute 
lour!lt subject, !lte use of a bi-exponential model was not possible. In Ute Un'ee subjects, 
!lte initiaillalf-lile of EPA ranged fi'om 0.11 to 0.77 days (0.41± 0.19 days), whereas llalf-
life in Ute second pllase was 1.29-4.17 days (2.92 ± 0.86). 
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TIle concentration of different fatty acids in plasma cholcstcryl esters (CE) during daily intake of 
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acids in the CE fraction) . 
• p < 0,05 (rcpeated measurements analysis) 
•• p < 0.0001 (repeated measurements analysis) 
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For the decrease of DHA in plasma TAG, comparable results were found (Table 
5.3). A half-life ranging from 0.89 to 2.57 days was fmUld with a mean of 1.63 days when 
using the mono-exponential model. Use of Ule bi~exponelltia1 model resulted in an increase 
of the MSC value. The initial half-lire ofDHA in plasma TAG ranged fi'om 0.18 to 0.38 
days, followed by a half-lite of 3.81-5.32 days in the second phase (4.75 ± 0.33 days). 
Discussion 
Our study demonstrates dlat n-3 fatty acid EE afe absorbed from dIe intestine, as 
was shown by the significant increase of EPA and DHA in different plasma lipid fractions 
during supplementation. In general, a relatively cOlL~istent pattern of incorporation and 
washout was shown in most lipid fractiom WWl small deviations between subjects. 
EPA was incorporated into PL and CE, as well as in TAG. In contrast, dIe DHA 
incorporation pattern was quite different: a velY low incorporation into CE, but a high 
inCOll'oration into TAG which was even higher dUUl that of EPA. Although not all data 
could be used for the calculation of plasma half-lives, this study provides pilot infonnation 
regarding washout of EPA and DHA from plasma. During washout, the decrease of EPA 
in PL and CE was found to be mono-exponential Witil mean halt'lives of 1.97 and 3.27 
days, respectively. In plasma TAG, however, the data of EPA and DHA were better fitted 
by a bi-exponential washout model, Witil a short initial half-lire of less tiWI I day, 
followed by a longer half-lite of several days. 
The incorporation of EPA into plasma lipids \VdS cOlLsiderably higher dUIIl the 
incorporation of DHA in mo· study. This finding is consistent with results fi'om otiler 
studies investigating the incOlporation of n-3 fatty acid TAG92,156 as well as studies in 
which EE were used,74,123,207 Only Blonk et al.,27 who used a supplement of 11-3 futty 
acid edIYI esters, did not find any difference in incorporation between EPA and DHA into 
plasma PL after 12 week.s of supplementation. In tilese studies, supplementation ranged 
from a single dose74 until one year of supplementation.t23 The pattern of incorporation of 
different fatty acids appeared to be independent of the different fish oil types and dosages. 
Sadou et al. investigated whedler the intramolecular structlll'e of n-3 futty acid TAG affects 
the incorporation of EPA and DHA.185 They fOlUld that DHA (mainly situated at the sn-2 
position) was mainly incOlporated into plasma TAG, while EPA (predOmllWltly situated at 
sn-1I3) was mainly incorporated into plasma pL.185 They concluded timt the difterence in 
incorporation was due to the intramolecular structme. However) our study shows that a 
supplement containing EE instead of TAG resulted in a similar plasma distribution, which 
would suggest timt the incOlporation pattern is the result of pmperties of EPA and DHA 
ratiler than of the position of tile fatty acid all tile glycerol backbone. 
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Table 5.3 
Half-lives of EPA and DHA (days) in different plasma lipid fractions, 
calculated by a mono-exponential and a bi-exponential model. 'Ibe higher the 
value of the Model Selection Criterion (MSC; an indicator for the suitability of 
the model), the heUer the model. 
Mono·exponential 
Subject half·life (MSC)' half·life 1 
EPA in PL' 1 2.02 (5.1) 
2 2.31 (3.9) 
3 1.63 (3.6) 
4 2.27 (3.8) 
5 1.65 (3.5) 
Mean 1.97 
SE 0.16 
EPA in CE' 1 
2 4.08 (1.9) 
3 3.59 (2.9) 
4 3.80 (4.7) 
5 1.63 (1.5) 
Mean 3.27 
SE 0.56 
EPA in TAG' 0.47 (3.6) 0.11 
2 1.05 (4.0) 
3 1.37 (27) 0.77 
4 1.06 (2.0) 0.33 
5 1.63 (1.5) 
Mean 1.12 0.41 
SE 0.19 0.19 
DHAinTAG' 0.89 (1.9) 0.35 
2 1.18 (2.0) 0.38 
3 2.57 (0.9) 0.35 
4 1.89 (0.9) 0.18 
5 
Mean 1.63 0.31 
SE 0.38 0.04 
Bi·exponential 
half·life 2 (MSC)' 
(5.4) 
4 (2.8) 
3 (3.6) 
3 
0.86 
5 (3.5) 
4 (4.4) 
5 (1.1) 
5 (2.2) 
5 
0 
• PL, phospholipids; CE, cholestel),1 esters; TAG, triacylglycerols; MSC, Model Selection Criterion, 
b No bi-exponential fit possible due to good fit of mono-exponential model. 
C No suitable fit due to high scaUer of data, 
d No suitable fit because parameter value was equal to estimated upper constraint. 
o No suitable fit due to negative value of half· life 2. 
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A more plausible explauation for the difterence in incorporation between EPA and 
DHA was given by Subbaiah et a1..207 These authors suggested that the difference is 
caused by U,e fuct dlat EPA and DHA afe competitors for U,e enzymatic transfer of fatty 
acids fi'om PL to CEo The affinity of the enzyme lecithin-cholesterol acyltransferase is 
higher for EPA than for DHA. Thus, U,e conversion of EPA fi'om PL to CE is higher 
compared to DHA. This would explain why, in our study, incOI]loration of EPA into CE is 
high, while U,e incorporation of DHA in CE is negligible. It would also explain why DRA 
incorporation into PL was more rapid than into CE, a finding that has also been described 
in oUler studies.29, 185,207 
When tile trar"fer of DHA fi'Om PL to CE is reduced, a relative acclUnulation of 
DHA in PL would be expected. Indeed, in am' study DHA in PL was still increasing after 
one week of supplementation. However, the increase of DRA in PL was less rapid than 
the increase of EPA. Tlris could be explained by a relatively higb clearance of DHA 
compared to EPA from the plasma towards the adipose tissue, since DRA has been 
suggested to be the preferred storage form of n-3 fatty acids. 113 
N-3 futty acid supplementation was also shown to induce changes in other fatty 
acids than EPA arId DHA in the present study. We observed a small increase in 20:4n·6 in 
plasma PL on day 2 arId 3, followed by a decrease in concentration. It is likely that Ule 
observed increase is the result of the small arnount of 20:4n-6 in dIe supplement. 
However, this increase does not correspond to other studies, which generally report a 
decrease in 20:4n·6 during n·3 fatty acid supplementation, 92,120,135,171,177 most likely as 
a consequence of competition between the n-3 and n-6 futty acids. Yet, when examining 
literatme data in detail, some of these studies show a temporary increase in 20:4n-6 during 
the first week of supplementation, 92,177,224 which is in accordance with our findings. This 
observation combined Widl the sigrrificant decrease of 18:2n·6 in PL indicates Ulat 
incorporation of EPA arId DHA into PL in U,e first days of supplementation mainly occurs 
at the expense of 18:2n-6 and not of20:4n·6. 
Not only was the incOl]lorationlevel of EPA higher than drat ofDHA, but also U,e 
incorporation rate. Similarly, the decline during washout was more rapid for EPA dIan for 
DHA. The same finding has also been described by oUlers98,135,136,207 who showed Urat 
DHA had not retumed to baseline values within 4 weeks of washoul. So fur, no 
infornrationlras been available about dIe washout in U,e separ'ate plasma lipid fractions. 111 
am study, the decrease of EPA in the PL arId CE fi'actiOlLS lVas mono-exponential, 
implicating ilrat EPA probably originates fi'om one pool, i.e. plasma PL. Unforllmately, it 
was not possible to calculate lralf-life ofDHA in PL and CE due to U,e high intraindividual 
scatter arId the slow rate of washout. 
As for plasma TAG, am results would indicate a bi-exponential washout of EPA as 
well as DHA. The slow decline in U,e second plrase of washout may be due to the release 
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ofn-3 fatty acids /i'om body stores. EPA and DHA are incorporated into TAG by the liver 
to be incorporated into VLDL and to re-enter the plasma pool. The half-lite in the second 
phase is longer tor DHA than tor EPA, which is consistent with the notion that DHA is tlle 
main storage form of the n-3 futty acids.1 13 
In SmlllDaIY, we conclude that n-3 fatty acids ethyl esters are sufficiently well 
incorporated into plasma lipids to allow tlle lise of n-3 futty acid ethyl esters in clinical 
practice. Our results suggest that the washout of EPA and DHA from plasma PL and CE is 
mono-exponential, but tlmt EPA and DHA washout from TAG may follow a bi-exponential 
pattern. Based on the relatively long Imll'lite of the n-3 fatty acids in plasma, we conclude 
tlmt ;1'pplementation Witll 6g of EPA in a fi'equency of once per 24 homs wOldd probably be 
",fficient to obtain a slIbstantial increase in plasnm EPA alld DHA levels. 
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Abstract 
Supplementation Witll fish oil may playa role in the prevention and treatment of 
cardiovascular diseases by l~ducing senUIl triacylglycerol (TAG) and fi'ee tatty acid (FFA) 
concentratioll5. AldlOngh dle mecbanism lllldedying dils effect has not yet been clarified, 
reduced lipolysis and/or increased lipid oxidation may playa role. The aim of the present 
stndy was to assess the effucts of short-term eicosapentaenoic acid-edlyl ester (EPA-EE) 
snpplementation on lipolysis and lipid oxidation in healtllY subjects. 
In sixteen heaWlY subjects (10M, 6F; age 40- 75y), whole-body lipolysis (using 
[I, I ,2,3 ,3-'H,jglycerol) and pabliltic acid release (using Il-"qpalmitic acid) were 
mea>1u'ed at baseline, and after 2 and 7 days of EPA-EE (6 g/d) or placebo (oleic acid-EE, 
OA-EE; 6 g/d) supplementation using a donble-blind, randomized study design. Palmitate 
oxidation was detennined by measming "CO, enrichment in expired breath. 
No significant differences in whole-body lipolysis, pabnitate oxidation, or pabnitic acid 
release were detected between dle gronps receiving EPA-EE and OA-EE supplementation for 
one week. It was remarkable, however, dlat bodl pabnitic acid release and pabrtitate 
oxidation showed substantial reductions in bodl treatment groups as compared Witll 
baseline values. 
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Introduction 
Epidemiological studies have suggested that cardiovascular disease 10,78, III, 149,202 
and non-insulin-dependent diabetes mellitus (NIDDM)67,165 are associated with elevated 
levels of triacylglycerol (TAG) andlor free futty acid (FFA) in blood, and dtat it lltay be 
beneficial to reduce plasllta lipid concentrations in subjects at risk.4 Since it ltas been 
shown that supplementation of fish oil reduces senUli TAGI,81,166,175 and FFA45 levels, 
fish oillltay playa role in the prevention and treatment of cardiovascular diseases42,138, 160 
and NIDDM,77 
The ntain cOl1stituents of fish oil ale eicosapentaenoic acid (EPA; 20:5n-3) and 
docosahexaenoic acid (DHA; 22:6n-3). Several studies showed dtat EPA, but not DHA, is 
responsible lor the TAG-lowering effect of fish oil,71,175,231 although other investigators 
reported that both EPA and DHA had a TAG-lowering etrect. 81 Despite extensive 
research, dlere is still much lUlcertainty about the mechanism by which n-3 fatty acids 
reduce plasllta lipid concentrations. The decrease in selUlll TAG concentrations appears to 
be caused by a reduction in hepatic TAG synthesis. 88,183 This reduction lltay in part be 
related to low substrate availability due to decreased plasllta FFA concentra-
tiollS. 45,89,109,182,198 
Two different mechanisms have been proposed to explain the reduction in plasllta 
FFA concentrations by n-3 fatty acids. Firstly, reduced peripheral lipolysiS ntay be 
involved, since EPA was shown to inhibit lipolysis ill vitm.213 Secondly, elthanced fatty 
acid (FA) oxidation may playa role, since mitochondrial andlor peroxisolltal p-oxidation 
appeared to increase during fish oil supplementation. I ,70,231 However, a study in rats 
showed a reduction ratller dtan an increase in whole-body fut oxidation widl fish oil, 
despite increased hepatic peroxisontal FA oxidation. 181 In view of these paradoxical 
findings, it relltains lUlclear whether reduced lipolysis or increased fut oxidation is the 
prevalent mechanism by which fish oil attenuates senun TAG concentrations. 
The aim of the present study was to assess the elfects of short-tenn EPA-ethyl ester 
(EPA-EE) supplementation on lipolysis and lipid oxidation in healthysubjects. 
Subjects and methods 
Subjects and study design 
Sixteen weight-stable, healthy subjects (10 M; 6 F) aged 40 - 75 Y were included in 
the study. The study was approved by dle Medical Etllics Committee of dle Erasmus 
University Medical Center Rotterdam, and written infonned consent was obtained Ii-om all 
subjects prior to stali of dle study. Exclusion criteria were: smgery in dle last two montllS, 
lUlderlying metabolic disease such as liver disease, diabetes, hyper- or hypodlYroidism, 
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hart failure or fever, treatment with anti-epileptic dntgs, corticosteroids or xanthine 
deviates, anorexia, extremely restrictive diets and alcohol conslUnption > 15 units per 
week. 
After a baseline measurement of whole-budy lipolysis and palmitate oxidation on 
day 0, subjects were randomized over two groups according to a double-blind study 
design. One group received a supplement of 6 grams of EPA-EE (pmity 96.8 %, 
EPA95EE; Pronova, Sandefjord, Norway) per day for one week, and tlle other group 
received 6 grams of oleic acid (OA)-EE (purity 79%, Ethyl Olivate; Croda Oleochemicals, 
North HlUuberside, England) as a control tor one week. Supplements were provided in 
0.5g capsules, to be taken as 3x2g Witll the main meals. On days 2 and 7, measurements of 
lipolysis and palmitate oxidation were repeated according to tlle same protocol as on day O. 
All participants filled in dietalY records Ii-Oln tOIll· days before tlle first measm-ement until 
tlle end of the study period. 
Measurelllellf of lipolytic rate alld CO, productioll 
On day 0, subjects attended Ole outpatient department between 8 and 9 a.m. after 
an overnight fast of approximately 12 hours. Fifteen minutes aller arrival, teflon catheters 
were inserted into Ole antecubital vein of one aIm and into tlle contralateral dorsal hand 
vein or foreanl1 vein of the other ann. Baseline blood and breath samples were taken, 
blood was centril\lged immediately al1(1 plasma was stored at -80'C Illider nitrogen lUltil 
allalysis. Aller baseline salllpling, infilSion of a pasteurized plaSllla protein solution (40 g 
protein!l, alblUllin ;>85 %; CLB, AmsterdaJll, The Netllerlands) containing [1,1,2,3,3-
'H5]glycerol (MassTrace, Woburn, USA) and 11-13C]pahllitic acid (MassTraee) was 
started using a calibrated syringe PlUllP (perfusor Seeura; B.BralUl, Melsungen, Gelmany). 
Glycerol was administered by primed-constallt infilsion with a priming dose of 1.2 
fUllollkg and an infusion rate of approxinlately 0.08 fUllollkg.min and pahnitic acid was 
given by a eonstallt infilsion rate of approxinlately 0.04 flmollkg.min. To prime the plasnla 
bicarbOllate pool, a bolus of NaH"COJ dissolved in saline (1.7 ~mollkg) was administered 
intravenously. The exact infilSion rates were detennined aftelWal"ds by measuring isotope 
enricillllent in tlle infusate. During isotope infilSion, CO, production was measured for 30 
minutes by indirect ealorilllehy using a ventilated hood system (DeltatracTM MBM-IOO, 
DATEXfItlStnlUlentarilllll Corp., Helsinki, Finland), using only data fi·om the last 20 
minutes for allalysis. RespiratOlY quotient (RQ) was calculated using CO, production and 
0, conslllnption. After 50, 60, 70, 80 alld 90 minutes of infilsion, arterialized venous 
blood salnples239 were taken for deternmlation of plasma ['H5jglycerol and [1-
"Cjpalmitate em·icbment. Blood samples were placed on ice immediately, and centrifilged 
alld stored at the end of the infilsion period. Breatll sanlples were taken to measure "CO, 
enrichment. Weight and height were measured. 
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Ana(ysis of blood samples 
Plasma [,H,]glycerol and [1-13C]palmitate enrichment were measnred as reported 
previously (Chapter 2). In brief, for measuring plasma ['H,]glycerol enrichment, plasma 
was deproteinized by subsequently adding and mixing water, CuSO. and Na,WO •. After 
centrifugation, the supernatant was applied to a mixed ionexchange colUlllll (AG50W-X8, 
AG l-X8, 200-400 mesh, 0.2 gram each; Biorad, Richmond, USA) and glycerol was 
converted to its derivative by MTBSTFA dW'ing a one-hour incubation at 60°C. For 
measming plasma [l-I3C]pahnitate enriclllnent, lipids were extracted from plasma using 
chlorofOlmlmethanol according to Folch et al.,66 plasma FFA were isolated by thin layer 
chromatography (silica plates; Merck, 5721) and converted to their derivatives by 
MTBSTFA (N-medlyl-N-(tert-butyhnedlylsilyl)-trifluoroacetamide; Pierce, Rockford, IL). 
Plasma enrichment of free ['H,]glycerol and [1-I3C]palmitic acid was analyzed on a 
Carlo Erba GC8000 gaschromatograph coupled to a Fisons MD800 mass spectrometer 
(Interscience BY, Breda, The Nedlerlands). Natural glycerol and I'H,]glycerol (fragments 
mJz 377 and 381) and natural pahnitic acid and [1-I3C]palmitic acid (fi'agments mJz 313 
and 314) were measmed by selected ion monitoring. Breath samples were analyzed on an 
isotope ratio mass spectrometer (ABCA; Europa Scientific, Yan Loenen InstnUllents, 
Leiden, The Netherlands). 
Senun TAG concentrations were meastu·ed using a standard enzymatic assay from 
Boehringer-Mannheirn (no. 917; Matmheinl, Gennany), FFA were detennined using an 
enzymatic colorimetric method (NEFA C test kit; Wako Chemicals, Neuss, Germany). 
Plasma glucose was measured by standard techniques, and plasma insulin was measured by 
radioimmunoassay (Biosource, Fleuros, Belgillln). 
Calculations 
Calculations of whole-body lipolysis (glycerol) and palmitic acid release were made 
according to Klein et al. ,116 using the equation described by Steele:205 
Rate of appearance (R,; fUnol/kg.min) = (IEJIE, - I) • F, where F is dIe isotope inlhsion 
rate (~mol/kg.lllill), IE; is the isotopic enriclllllent of the infusate (atom percent excess) and 
IE, is the isotopic enrichment (atom percent excess) in plasma during steady state 
conditiolL~. 
Pahnitate oxidation was calculated according to the following equation: 
Palmitate oxidation (funol/kg.min) = (JEc02/IE,) * Yco,{BW, where lEco, is the isotopic 
enrichment of dIe expired CO, (atom percent excess), VC02 is dIe CO, production 
(flmol/min) and BW is body weight (kg). 
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Table 6.1 
Characteristics of study participants," 
Body weight (kg) 
Body mass index (kglm') 
Age (yr)b 
Sex 
a Mean ± SD unless otherwise stated 
b Median (range) 
Statistical al/a(yses 
EPA group 
75 ± 11 
24 ± 3 
51 (40 - 65) 
4 M; 4 F 
OA group 
79 ± 17 
27 ± 5 
55 (48 - 75) 
6M; 2 F 
Data are expressed as mean ± SEM or as median (range) (as indicated). As R. of 
palmitate, R, of glycerol and palmitate oxidation showed a skewed distribution, log-
transfollned data were used for Ule statistical analyses. To analyze treabnent effects, the 
Proc Mixed procedtU'e lor repeated measures of U,e statistical software package of SAS 
(SAS Inc., Cary, N.C. USA) was used. Tllis procedure carl be used for longitudinal 
regression analysis in which observations are collected on Ule same subjects over time.137 
The independent variables in tl,e model were the treatment indicator variable, baseline 
measurement, time and interaction between time and treatment. Spearman's correlation 
coefficients were calculated. P-values less than 0.05 were considered statistically 
significant. 
Results 
Characteristics of subjects are slllnmarized in Table 6.1. No differences in body 
weight, body mass index, age or sex were obselved, altllough age tended to be lower in 
the group receiving EPA-EE than in the group receiving OA-EE. All subjects had nonnal 
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Figure 6.1 
Steady slalc conditions were obtained for 2HS-glyccroI, Be-palmitate and l3e02 
within 60 minutes during the turnover studies. 
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Table 6.2 
Dietary intake during the study.a.b.G 
Energy intake (kJ/d) on day before day 0 8513 
on day before day 2 8288 
on day before day 7 8013 
Mean E-intake (kJ/d) on 4 preceding days 8927 
during study 8919 
Mean E%-fat on 4 preceding days 36 
during study 34 
Mean E%-carbohydrate on 4 preceding days 47 
during study 51 
Mean E%-protein on 4 preceding days 17 
during study 16 
8 Mean ± SD 
b No significant differences between trcatment groups or between days 
C E %: energy percentage 
EPA OA 
± 2649 8422 ± 2894 
± 1626 8880 ± 2763 
± 2074 8435 ± 1928 
± 1694 9027 ± 2548 
± 1556 8956 ± 1474 
± 7 36 ± 6 
± 4 36 ± 5 
± 7 47 ± 4 
± 5 47 ± 5 
± 3 16 ± 4 
± 3 16 ± 3 
liver fimction tests. No significant differences were detected between the two treatment 
groups Witll regard to energy intake on tlle days preceding each measurement, nor in 
energy intake or energy percentages of fut, carbohydrate or protein (Table 6.2). During the 
measlll'ements, isotopic steady state (as shown in Figme 6.1) was reached after 
approximately 60 minutes in all subjects_ 
No significant differences in whole-bndy lipolysis, palmitic acid release, palmitate 
oxidation, or RQ were observed between the groups receiving EPA-EE and OA-EE (Table 
6_3). It WdS remarkable, however, tlrat bodl palmitic acid release and palmitate oxidation 
tended to decrease witll EPA-EE as well as WWI OA-EE supplementation. 
No significant dillerences in senuu TAG, FFA, glucose or insulin concentratiolL< 
were detected between tlle two treatment groups (Table 6.4), despite a substantial 
reduction in semm TAG concentrations dllling boUI EPA-EE and OA-EE supplementation 
when compared WWI baseline values. Baseline plasma FFA or TAG concentrations were 
not significantly correlated with whole-body lipolysis, pahnitic acid release or palmitate 
oxidation (P > 0.25). A significant correlation between tlle changes in whole-body 
lipolysis and senun TAG concentrations was only detected after two days of EPA-EE 
supplementation (R = -0.85, P < 0.01). 
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Table 6.3 
Whole-body lipolysis (as measured by 2H'i-glycerol). palmitate release (as measured by 
I3C-palmitate) and palmitate oxidation at baseline, and after two and seven days of eicosapentaenoic 
acid (EPA: n=8) or oleic acid (OA; n=8) ethyl ester supplementation (6 g/d)." 
day 0 day 2 day 7 
Whole-body lipolysis' EPA' 4.05 ± 0.46 3.19 ± 0.54 3.77 ± 0.44 
OA 5.39 ± 0.73 5.48 ± 0.65 5.57 ± 1.01 
Palmitate release' EPA' 2.92 ± 0.47 2.78 ± 0.21 2.62 ± 0.36 
OA 3.79 ± 0.18 2.89 ± 0.13 3.28 ± 0.10 
Palmitate oxidation' EPA' 1.40 ± 0.23 1.11 ± 0.11 1.17 ± 0.17 
OA 1.54 + 0.14 1.29 + 0.08 1.39 ± 0.07 
• Median ± SEM 
b Prox Mixed lor repeated measures analysis, comparison with baseline (see Methods) 
C PmoVkg.min 
d No significant differences between treatment groups (proe Mixed for repeated measures) 
Discussion 
P-valueb 
0.23 
0.52 
0.03 
0.002 
0.01 
0.002 
Despite extensive studies on the effects of fish oil on lipid metabolism, tile 
mechanism by which n-3 frltty acids reduce senun TAG concentrations has remained 
lUlresolved. Tn tile present stlKly we investigated the effects of EPA-EE on whole-body 
lipolysis and lipid oxidation in sixteen healthy snbjects using stable isotope tracer 
techniques. Results showed tlrat whole-body lipolysis, palmitic acid release and palmitate 
oxidation were not significantly difrerent between the groups receiving EPA-EE and OA-
EE. It was remarkable, however, tlrat botll palmitic acid release and palmitate oxidation 
tended to decrease ill both treatment groups. 
Tn a previous study in healthy subjects, fish oil reduced plasllIa FFA concentrations 
by approxilllately 40 percent within one day of supplementation.45 The observed effect 
was not explained by increased hepatic p-oxidation and/or ketogenesis alone, since blood 
concentrations of ketone bodies did not show any change. It was suggested tllat reduced 
lipolysis might be involved in the reduction of senun TAG levels by fish oil. 45 III vitro 
stlldies supported this suggestion by showing tlmt EPA inhibited lipolysis in incubated 
adipocytes. 170,213 In tile present stlldy, however, no reduction in whole-body lipolysis was 
detected during EPA-EE supplementation. This nray be related to tile observation tlrat ill 
vitro measmements of lipolysis are not directly related Witll ill vivo FFA metabolism. 126 
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Table 6.4 
Plasma concentrations of free fatty acids (FFA), triaeylglycerols (TAG), glucose 
and insuline at baseline, and after two and seven clays of EPA or oA ethyl ester 
supplementation (6 g/d; n = 8 + 8),a 
day 0 day 2 day 7 P_valueb 
FFA (~moI/L) EPA' 794 ± 92 645 ± 77 633 ± 83 0.14 
OA 893 ± 97 840 ± 95 880 ± 107 0.20 
TAG (mmo~L) EPA' 1.04 ± 0.15 0.81 ± 0.12 0.83 ± 0.11 0.0004 
OA 1.19 ± 0.25 0.99 ± 0.2 0.97 ± 0.15 0.06 
Glucose (mmollL) EPA' 4.40 ± 0.1 4.30 ± 0.1 4.40 ± 0.1 0.97 
OA 4.80 ± 0.2 4.60 ± 0.2 4.40 ± 0.2 0.26 
Insulin (mmo~L) EPA' 5.94 ± 0.57 7.11 ± 0.9 6.65 ± 0.84 0.35 
OA 8.44 ± 1.38 7.60 ± 1.30 8.46 ± 1.44 0.20 
a Mean ± SEM 
" Prox Mixed for repeated measures analysis, comparison with baseline (see Methods) 
C No significant dirferences between treatment groups (prac Mixed for repeated measures) 
Our rmdings suggest that factors other than reduced lipolysis are involved in the TAG 
reducing etrects of fish oiL 
Although increased rat oxidation has been asslUned to playa role in dIe effects of 
EPA on lipid metabolism, l4l in the present study, palmitale oxidation tended to be reduced 
instead of increased during EPA-EE supplementation, The generally made asslUnption drat 
fat oxidation is increased widl EPA appears to be based on the observation that 
peroxisomal Il-oxidation, as measlll'ed by enzyme activity ill vitro, was increased in 
hepatocytes from fish oil-fed rats.1,82,89 It is, however, questionable whedler an increase 
in peroxisomal Il-oxidation would substantially elthance whole-body lipid oxidation since 
peroxisomaill-oxidation in rat tissue ill vitro was shown to make up for only 14-46% of 
total fut oxidation, depending on dIe tissue and the type of fatty acid, 178 In adler words, 
peroxisomaill-oxidatioll is probably not representative for overall fatty acid oxidation, 
A study in fish oil-fed rats showed Urat total FA oxidation as measured by indirect 
calorimetry was reduced whereas whole-body energy expenditlU'e was not atrected by fish 
oil supplementation in tilese rats, indicating tlrat tile reduction in lipid oxidation was 
compensated for by increased carbohydrate utilization,18l As far as we know, no studies 
lrave been reported on the efrects of fish oil supplementation on whole-body lipid oxidation 
77 
Chapter 6 
in htunans. Results from Ule present study suggest Ulat the well-known reduction of senun 
TAG by EPA is not explained by increased lipid oxidation. 
In the present study, no significant cbanges in plasma FFA levels were detected 
with EPA-EE which is in contrast with an earlier study in healthy subjects supplying a 
comparable dosage of EPA as TAG instead of EE for one week. 45 This inconsistency Imy 
imply that the esterification of EPA Imy afiect Ule effects on lipid metabolism. A previous 
study in tlllnor-bearing rats showed dlat EPA-EE and EPA as ft'ee acid exerted different 
effects on weight loss. 100 It is possible Ulat Ule cbemical form and composition of the EPA 
supplement influences its physiological eflects. Clearly, Ulis issue would require furdler 
study. 
It was renlarkable that wbole-body lipolysis, palmitic acid release and palmitate 
oxidation tended to decrease in the OA-EE group as well. Since we were not able to 
identity tactors other Ulan tatty acid supplementation that might llave allected study 
outcome, the possibility cannot be excluded Ulat OA-EE supplementation aflected lipolysis 
as well. OA-EE migbt therefore not be suitable as a placebo supplement. 
We conclude that supplementation of EPA-EE does not afleet wbole-body lipolysis, 
pabnitate oxidation and palmitic acid release in comparison with OA-EE as a placebo 
supplement. 
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Abstract 
Recent reports suggested dlat weight loss in cachectic cancer patients Imy be 
inhibited by supplementation of dIe n-3 futty acid eicosapentaenoic acid (EPA; 20:5n-3), 
preswnably due to inhibition of lipolysis. The aim of Ule present double-blind randomized 
trial was to assess whether short-tenn oral EPA ethyl ester (EE) supplementation inhibits 
lipolysis and lipid oxidation in weight-losing cancer patients. 
Seventeen weight-losing cancer patients of different ttunor types and 16 healthy 
subjects were randomized to receive EPA-EE (6 g/d) or placebo (oleic acid (OA)-EE; 6 
g/d) for seven days. At baseline (day 0) and during supplementation (days 2 and 7), whole-
body lipolysis and palmitic acid release were measmed in Ule ovemight fusting state using 
[l,1,2,3,3-'Hs]glycerol and [l-lJC]palmitic acid. Pahnitate oxidation was determined by 
measm'ing BCO): enrichment in expired breath. 
No significant differences in whole-body lipolysis, palmitate oxidation, or palmitic acid 
release were detected between the groups receiving EPA-EE and OA-EE supplementation for 
one week. Al,o resting energy expenditme and plasma CRP concentratiom did not ditrer 
significantly between Ule two treatment groups. 
We conclude dlat EPA-EE do not significantly inhibit lipolysis or lipid oxidation in 
weight-losing cancer patieuts dlU'iug short-telm supplementation when using OA-EE as a 
placebo supplement. 
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Introduction 
Cachexia is a !Tequent problem in cancer patients which is cllaracterized by weight 
loss, impaired perfonnance and futigue. 75 ,127 In general, administration of nutritional 
support does not improve tlle condition,155 nor has any other adequate treatment become 
available. 127 The mechanisrns wlderlying cancer cachexia are IXlDrly lUlderstood,79 but it 
was suggested tlmt increased lipolysis nmy playa role,212,213 TIllS is supported by tile 
recent isolation of a lipid-mobilizing factor (LMF) !Tom mine of weight-losing cancer 
patients97,219 and by the increased whole-body lipolysis observed in cancer patients. 124, 192 
Recent studies showed that the lipid-mobilizing effect of LMF ill vitro was 
effectively aHenuated by the n-3 fatty acid eicosapentaenoic acid (EPA), due to inhibition 
of tlle adenylate cyclase activity. 170 Furtllennore, lmcontrolled clinical studies in patients 
with pancreatic cancer suggested t1mt EPA supplementation reversed weight loss for at 
least three months. 17,230 TIllS IVas attributed to down-regulation of the acute-phase 
resllDnse by EPA as suggested by the decrease in senun C-reactive protein (CRP) 
concentrations.229 
The aim of the present double blind, randomized study was to assess whether EPA 
etllyl esters (BE) inhibit lipolysis and lipid oxidation in weight-losing cancer patients 
during short~tellll supplementation. 
Subjects and methods 
Stlldy design 
In 17 weight-losing cancer patients, wllole-body lipolysis, palmitic acid release, 
palmitate oxidation, and resting energy expenditme (REE) were measured. Thereafter, 
patients were randomized according to a double-blind study design. Nine patients received 
a supplement of 6 grarns of EPA-EE (purity 96.8%, EPA95EE; Pronova, Sandefjord, 
Norway) per day for one week. The other patients received 6 grams of oleic acid (OA)-EE 
(purity 79%, Ethyl Olivate; Croda Oleochemicals, North Hlll'llberside, England) as a 
control for one week. The supplements, provided in O.5g capsules, were taken as 3x2g 
witll tile main meals. Measurements of lipolysis and lipid oxidation were repeated on days 
2 mid 7, according to the same protocol as on day O. Indirect calorimetry was only 
repeated on day 7. From lour days before the first meaS1U'ement until tlle end of the study 
period, all patients recorded t1leir dietary intake. The same protocol was performed in 16 
heaWlY subjects, randomized to receive EPA-EE or OA-EE. 
EUllcal pemllssion was granted by tlle Medical Etllics Connniuee of the Erasmus 
University Medical Center of RoUerdmll, and wriuen inlanned consent was obtained ft"om 
each subject. 
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Subjects 
Seventeen weight-losing cancer patients were included in the study. Weight loss 
was defIned as loss of body weight of more tilan 5 % in the previous 6 months. Patients 
treated WiOI chemotherapy or radiation tilerapy 2 weeks before start of the study, or 
elective surgelY in the last 2 months were excluded from the study, as well as patients with 
corticosteroid treatment, insulin-dependent diabetes mellitus, IllIcontrolled hyper- or 
hypothyroidism, edema or fever. 
The patient group receiving EPA-EE consisted of nine patients Witil the following 
tlUnor types: cancer of the upper gastrointestilJal tract (4), pancreatic cancer (I), rectal 
cancer (1), reml cancer (I), breast cancer (I) and non-small cell IlllIg cancer (I). All but 
one patient had metastatic disease and/or a locoregional relapse. Weight loss ranged from 
6.9 to IS.1 % in the preceding six monOls. The patient group receiving OA-EE consisted of 
eight patients with the following tlUllor types: esophageal cancer (I), pancreatic cancer (I), 
breast cancer (1), ceIvical cancer (1), carcinoid (1), adenocarcinonla of unknown prinJalY 
(I), non-small cell IlllIg cancer (I) and mesoOlelioma (I). Seven patients had metastatic 
disease and/or a locoregioml relapse, whereas tile patient with mesothelioma had direct 
invasion of tile right liver lobe. Weight loss ranged from 5.3 to 17.1%. FIll·thermore, 
sixteen healthy subjects (10 M; 6 F) aged 40 - 75 Y (54 ± 10 y; mean ± SD) were included 
in the study as a reference. 
Measurements of Iipo()'tic rate and REE 
After an ovel1light fast of approximately 12 hOIO·S, subjects attended the outpatient 
department between 8 and 9 a.m. on Ole first day of Ole study period (day 0). Fifteen 
minutes after arrival, teflon catheters were inserted into the antecubital vein of one arru 
and into the contralateral dorsal hand vein or forearm vein of the other ann, Baseline 
blood and breath samples were taken, blood was centrinlged immediately and plaSlIJa was 
stored at -SO'C under nitrogen uutil alJalysis. After baseline sampling, innlSion of a 
pastemized plasma protein solution (40 g protein/I, albumin ;o:S5 %; CLB, Alllsterdanl, The 
NeOlerlands) containing [I-"C]palmitic acid (MassTrace, Woblml, USA) and [1,1,2,3,3-
'H,]glycerol (MassTr"ace) was started using a calibrated syringe pmnp (pernlSor Secma; 
B.Brallll, Melsnngen, Germany). Glycerol was administered by primed-constant infusion 
with a priming dose of 1.2 runollkg and an inftlsion rate of approxulJately O.OS 
flmoVkg.min and palmitic acid was given by a cOllStant ulfllsion rate of approximately 0.04 
rlmol/kg.min. To prune the plasma bicarbollate flool, NaH"CO, dissolved Ul saline was 
administered ullravenously (1.7 runol/kg). The exact innlSion rates were determined 
afterwards by measuring isotope enrichment in the infusate. 
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During isotope inl\lsion, resting energy expenditure (REE) was measw'ed for 30 
minutes by indirect calorimetlY using a ventilated hood system (DeltatracTM MBM-IOO, 
DATEX/Inslnunentarium Corp., Helsinki, Finland). REE and respiratOlY quotient (RQ) 
were calculated using the amowl! of 0, cou,wned and of CO, produced during dIe last 20 
minutes of the measurement. After 50, 60, 70, 80 and 90 minutes of infusion, arterialized 
venous blood samples239 were taken for detennination of plaslna ['H,]glycerol and [1-
\3C]pahnitate eurichment. Blood samples were placed on ice inunediately, cenu'ilhged and 
stored at the end of the infusion period. Breath samples were taken to measnre IlCO, 
enrichment. Weight and heigUt were measured. 
Ana(ysis of blood samples 
Plasma ['H,]glycerol and [1-IlC]pahnitate enricll1llent were measured as described 
in Chapter 2. In blief, lipids were extracted fi'om plasma using chlorofonn/methanol 
according to Folch et al.. 66 Plasma liee fatty acids were isolated by dlin layer 
chromatography (silica plates; Merck, 5721) and converted to their derivatives by N-
methyl-N -(tert -butyldimethylsily l)-trifluoroacetamide (MTBSTFA, Pierce, Omnilabo, 
Breda, The Netherlands). To isolate plasma glycerol, plasma was deproteinized by 
subsequently adding H20, CUS04 and Na,W04. After centrifugation, tlle supernatant was 
passed dlroUgU a mixed ionexchange cohunH (AG50W-X8, AGI-X8, 200-400 mesh, 0.2 g 
each; Biorad, Ricillnond, USA). Derivatives of glycerol were fanned during incubation 
with pyridine and MTBSTFA for one hour at 60'C. 
Plasma enrichments of fi'ee ['Hs]glycerol and [1)'C]pahnitic acid were analyzed on 
a Carlo Erba GC8000 gaschromatograph coupled to a Fisons MD800 mass spectrometer 
(Intersciellce BV, Breda, The Netherlands). Natural pahnitic acid and [1-IlC]pahnitic acid 
(fi'agments miz 313 and 314) and lLaturat glycerol and ['H,]glycerol (fi-agments miz 377 
and 381) were measured by selected ion monitoring. Breath samples were analyzed on an 
isotope ratio mass spectrometer (ABCA; Europa Scientific, VaH Loenen Instnl1llents, 
Leiden, The Netherlands). 
CRP, albumin and prealbmnin were measured by standard techniques. 
CalClllations 
Calculations of pahnitate and glycerol tlmlover were made according to Klein et 
al.,116 using the equation described by Steele.205 
The rate of appeal""ce (R,) of pahnilate and glycerol was calculated as !llllows: 
R, ([HnoVkg.mio) ~ (lEi/IE, - I) * F, where F is the paIrnitate isotope infusion rate 
(}1lIlol/kg.min), IE. is dIe isotopic enrichment of the infusate (atom percent excess) and IE, 
is the isotopic enrichment (atom percent excess) in plasma during steady state conditions. 
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Palmitate oxidation was calculated according to the following equation: 
Palmitate oxidation (rllnoVkg.rnin) = (IEcovffip) * Vcm/BW, where ffic02 is the isotopic 
enrichment of the expired C02 (atom percent excess), Vcm is dIe C02 production 
(rtmoVrnin) aod BW is body weigbt (kg). 
Statistical aI/a lyses 
Data are expressed as mean ± SEM, Illlless stated otllelwise. To analyze treannent 
effects, tlle Proc Mixed procedure for repeated measures of the statistical software package 
of SAS (SAS Inc., Cary, N.C. USA) was used. This procedure can be used for 
longitudinal regression analysis in which ohselvations are collected on the same subjects 
over time.l37 The independent variables in the model were tlle treatment indicator 
variable, baseline measurement, time and interaction between time and treatment. In 
addition, energy intake on Ule day preceding the measuremenl was included as a covariate. 
Spearman's correlation coefficients were calculated. P-values less Uran 0.05 were 
considered statistically significaut. 
Table 7.1 
Characteristics of weight-losing cancer patienls,a 
EPA group 
(n=9) 
Age (y) 64 ± 3 
Sex 8 M; 1 F 
Weight (kg) 67 ± 3 
BMI (kglm') 22 ± 1 
Weight loss (%) 13 ± 
Albumin (gil) 39 ± 
Prealbumin (gil) 0.17 ± 0.Q1 
"Mean ± SEM 
Results 
OAgroup 
(n=8) 
64 ± 2 
5M; 3F 
63 ± 3 
22 ± 1 
10 ± 2 
40 ± 2 
0.18 ± 0.Q1 
Characteristics of the patients included in Ule study are slllllmarized in Table 7.1. 
No differences in age, sex, weight or biochemical parameters were observed between Ule 
treatment groups. In two patients receiving EPA-EE aut! two patients receiving OA-EE, 
Ule second measurement (i.e. after two days of supplementation) could not be performed 
due to physical weakness and no patent venous access, respectively. The meaSlllement on 
day 7 could not be perlbnned in one patient receiving EPA-EE because of surgery on 
day 4. 
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Table 7.2 
Mean dietary intake (kJ/d) before and during EPA or OA .supplementation 
(6 g/d), and dietary intake on the days preceding the measurements." 
Mean energy intake 
-At baseline (week 0) 
- During supplementation (week t) 
EPA group 
(n=9) 
8249 ± 942 
88t4 ± 1072 
Energy intake on the day preceding Ihe measurement on: 
-dayO 7701 ± 1113 
- day 2 
- day 7 
3 Mean ± SEM 
b P :5 0.05 compared to day 0 
9695 ± 1224b 
7847 ± 1160 
OA group 
(n=8) 
6130 ± 720 
6494 ± 594 
5157 ± 580 
6457 ± 819 
6033 ± 700 
Despite randomization, energy intake at baseline was higher in tile EPA-EE group 
tllan in tile OA-EE group. During supplementation, a temporary rise in dietaIY energy 
intake on tile day preceding the measurement on day 2 was observed in patients receiving 
EPA-EE (P < 0.01; Table 7.2), which had rettuned to baseline values on the day 
preceding the third meaSlll'ement on day 7. Compared to the OA-EE group, the increase in 
energy intake on day 2 in tile EPA-EE group did not reach statistical significance. Since it 
was previously reported tllat lipolysis is negatively associated with total daily energy 
intake,34,114 it was decided to include energy intake as a covariate in the statistical 
aIll\lyses. 
No significaIlt differences in whole-body lipolysis or palmitic acid release were 
observed between tile two treaonent groups (Figures 7.1 and 7.2, respectively). Although 
palmitate oxidation tended to decrease during EPA-EE supplementation, tile difference 
between the groups did not reach statistical significance (Figure 7.3). 
Plasma CRP concentrations did not change significantly with EPA-EE (37±15 and 
41±17 mg/L, respectively) or with OA-EE (37±14 aIld 31±8 mg/L, respectively). Also 
REE did not sllow aIly changes dming EPA-EE supplementation (93.7±2.9 kJ/kg.24h at 
baseline, aIld 94.6±3.7 kJ/kg.24h dming supplementation), or dming OA-EE 
supplementation (98.2±4.7 kJ/kg.24h at baseline, and during supplementation 100.0±3.9 
kJ/kg.24h). 
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Figure 7.1 
-lr--patients-OA 
__ palienls-EPA 
- - c- - . heallhy-OA 
- - .- - ·healthy-EPA 
Whole-body lipolysis as measured by the rate of appearance of 2Hs-labeled glycerol in 
plasma of weight-losing cancer patients during supplementation of EPA (black symbols) 
or OA (open symbols). In comparison, whole-body lipolysis during EPA or OA supplementation 
in healthy subjects is shown (clotted lines). Mean ± SEM. 
Discussion 
In tile present study, we investigated whether short-teon supplementation with 
EPA-EE inhibits lipolysis and lipid oxidation in weight-losing Callcer patients. Whole-body 
lipolysis, pahnitic acid release, palmitate oxidation and REE were measnred at baseline 
and during EPA-EE or OA-EE supplementation. Results revealed tirat EPA-EE 
supplementation does not afrect whole-body lipolysis, palmitic acid release, pahnitate 
oxidation or REE when compared with OA-EE as a placebo supplement. 
In our study, no cbange in REE was detected during EPA supplementation, which is in 
agreement with a previous study reporting stabilization of REE during EPA 
supplementation.230 Although we did not detect any significant changes in eRP 
concentrations, recent studies have reported significant reductions in CRP concentrations 
and stabilization of body weight after one month of supplementation of EPA as a free 
acid. 15,t7,229,230 It is possible tbat our study period of one week was too short to detect 
any significant clranges in lipolysis or plasma CRP levels. Findings by Dagnelie et al. 45 
suggested, however, tirat the effect of EPA on lipid metabolism would be rapid, since 
plasma FFA levels were significantly decreased witilin one day of fish oil supplementation. 
Furtilennore, a previous study showed that EPA-EE were rapidly incorporated into plasma 
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Figure 7.2 
Palmitate release of DC-labeled palmitic acid in plasma in weight-losing 
cancer patients during supplementation of EPA (black symbols) or OA (open symbols), 
In comparison, palmitate release during EPA or OA supplementation in healthy subjects is 
shown, Mean ± SUM. 
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13C-Palmitate oxidation rate in weight-losing cancer patients 
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during supplementation of EPA (black symbols) or OA (open symbols), 
In comparison, the rate of palmitate oxidation during EPA or OA supplementation in 
healthy subjects is shown (dotted lines), Mean ± SEM, 
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lipids, especially plasma phospholipids, witilin tom' days of supplementation (Chapter 5) 
which suggests that EPA may have rapid metabolic effects within the hmllan body. It is 
possible 
that the effects of EPA differ between EE and free acids, and also timt tile effects of EPA-
EE vruy runong tile different groups of eruleer patients. 
H is remarkable illat whole-body lipolysis, palmitic acid release and pahnitate 
oxidation tended to decrease in tile OA-EE group as well. Despite careful standardization 
of procedures on different study days, the possibility CaJlllOt be excluded that the observed 
changes were in fuct caused by fuctors such as the physical activity level or sleeping 
pattern. Else, it is possible that the use of OA-EE as a placebo supplement has affected 
study outcome, since OA-EE might Imye inhibited lipolysis as well. 
In tile present study with OA-EE as a placebo supplement, we concllKle timt 
lipolysis is not inhibited by EPA-EE dm'ing short-term supplementation, and timt inhibition 
of lipolysis is probably not the mechanism by which EPA aptJeru's to inhibit weight loss in 
weight-losing cancer patients. 17 
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Abstract 
Fish oil supplements of different compositions have heen used to study the effects 
of n-3 futty acid supplementation on senml lipid concentratiom. The aim of the present 
study was to assess whedler n-3 futty acids administered as triacylglycerols (TAG) or as 
ethyl esters (EE) have different effects on senun lipid concentrations on short teon, and 
whether dIe effect of eicosapentaenoic acid (EPA; 20:5n-3) alone is different from drat of a 
mixture of EPA and docosahexaenoic acid (DHA; 22:6n-3). 
Forty-nine healthy subjects were randomized over five groups to receive a 
supplement containing 6g EPA per day (l6g EPAIDHA-TAG/d; l2g EPAlDHA-EE/d; or 
6g EPA-EE/d), or a supplement containing oleic acid (OA; l6g OA-TAG/d; or 6g OA-
EE/d) for seven days. Extra butler was supplied to all groups wiOl supplement dosage < 16 
g/d. Ovemight-fusted blood samples were taken at baseline and after 2 and 7 days of 
supplementation to measme serum lipid concentrations. 
Senml TAG concentrations decreased significantly during EPA supplementation (P 
< 0.05). Both EPAIDHA-TAG and EPAIDHA-EE reduced totaVHDL-cholesterol ratios 
(P < 0.05 and P < 0.01, respectively). However, dlis was caused by a reduction in total 
cholesterol concentrations in the EPAIDHA-TAG group (P < 0.05), but by an increase in 
HDL-cholesterol in dIe EPA/DHA-EE group (P < 0.05). No effects of EPA-EE on senun 
total or HDL-cholesterol concentrations were observed. 
The effects of n-3 fatty acids on sennn lipid concenu'ations on short telID are 
affected both by dIe presence of DHA and by dIe type of esterification, which should he 
taken into acconnt in future studies using n-3 fatty acids, 
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Introduction 
Early epidemiological studies suggested timt fish consmnption and fish oil 
supplementation nmy be beneficial in the prevention and treatment of corOlmry heart 
disease (CHD).31,56,121 Since high plasnm lipid concentrations are considered as an 
important risk fuctor for CHD, 4 many studies have assessed the efrects of fish oil 
supplementation on blood cholesterol and triacylglycerol (TAG) concentrations. Results 
showed that postabsorptive7t,81, 109, 175 as well as postprandial226 senUll TAG 
concentmtions are markedly reduced by supplementation of eicosapentaenoic acid (EPA; 
20:5n-3) andlor docosahexaenoic acid (DHA; 22:6n-3). These efrects appear to be related 
with reduced TAG and VLDL syntilesis as well as increased catabolic rate of VLDL.42 
Results of studies on tlle effects of n-3 latty acids on senun cholesterol concentrations are 
inconsistent. 27, 7l, 94, 99, 224 
Less attention Ims been paid to the effects of fish oil supplementation on plasma 
free fatty acid (FFA) concentrations which may also play an important role in the 
development of cardiovascular disorders.67 Alterations in FFA concenu'ations nmy provide 
important information on the underlying mechanism of the effects of n-3 fatty acid 
supplementation on lipid metabolism and may act as an early indicator of clmnges in lipid 
metabolism. Tltis is supported by the linding in healthy subjects that the decrease in plasma 
FFA concentrations was complete witilin one day of fish oil supplementation, whereas 
senun TAG concentrations continued to decrease tUltil at least three days of 
supplementation.45 
Many investigators used native pmified fish oil as TAG as tlle somce of EPA 
and/or DHA. In recent years, however, an increasing I1lUllber of studies Imve used n-3 
fatty acid supplements consisting of ethyl esters (EE) instead of TAG,27,71,81,91,135 since 
this allows adminiso'ation of specitic futty acids without interlerence by other components. 
Fmthermore, the runOUllt of oil required to obtain clinical effects can be reduced recause 
of the high concenU'ations of specilic fatty acids in EE-supplements. Since the intesti1l31 
aosOl]Jtion and plasma lipid incorporation of EPA and DHA did not differ between EE and 
TAG supplements, 90,92,120,136,156 it is generally aSSlUlled timt tile physiological effects of 
n-3 fatty acid EE are similar to tilOse of n-3 fatty acid TAG. However, since routes of 
absorption may differ between n-J fatty acid EE and TAG,2,105,106,154 it remains possible 
that n-3 tatty acids administered as TAG or as EE Imve different effects on senun lipid 
concentrations. Indeed, two recent studies at our department showed tlmt EPA and DHA 
administered as TAG sigItificantly reduced plasma FFA,45 whereas EPA administered as 
EE did not (Chapter 6). 
The aim of the present study was to assess wheUler n-3 fatty acids administered as 
TAG or as EE Imve different efrects on senun TAG-, FFA and cholesterol concellU'ation); 
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on short term, and whetller tlle eftect of EPA alone is different fi'om that of a mixttu'e of 
EPA and DHA, 
Subjects and methods 
Subjects alld study design 
Fifty healthy subjects, 18 men and 32 women, with stable weight Witllout any 
gastrointestinal, metabolic or endocrine diseases were included in the study, Subjects witll 
plasma TAG concentratiollS > 3 nmlOl/L were excluded from participation, as were 
pregnant women, The study was approved by the Medical Etlrical Committee of the 
Erasmus University Medical Center Rotterdam, and written informed consent was obtained 
from all subjects prior to start of the study. After an overnight fast starting at 20.00h the 
preceding evening, subjects attended tlle outpatient department between 7.00 and 9.30h. 
Weight and height were recorded, and baseline blood samples were taken after at least ten 
minutes of rest. EDTA blood samples were centrifuged immediately at 15000 g for 10 
minutes at 4'C and blood samples for determination of senun TAG, cholesterol and HDL· 
cholesterol were cenu'ifilged in a sinrilar way after clotting. Senull TAG concentratiollS 
were detelmined witllin 4 hours after sampling, whereas EDTA plasma and senun for 
cholesterol determination was frozen at -80 "C tulder nitrogen until analysis within 4 
weeks. 
Subjects were randonrized over five groups to receive difterent EPA (approximately 
6 g/d) or OA (5 or 12 g/d) supplements. Extra butter was added to supplements containing 
< 16g fat to achieve a total fut amolmt of 16 grams per day in all groups. The following 
supplements were used: 
Group I: EPA plus DHA as TAG (EPAlDHA·TAG; Tliomar; Pronova, Lysaker, 
Nonvay); 
Group II: EPA plus DHA as EE (EPA/DHA-EE; Omacor; Pronova, Lysaker, 
NOlway); 
Group ill: Purified EPA administered as EE (EPA·EE; plll"ity 96.8%, EPA95EE; 
Pronova, Sandefjord, Norway); 
Group IV: OA·tatty acid·mixture administered as TAG (OA·TAG; Super Refined Olive 
Oil; SR3912; Croda Oleochemicals, East Yorkshire, England) (selving as a 
control tor EPAIDHA·TAG); 
Group V: OA·EE (pUlity 79%, Ethyl Olivate; Croda Oleochenricals, North 
Hmnherside, England) in group V (selving as a control for EPAlDHA·EE 
and EPA·EE). 
Details of the supplementation schedule are stunmarized in Table 8.1. 
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Table 8.1 
Detailed information about the fatty acid supplementation. 
Treatmenl Capsule F ally acid in 
group' size su~~lemenl (9!d (%b)) 
(g) OA EPA DHA Suppl. 
EPNDHA-TAG' 1.0 1.1 4.9 3.2 16 
(7%) (31%) (20%) 
EPNDHA-EE' 1.0 0 5.9 4.2 12 
(0%) (49%) (35%) 
EPA-EE' 0.5 0 5.8 0 6 
(0%) (97%) (0%) 
OA-TAG' none 9 12.6 0 0 16 
(79%) (0%) (0%) 
OA-EEh 0.5 4.7 0 0 6 
(79%) (0%) (0%) 
a EPA, cicosapcntaenoic acid (20:5n-3)j DUA, docosahexaenoic acid (22:6n-3); 
OAj oleic acid (18:1n-9); TAG, lriacylglyccrols; EE, ethyl esters 
b Weight I weight% 
C Triomar (pronova, Lysakcr, Norway) 
d Omacor (pronova, Lysaker, Norway) 
e EPA95EE (pranova, Sandefjonl, Norway) 
f SR3912 (Croda Oleochemicals, Eust Yorkshire, England) 
g Administration by pre-weighed bottles (SAg) instead of capsules 
h Ethyl Oliva(e (Croda Oleochemicals, North Humberside, England) 
Dosage (g1d) 
Buller Tolal fal 
0 16 
4 16 
10 16 
0 16 
10 16 
After two and seven days of supplementation, blood samples were taken after a 
similar overnight fast to measure plasma FFA and TAG concentratiolL'i, according to the 
same protocol as on day O. In addition, a questiollllaire regarding side effects was filled in 
by each subject. 
LaboratOl)l analyses 
Senull TAG, total cholesterol and HDL-cholesterol concentrations were measured 
using standard enzymatic colorimetric tests fi'oIll Boehringer-Mannheim GmbH, 
Mannheilll, Germany. Plasma FFA concentrations were determined using an enzymatic 
colorimetric method (NEFA C test kit; Wako Chemicals, Nellss, Gennany). 
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Statistical alla(l'ses 
Data are expressed as mean ± SEM. The Proc Mixed procedlll'e for repeated 
meaSlll'es of the statistical software package of SAS (SAS Inc., Cary, N.C. USA) was 
used, a procedme suitable for longitudinal regression analysis in which observations are 
collected 011 the same subjects over time. l37 Gender was included as a covariable due to 
differences between groups. For pairwise comparisons of treatment groups, the 
independent variables in Ole model were: Ole treatment indicator variable, baseline 
measurement, gender, time, and interaction hetween time and treatment. To compare data 
with Oleir baseline values within treatments, the indepeodent variables in Ole model were: a 
value to indicate Ule absence (day 0) or presence (day 2 aod 7) of supplementation, gender, 
and time. P-values less than 0.05 were considered statistically significant. 
Results 
Characteristics of healthy subjects included in Ole study are summarized in Table 
8.2. Fifty subjects were randomized over five groups, but one subject in Ole EPAlDHA-
TAG group wWIdrew fimn the study il,r personal reasons wiOlin two days after 
randomization. This resulted in an EPAIDHA-TAG group of nine subjects and a total 
nlU'llber of evaluable subjects of 49. The mean age of the groups ranged fi'om 31 to 40 
years (individual range 18-69), WiOI all subjects having normal weight for height. Since, 
despite randomization, groups were different WiOI regard to gelIder distribution, gender 
was incllIded as a potential confOllllder in all subsequent statistical analyses. No apparent 
side effects of supplementation were reported, except tor etUctation mainly in the groups 
receiving EPAIDHA-TAG and EPA-EE. 
Table 8.2 
Characteristics of healthy suhjects.a 
T realment groupb n Age (y) Sex Weight (kg) 8MI (kglm') 
EPNDHA-TAG 9' 35 ± 3 1 M; 8 F 65 ± 4 22 ± 1 
EPNDHA·EE 10 36 ± 3 2 M;8 F 64 ± 2 22 ± 
EPA-EE 10 38 ± 4 8 M; 2 F 77 ± 4 23 ± 1 
OA-TAG 10 31 ± 4 4 M; 6 F 70 ± 3 24 ± 1 
OA-EE 10 40 + 4 3M;7F 68 
" 4 23 + 1 
a Mean ± SEM 
10 EPA, eicosapcntaenoic acid; DBA, docosahcxaem1ic acid; OA, oleic acid; 
TAG, triacylglyccrols; EE, ethyl esters 
C One subject withdrew from the study for personal reasons within two days afier randomization. 
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Figure 8.1 
Effects of EPA/DHA-TAG (.6.), EPAIDHA-EE (III), EPA-EE (CD), OA~TAG ( ..... ) or 
OA-EE (0) supplementation on serum triacylglyccrol concentrations. Mean ± SEM. 
Statistical analysis: Repeated measures; P < 0.05) 
• Significantly different from baseline values 
to Significantly different from EPA-EE 
C Significantly different from OA-TAG 
d Significantly ditTerent from OA-EE 
Significant decreases in senun TAG concentrations were detected in all duee 
groups receiving EPA, whereas semm TAG concentrations in the OA groups did not show 
any significant cbange (Figure 8.1). However, tlle reduction of senun TAG during EPA-
EE supplementation (17%) was significantly less than during EPA/DHA-TAG 
supptementation (42 %). Supplementation of EPA/DHA-EE bad an intennediate effect on 
selum TAG concentratiOl" which did not differ significantly from tlle otller two EPA 
supplements. Tbe change of senun TAG in the EPAIDHA-TAG group differed 
significantly Ii'om the EPA-EE group (P ~ 0.013) as well as from the OA-TAG group (P 
~ 0.012). 
Plasma FFA concentrations dlll'ing supplementation showed a strikingly dissinrilar 
pattern in different groups. A siglrificant reduction was observed in the group receiving 
EPAIDHA-TAG, but not in any of the odler groups (Figure 8.2). In t1ris group, plasma 
FFA concentrations decreased by 23% and 33% after 2 and 7 days of EPAIDHA-TAG 
supplementation, respectively (P ~ 0.03). Compared to OA-TAG supplementation, the 
change In plasma FFA concentrations during EPAlDHA-TAG supplementation was bighly 
significant (P ~ 0.002). 
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Eft,c's of EPAfDHA-TAG (A), EPA/DHA-EE (1111), EPA-EE (Ell), OA-TAG (LI) or 
OA-EE (0) supplenlenlalion on plasma free fatty acid concentrations. Mean ± SEM. 
Statistical analysis: Repeated measures; P < 0.05) 
" Significantly different from baseline values 
b Signitlcantiy different from EPA-EE 
C Significantly different from OA-TAG 
The totallHDL-cholesterol ratio showed a significant reduction both during 
EPAlDHA-TAG and EPAlDHA-EE supplementation (P ~ 0.02 and P ~ 0.008, 
respectively; Figure 8.3A), but not during supplementation of EPA-EE, DA-TAG or DA-
EE. In comparisonwiili oilier treatment groups, EPA-EE supplementation had significantly 
less effect on ilie total/HDL-cholesterol ratio dmn supplementation of EPA/DHA-TAG or 
EPA/DHA-EE (P < 0.05). Supplementation of EPAIDHA-TAG also differed significandy 
Il'om dmt ofDA-TAG (P < 0.05). 
Senull total cholesterol concentration was significantly reduced by approximately 
14% duriog EPAlDHA-TAG supplementation (P = 0.02), but, remarkably, was not 
affected in the group receiviog EPAlDHA-EE not' io any odIeI' treatment group (Figme 
8.3B). The change in senUll cholesterol concentration in ilie EPA/DHA-TAG group was 
significantly different Ii'om the groups receiviog EPA-EE (P < 0.01) and DA-TAG (P < 
0.01). 
In contrast to total cholesterol concentrations, senun HDL-cholesterol 
concentrations were only affected in the EPAIDHA-EE group where dley showed a 
significant increase of approximately 19% (P = 0.03; Figure 8.3C). No significant change 
in HDL--cholesterol from baseline was observed in any odler treatment group. No 
significant dillerences were detected between any of dIe groups. 
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OA-EE (0) supplementation on serum lipoprotein concentrations. Mean ± SEM 
Statistical analysis: Repealed measures; P < 0.05) 
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b SigniHcantly different from EPA-EE 
C Significantly different from OA-TAG 
C Significantly different from OA-EE 
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Discussion 
In tile present study we investigated whether n-3 fatty acids administered as eitiler 
TAG or EE have different eftects on senllll TAG, PPA and cholesterol concentrations, and 
whedler tile effect of pure EPA is difterent tram timt of a mixture of EPA and DHA. 
Results showed tlllIt senllll TAG concentrations signitlcantiy decreased during n-3 fatty 
acid supplementation, although tile decrease was significantly greater in tile EPAIDHA-
TAG group than in the EPA-EE group. BOtil EPA/DHA-TAG and EPAIDHA-EE reduced 
tile totalfHDL-cholesterol ratio, however titis decrease was caused by a decrease in total 
cholesterol concentrations in the EPAIDHA-TAG group but by an increase in HDL-
cholesterol in the EPAIDHA-EE group. No eftects of EPA-EE on senllll total or HDL-
cholesterol concentrations were observed. A statistically significant reduction in plasma 
PPA concentrations was only observed in the group receiving EPA/DHA-TAG. It should 
be noted, however, tlllIt post-hoc power calculations showed tlllIt the study was 
Imderpowered for measuring FPA levels because of witltin-subject variability. 
In 1989, Harris showed in an extensive review timt tile effects of n-3 fatty acid 
supplementation on plasma lipid concentrations valY considerably between difterent 
studies. 93 Systematic difterences between studies may be induced by frlctors such as study 
population, dosage and dmation of tile study, and differences have also been repOlled 
between alliuml alld hlUllaIl studies. 94 As shown by tile present study, the use of different 
n-3 fatty acid supplements by difterent authors may give another explamtion for tile 
markedly different effects of n-3 fatty acids on lipid metabolism. VelY little is known 
about mechanisms IUlderlying tile observed differences in effect between the TAG- alKI 
EE-containing supplements, but dIe route of intestinal absorption of fatty acids nmy diller 
between n-3 fatty acid EE and TAG.2 [n general, fatty acids esterified as TAG are 
hydrolyzed in the intestiml IlUllen by paIlcreatic lipase to yield FFA alKI 
monoacylglycerols (MAG). FFA alld MAG diffhse tiuough dIe cell membraIle and are 
reesterified into TAG witilin the enteracyte. Subsequently, the TAG are excreted as 
chylonlicrons into the lymphatic system to enter tile circulation via the vena cava. The 
same may, however, not be tme for tIle absorption of futty acid BE. Some studies have 
reported tlmt the rate of hydrolysis of EE by pallCreatic lipase ill vitro is lower thall timt of 
TAG,120,236 altllough tllis may not be releVallt to the more complex ill vivo situation. 
Ackman2 suggested that hydrolysis of EE may not take place in the intestuml IlUnen, but 
ratiler after absOlption in tile ultestuml wall, followed by transport of FFA to tile liver via 
the portal veul. However, if indeed n-3 futty acids were directly tral"ported to the liver, 
one would expect tiillt tile eftect of n-3 fatty acid EE on liver metabolism would be more 
pronOllllced timn dlat of n-3 fatty acid TAG. This is, however, not consistent Witll our data 
wltich show timt tile eltect of n-3 futty acid EE on senUll TAG alld cholesterol 
concentratiolL' is less than tlmt of n-3 futty acid TAG. 
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A more plausible explanation lor 1I1e differential effects of EE and TAG 
supplements may be a reduced rate of intestinal absorption of n-3 fatty acid EE. In rats, 
EPA- and DHA-EE were recovered in lymph at a much slower rate than EPA and DHA 
administered as TAG or as free acid. 105,237 The slower rate of recovelY could be due to 
differences in metabolic pathways between EE and TAG within the enterocyte.235 Fatty 
acids administered as EE have been proposed to lUldergo an additional metabolic step via 
the phosphatidic acid palllway prior to conversion into TAG.235,238 
Besides 1I1e type of esterification of EPA, tile futty acid composition of the 
supplement also appears to playa role in 1I1e effect of EPA on senllll lipid concentrations. 
Although some autllors suggested EPA and not DHA to be respolLsible for the senun TAG 
reducing elrect of fish oil,7!,n,175 olllers reported that both EPA and DHA have TAG 
lowering effects in healthy subjects.81 ,92 Results of the present study show that the lipid-
reducing effect of a supplement containing bolll EPA and DHA is markedly difterent from 
a supplement containing only EPA. Our observation tllat the EPAIDHA-EE supplement 
increased HDL-cholesterol concentrations whereas oilIer supplements did not, is consistent 
with a previous report of Grimsgaard and coworkers81 who fOlll!d llrat DHA-EE increased 
HDL-cholesterol concentratiolLS, whereas EPA-EE reduced senun total cholesterol 
concentratiolLs. It lras been suggested llrat the cholesterol-lowering effect of EPA-EE may 
be secondaJY to the senun TAG-reducing etl'ect'?! If tllis is t11le, 1I1e present study may 
have been too short to induce any effect of EPA-EE on senun total cholesterol 
concentratiolLs. A study in rats suggested tllat EPA-EE may inhibit intestinal cholesterol 
abSOl]ltion and hepatic cholesterol biosynlllesis.150 To our knowledge, tile mechanism hy 
which DHA increases HDL-cholesterol is not yet resolved. 
It cOldd be argued llral tile admi1listration of a small amOllllt of extra butter in the 
EPA-EE receiving group uligll! lrave counteracted a possible reduction in sennn 
cholesterol concentratiowi during EPA-BE supplementation. If so, however, one would 
expect senUll cholesterol concentJ'atiOll' to increase in the OA-EE group, since Ulis group 
received extra butter as well. The frlct llrat we did not observe aJly signifiCaJlt effects of 
OA-EE on plasnra lipid paraJlleters suggests llrat the small amount of additiOlral butter did 
not aftect study outcome. 
Tn conclusion, although it is not possible to draw conclusions on underlying 
mechanisms, it is quite clear from these results that the short-tel1ll effect of n-3 fatty acids 
as EE on plasma lipid concentratiol1S is not equivalent to n-3 latty acid as TAG. Moreover, 
DHA may interact WWl the physiological effects of EPA. Our results strongly suggest that, 
on short term, use of n-3 futty acid TAG is superior to llrat of n-3 futty acid EE in 
reducing senllll TAG, FFA alld total cholesterol conceutt·ations. Future studies willlrave to 
show whelller these differential eflects of the n-3 fatty acid supplements persist dlll'ing 
long-tenll supplementation, and to unravel the l.U1derlyillg mechanisms. 
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Abstract 
Previous IUlcontrolled studies suggested illllt supplementation of eicosapentaenoic 
acid (EPA; 20:5n-3) may inhibit weight loss in cachectic cancer patients. The aim of the 
present double-blind, randomized study was to obtain pilot information on ille effects of 
EPA supplementation on body weight, body cOUlposition and biochemical parameters in 
weight-losing cancer patients. 
Nineteen weight-losing cancer patients of different Itllllor types were randomized to 
receive EPA ethyl esters (EE) (6g/d) or oleic acid (OA)-EE (6g/d) as a placebo for a 
maximlllll period of 12 weeks. At baseline and afier I, 4, 8 and 12 weeks, antropometric 
measlll'es and blood samples were taken, and dietaty intake was recorded for 4-7 days 
preceding the measurements. 
For reasons of surgelY, progressive disease and death, only 11 patients (EPA, 
n=4; placebo, n=7) were assessable tor statistical atlalyses afier four weeks of 
supplementation. 
Repeated measures analysis showed a statistically significatlt favourable effect of 
EPA on body weight, fat mass atld S\llll of tour skinfolds afier conection for baseline 
values (P = 0.03; P = 0.001 atul P = 0.002, respectively). No significatll effects of EPA 
on fat-free mass, mid-ann muscle circumference, or arm, hip or mid circumference were 
detected. A significant favourable effect of EPA was also detected on senun C-reactive 
protein (CRP) concentrations, since CRP remained stable in ille group receiving EPA atld 
increased in ille placebo group (P = 0.01). 
In conclusion, although selective patient dropout in the EPA group may have 
affected study outcome, Olll' results are C0111istent wiill literaltlre reports suggesting illat 
body weight, lilt mass and blood CRP levels appeat· to improve during long-term EPA 
supplementation. 
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Introduction 
Many cancer patients suffer fi·om cachexia WiOl invohUltary weight loss, impaired 
condition, reduced quality-of-life and shortened dmation of mrvival,75,127 In general, 
cachexia is not effectively reversed by nutritional support, 155 and adeqnate treaunent is not 
available. 127 Metabolic derangements such as elevated energy metabolism, an ongoing 
acute-phase response, and excessive breakdown of muscle protein and adipose tissue are 
common in cachectic cancer patients, 179 but the lllillerlying mechanisms have not yet been 
clarified. Cytokines as well as hUllor-derived proteolytic131 and lipolytic219 factors may 
contribute to weight loss in cancer patients by stimulating catabolism. Recently, n-3 futty 
acids fi·om fish have aroused interest as a potential promising tool in dIe treaunent of 
cancer cachexia230 Animal studies showed drat n-3 futty acid supplementation inhibited 
weight loss in a mmine cancer cachexia model. 214 Eicosapentaenoic acid (EPA; 20:5n-3) 
was suggested to be the active component, since purified EPA was found to inhibit loss of 
body weight in tlUnor-bearing mice to die sallie extentJI,213 OtIler studies, however, 
reported that docosahexaenoic acid (OHA; 22:6n-3) also inhibited weight loss in hlmor-
bearing mice. 158 Til vitro studies suggest tIrat inhibition of lipolysis and proteolysis may 
playa role in the observed efiect, since EPA inhibited ttunor-uilluced lipolysis212,213 as 
well as proteul degradation21 ,212 ill vitro. Fmthermore, supplementation of EPA was 
shown to inhibit hUllor growth and to prolong survival in mice.21 
In a recent double-blind, randomized shKly, we investigated whedler EPA inhibited 
tipolysis in weight-losing cancer patients after one week of supplementation (Chapter 7). 
At die end of the week, patients were asked to continue snpplementation for anodler II 
weeks to obtaul pilot infOimation on dIe long-term clinical effects of EPA supplementation. 
This report presents pilot ulfol'lnation on dIe long-tellll effects of EPA supplementation on 
weight loss, body composition, biochemical blood parameters and qnality-otClire in these 
weight-Iosulg cancer patients. 
Methods 
Subjects 
The shilly was approved by dIe Research Ethics Committee of the University 
Hospital of Rotterdam and written informed consent was obtauled fi·om all participants 
prior to dIe start of dIe strKly. Nineteen cancer patients of different trUllor types WitIl 
weight loss G5 % UI dIe preceding 6 mondls were included in Ulis study. Patients treated 
with chemotherapy or radiation therapy in the previous 2 weeks or elective surgery in dIe 
previolls 2 months were excluded, as were patients with corticosteroid treatment, insulin-
dependent diabetes mellitus, llllcontrolled hyper- or hypodlyroidism, edelna or fever. 
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Study design and metflOds 
At start of the study, body weight, height, circwnferences of ann, waist and hip 
were measured. Skintbld tllicmess (biceps, u'iceps, subscapula, suprailiac) was measured 
using Harpenden calipers (Holtain Ltd, Crymich, UK) and fat mass was calculated 
according to Durnin and Womersly. 53 Mid-ann muscle circlllnference (MAMC) was 
calculated using the following equation: 
MAMC ~ MAC - n * TSF, where MAC ~ mid-ann circlUnference and TSF ~ 
triceps skintbld. 
Blood samples were taken to measure blood C-reactive protein (CRP), alblllllin, 
total protein, hemoglobin, leucocytes, thrombocytes, and triacylglycerol (fAG). Baseline 
nutritional intake was measured by a fOIll·day dietary record preceding start of tlle study 
aud quality-oflite was determined using tlle RoUenlam Symptom Checklist (RSCL),87 a 
validated questionnaire of quality-of-life in caucer patients. 
Patients were randomized in a double-blind fitshion to receive capsules containing 6 
grams of EPA as etllyl esters (EE) per day (purity 96.8 %, EPA95EE; Pronova, 
Sandefjord, Norway) or 6 grams of oleic acid EE (OA-EE) per day (purity 79%, Etllyl 
Olivate; Croda Oleochemicals, N0l1h HlUnberside, England) for a period of maximal 12 
weeks. Supplements were provided as 500 mg capsules to be taken as 3x4 capsules with 
the three main meals. 
Follow-up measurements of body weight, skinfolds, biochemical pal"dlneters, 
quality-of-life and nutritional intake (using a seven-day dietalY record) were perfonned 
after I, 4, 8 and 12 weeks of supplementation. 
Statistical {/na(l'ses 
Results are presented as cbanges ti-om baseline values and expressed as median 
(range) twless oUlenvise stated. Difierences over time between Ute two groups were 
examined by repeated measures analysis of covariance using the linear regression model, a 
procedme suitable for longitudinal regression analysis in wllich observatioll.s are collected 
on Ule same subjects over time. 137 To accoUllt fur Ule within-patient correlation in tlle 
measmements of the dependent variable, tlle Generalised Estimating Equations approach 
was followed. These analyses were pertbnned Witll the SAS procedure Proc Mixed 
(version 6.12-Windows; SAS Inc., Cary, NC, USA), using tlle independence working 
correlation stmcture. Independent variables in tlle model were tlle U'eatrnent indicator 
variable, baseline meastrrement, measurement time and interaction between time and 
treatment The model assmlles a linear relation bet\veen measmement and time in both 
treatment groups. Statistical significance of the treatment efiect was assessed by testing tlle 
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Table 9.1 
Baseline characteristics of weight-losing cancer patients,a 
EPA group OA group 
< 4wks ~ 4wks Total EPA group 
(n=5) (n=4) (n=9) (n=10) 
Age (y) 59 (49 - 74) 69 (59 - 75) 65 (49 - 75) 65 (55 - 74) 
Sex 5M 3 M; 1 F 8M; 1F 5M; 3F 
Body weight (kg) 66 (50 - 75) 72 (60 - 82) 66 (50 - 82) 63 (49 - 80) 
Body mass index (kg/m') 22 (14 - 23) 25 (20 - 25) 23 (14 - 25) 23 (18 - 26) 
Fat mass (kg) 11(5-17) 19 (12 - 23) 14(5-23) 17(6-27) 
Fat-free mass (%) 82 (77 - 90) 76 (61 - 81) 79 (61 - 90) 74 (58 - 88) 
Weight loss (%) 8(5-13) 10 (7 - 17) 10(5-17) 7 (3 - 13) 
Energy intake (MJ/d) 4.9 (3.3-12.3) 7.9 (7.9-7.9) 6.9 (3.3-12.3) 6.1 (3.5·8.5) 
Biochemical parameters: 
C·reactive protein (mgIL) 61 (4 -128) 7 (4 - 26) 9 (4 - 128) 21 (4 - 126) 
Albumin (g/L) 37 (35 - 45) 41 (38-42) 38 (35 -45) 41 (33-46) 
Hemoglobin (mmoUL) 7.1 (6.2 - 9.6) 6.8 (5.7 - 8.6) 7.1 (5.7 - 9.6) 7.0 (6.0 - 9.0) 
Leucocytes ('10.e'/L) 8.8 (5.0 - 11.8) 5.9 (5.4 - 6.8) 6.8 (5.0 - 11.8) 6.4 (3.4 - 12.5) 
Thrombocytes ('10.e'/L) 300 (216 - 502) 285 (231 - 345) 300 (216 - 502) 305 (255 - 651) 
a Median (range) 
null-hypotilesis tilat the coefficients of the treatment indicator and its interaction with time 
are sum~taneously equal to zero. P-values less than 0.05 were considered significant. 
Results 
The patient group receivulg EPA COll~isted of nitle patients WiOl tile following 
tumor types: cancer of tile upper gastrointestulal tract (4), pancreatic cancer (I), rectal 
cancer (I), renal cancer (1), breast cancer (t) and non-small cell lung cancer (I). All but 
one patient had metastatic disease and/or a loco regional relapse. The patient group 
receiving OA-EE consisted of ten patients witil tile following tumor types: oesophageal 
cancer (I), pancreatic cancer (2), gall bladder (I), breast cancer (1), cervical cancer (1), 
carculoid (1), adenocarculoma of llllknown prunary (I), non-small cell hlllg cancer (1) and 
mesothelioma (1). Seven patients had metastatic disease and/or a locoregional relapse, 
whereas the patient wiOlmesotheliOlna had direct invasion of the right liver lobe. 
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Figure 9.1 
Trial profile 
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Figure 9.2 
Individual changes in hody weight, fat mass and fat-free mass during EPA (left) or 
OA (right) supplementation in weight-losing cancer patients. 
P = 0.03 
P = 0.001 
P = 0.27 
TIle Proc Mixed procedure for Repeated Measures was used for statistical analyses. 
No differences in any of Ille baseline patient characteristics such as age, sex, weight 
or biochemical parameters were observed between the treatment groups (Table 9.1). Of Ille 
randomized patienls, one patient from Ille placebo group was excluded fium Ille analysis 
because of non-malignant disease, and two patienls limn Ille placebo group withdrew from 
the study willlin fom' weeks because of progressive disease. Five patients fi'om ille EPA 
group dropped out before the fbllow-up measurement al four weeks due to dealh (l 
patient), progressive disease (2 patienls), and operations which were already scheduled at 
the time of inclusion into the study (2 patients) (Figme 9.1). In the placebo group, one 
patienl willldrew within four weeks due to progressive disease. This resulted in a total 
munber of four assessable patients in Ille EPA group and seven assessable patients in the 
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placebo group (Figure 9.1). A comparison of baseline characteristics between assessable 
and non-assessable patients limn tile EPA group showed that dropouts had a lower hody 
weight, body mass index, fat mass and blood alblllnin than the assessable patients, wheras 
blood CRP concentrations, percentage of filt-free mass and leucocyte count were higher in 
tile non-assessable patients. No difterences in the percentage of weight loss were observed 
between the groups. 
EPA-group OA·group 
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Figure 9.3 
Individual changes in blood C-reactive protein (CRP) concentrations during EPA (left) or 
OA (right) supplementation in weight-losing cancer patients. Significant difference 
between the treatment groups. 111e Peoe Mixed procedure for Repealed Measures was used 
for statistical analyses. 
Repeated measures analysis showed a statistically significant favourable etrect of 
EPA on body weight, fat mass and SlUll of four skintblds after adjusunent for baseline 
values (P = 0.03; P = 0.001 and P = 0.002, respectively; Figure 9.2). Also individual 
skinfolds were higher with EPA than Witll placebo supplementation (biceps, P = 0.003; 
triceps, P = 0.08; subscapldar, P = 0.04; suprailiac, P = 0.06). No significant effects of 
EPA on filt-free mass (Figure 9.2), MAMC, or ann, hip or mid circwnrerence were 
detected. A significant favourable etrect of EPA was also detected on semm CRP 
concenu·ations after adjusunent for baseline values, since CRP remained stable in the 
group receiving EPA and increased in Ule placebo group (Figure 9.3; P = 0.01). Blood 
total protein, albumin, prealburnin, vitamin A and vitalnin E did not differ significantly 
between the treaUnent groups, although hoU, blood hemoglobin, leucocyte CotUlt and 
thrombocyte count tended to improve with EPA (Figure 9.4). 
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Figure 9.4 
Individual changes in blood hemoglobin concentrations, leucocyte count and thrombocyte 
count during EPA (left) or OA (right) supplementation in weight-losing cancer patients. 
The Proc Ivlixed procedure for Repeated Measures was used for slalislical analyses. 
No significant treatment effect for quality-of-life was observed, since the physical 
score, psychological score, activity score and overall score of the RSCL did not differ 
between patients receiving EPA or placebo. 
Although energy intake did not differ significantly between the treannent groups, 
the change in energy intake tended to be higher in the EPA group than in the placebo 
group (Figme 9.5; P == 0.08). 
109 
Chapter 9 
EPA·group OA·group 
5000 5000 
~ 2500 2500 
ID 0 0 ~ {1 
·2500 ·2500 iIi 
·5000 ·5000 
0 4 8 12 0 4 8 12 
Time (weeks) Time (weeks) 
Figure 9.5 
Individual changes in energy intake during EPA (left) or OA (right) supplementation 
in weight-losing cancer patients. 
The liroc Mixed procedure for Repeated Measures was used for statistical analyses. 
Discussion 
p ~ 0.09 
The aim of tile present study was to obtain pilot intonnation regarding tile effects of 
EPA all weight loss, body composition, biochemical pararoeters and quality-of·life in 
weight-losing cancer patients. Repeated measures analysis showed a significant favourable 
effect of EPA on body weight, fat lnass, skin fold thickness alKI senUll eRP concentratiolL~ 
after adjustment for baseline valnes. 
However, results may have been biased by the fuct tlrat only a minor Pal·t of tile 
patients included in tile study were able to complete the study. The relatively high sarople 
attrition in the present study was related to tile fuct tlrat patients had advallced disease, and 
that the study was initially designed to investigate the effect of EPA on lipolysis on short-
tenn. Therefore, several patients were included of whom it was suspected at the time of 
inclusion tlrat tlley would not be able to complete the period of folloW-Up. Disease 
progression in combination with short Iife·expectancy, forced several patients to withdraw 
fi"om tile study. Since some haseline chal'acteristics diftered between assessable and non· 
assessable patients in the EPA group, tile possibility may not be excluded that selective 
patiOllt dropout has affected study outcome. TIIis should be taken into accOtUlt when 
intelpreting the results of tlle study. 
Recently, a Iipid·mobilizing fuctor (LMF) has been identified in urine of weight· 
losing cancer patients,97,t86 which induced lipolysis in wlIite adipocytes by stimulation of 
cAMP production. tl5 This stimulation was inhibited in adipocytes pretreated with EPA. 170 
A proteolysis-inducing factor has also recently been identified which stimulated protein 
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degradation in mice.36.131 The effect of proteolysis·inducing factor was attenuated by 
EPA. 102. 130 These studies on the effects of EPA on lipolysis and proteolysis suggest Olat 
EPA cmdd be useful in the treatment of cancer cachexia. Tltis is supported by recent 
reports of lUlconU'olled clutical studies in weight-losing patients witll pancreatic cancer 
wltich showed tlUlt weight loss was inhibited and fat and fat-free nUlSS were preselved by 
EPA.16,17,230 Although Ole present resldts confirm the effects of EPA on body weight and 
fat nUlss, we cmdd not confum a significant effect of EPA supplementation on fut-free 
mass or MAMC. This lIUly be related with the small munber of patients and the relatively 
high drop out rate. 
OW' observation dmt the change in selUlll CRP was significantly snmller UI the EPA 
group t1mn in tile placebo group is COll~istent with recent reports dlat EPA reduces senun 
CRP concentrations Ul patients WiUl pancreatic canceL 15, 17,230 Tltis effect nmy be due to 
downregnlation of the acute-phase respol"e by EPA via suppression of interleukin-6 
production. 158,229 SUlce the presence of an acute-phase response is thought to play an 
iJnportant role in cachexia Ul pancreatic cancer64 as well as in otller !Junor types, 25,145,220 
the effect of EPA on tile acute-plmse response cmdd partly explain the beneficial effects of 
EPA in cancer cachexia,179 
Despite dIe small munber of patients and the potential bias by selective jUltient 
dropout, the present study does provide pilot infonnation concenting dIe effects of EPA on 
preservation of fat nmss and stabilization of CRP concentrations. Our fllldings confilm 
results reported so fur fi'om unconU'olled studies suggestulg tlUlt supplementation of EPA in 
cachectic cancer patients lIUly be beneficial. Furdler double-blind, randomized s!Jrdies with 
larger patient groups are therefore wananted to assess the effects of EPA on body weight, 
body composition, biochemical parameters and qlUllity-of-life. 
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lI2 
GENERAL DISCUSSION 
Whole-body lipolysis in weight-losing cancer patients 
Plasma fatty acid composition in cancer 
n-3 Fatty acid supplements: Intestinal absOlption of ethyl esters 
Effects of EPA eOlyl esters on lipolysis 
Conclusions 
Chapter 10 
The studies in this dlesis describe the alterations in lipid metabolism in cancer 
patients, the effects of short-term eicosapentaenoic acid (EPA; 20:Sn-3) supplementation 
on lipid metabolism in heaWlY subjects and cancer patients, and the long-term effects of 
EPA supplementation on weight loss, body composition and inflanunation in weight-losing 
cancer patients. 
The studies showed the lollowing results: 
Bodl whole-body lipolysis and plasma lipolytic activity ill vitro are higher in 
weight-losing cancer patients dIan in healthy subjects (Chapters 2 & 3) 
Plasma n-3 fatly acids are significantly reduced in pancreatic cancer and tend to be 
reduced in itmg cancer, but are unchanged or even increased in esophageal cancer 
when compared widl heaWlY subjects (Chapter 4). 
Supplementation of EPA edlyl esters induces a rapid increase of EPA in plasma 
phospholipids and cholestelyl esters witllln four to seven days in healthy subjects 
(Chapter 5). 
EPA ethyl ester supplementation does not inhibit whole-body lipolysis and lipid 
oxidation in healthy subjects (Chapter 6) nor in weight-losing cancer patients 
(Chapter 7) when compared with oleic acid (18: In-9) edlyl esters as a placebo 
supplement. 
The reduction of senUll o"iacylglycerol, free futty acid and cholesterol 
conceno'ations by a mixture of EPA and docosahexaenoic acid (DHA; 22:6n-3) 
adminstered as triacylglycerols is ditrerent fi"om dlat by pme EPA admiIllstered as 
ethyl esters (Chapter 8), 
'Pilot data in a limited group of cancer patients suggest that long·tenn 
supplementation of EPA edlyl esters inhibit the loss of body weight and fut mass 
and the rise in blood C·reactive protein (CRP) concentrations, which is not seen in 
patients receiving oleic acid edlyl esters as a placebo supplement (Chapter 9), 
Whole-body lipolysis in weight-losing cancer patients 
Weight loss in cancer patients comprises bodl loss of muscle and lat mass, 96 One of 
dIe mechanisms thought to be involved in dIe reduction of fat mass is increased lipolysis. 
Results of the present study show drat lipolysis and lipid oxidation were elevated in weight-
losing cancer patients in comparison WitIl heaWJy subjects (Chapter 2), which is consistent 
with some1l6,t24,192 but not aU lO8 studies in literature, Several tactors and mechanisms 
may llllderlie dIe obselved elevation in lipolysis, 
Firstly, measurements of lipolysis nray be affected by energy intake. In many 
cancer patients, load intake is reduced due to decreased appetite t46,t68 or meclwllcal 
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obstmction of the gastrointestinal U'act. 48 The observation in a previous study Ulat lipolysis 
was not only elevated in weight-losing cancer patients but also in weight-losing patients 
without caucer, 116 suggests that reduced euergy intake could be responsible for Ule 
observed elevation in lipolysis. Previous studies in healthy subjects have also shown that 
energy intake can affect whole-body lipolysis,34,114 and therelore, energy intake was 
included as a covariable in Ule data analyses of the present study. The difference in 
lipolysis between cancer patients and healUlY subjects, however, remained statistically 
significant after this correction for energy intake, and we dlerefore conclude that our 
results are not confounded by differences in lOod intake between patients and healthy 
subjects. 
Secondly, since lipolytic rate is usually presented per kilogram body weight, 
measmements of lipolysis may be distorted by changes in body composition. It has been 
shown Ulat lipolysis is related with Ule size of Ule filt-li-ee mass and not of dIe lat 
mass, 34,118 implying that Ule lipolytic rate per kilogram body weight may decrease when 
Ule percentage of fat-free mass decreases. Data analysis in our study showed, however, 
Ulat Ule percentage of fat-fi'ee mass was similar in patients and healthy contfols in the 
present study, and alterations in body composition can therefore not explain the observed 
differences in lipolysis between cancer patients and healthy subjects. 
Since our study showed Urat study results are not confounded by energy intake or 
body composition, it follows Ulat the observed elevated lipolysis in cancer patients was 
induced by oUler, disease-related lactors. Recent reports suggest that the presence of an 
inflanlllratOlY response may affect lipolysis.79,84 In Ule present study, however, no 
significant correlation between whole-body lipolysis and plasma CRP in cancer patients 
was detected. As anotiler potential mechanism, honHonal alteratiom such as altered 
insulin, glucagon and glucocorticoid levels6,19 may be involved in the observed elevation 
in lipolysis in cancer. A Ulird filctor that nray lrave stimulated whole-body lipolysis in 
cancel' patients is the presence of a lipid-mobilizing filctor in blood. IOI ,2IS To detennine 
wheUler this lipid-mobilizing factor was present in Ule blond of Ule patients, plasma 
lipolytic activity was measlll'ed (Chapter 3). The results confnmed tiral besides whole-body 
lipolysis ill vivo, also plasma lipolytic activity ill vitro was increased in cancer patients, 
indica ling Ulat the lipid-mobilizing filctor was present in Ulese patients. However, as dlere 
was no correlation behveell the ill vivo and ill vitro measmements, it seems tUlJikely that 
the presence of a lipid-mobilizing factor is the lnajor factor for the elevation in lipolysis in 
cancer patients. Based on current knowledge, it is not likely that one single factor is 
responsible for Ule elevation in lipolysis in weight-losing cancer patients. Rather, a 
combitration of Ule above-mentioned lactors nray stimulate lipolysis in cancer patients. 
Clearly, Ulis issue will require furUler research. 
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Plasma fatty acid composition in cancer 
Plasma total n-3 fatty acids were significantly reduced in paucreatic cancer and 
tended to be reduced in lllllg cancer, but were Ullcbanged in esophageal cancer when 
compared with healthy subjects (Chapter 4). Fatty acid composition was measured in 
plasma phospholipids and cholesteryl esters because Ule fatty acid composition of these 
fractions has a smaller day-to·day variation than plasma triacylglycerols. '51 The fatty acid 
composition of the plasma phospholipid fi'action is a valuable indicator for latty acid status 
because of Ule close relation with Ule phospholipids in platelet and eryduocyte 
membranes.28,169 
The obselvation tlrnt n-3 futty acid levels were significantly reduced in patients with 
elevated senun eRP concentrations (> 10 mgiL) suggests that the presence of an acute-
phase response may be one of the potential meclrnnisms underlying the reduction in plasma 
n-3 fatty acid concentrations in cancer. This is consistent with oU,er studies in non-cancer 
patients showing inverse correlatiolL~ between plasma n-3 fdtty acid levels and 
inflammatory state. 61 ,163,208 The observation tlrat pancreatic cancer patients with non-
insulin dependent diabetes mellitus (NIDDM) have higher levels of n-3 futty acids U,au 
those without NIDDM is not consistent with most studies in nOll-cancer NIDDM patients. 
These studies showed reduced plasma levels of n-3 and n-6 fatty acids in comparison with 
healthy subjects, t73,176,19O although one study in newly diagnosed NIDDM patients 
showed elevated levels of elongated n-3 and n-6 fatty acids in newly diagnosed NIDDM 
patients. 167 
n-3 Fatty acid supplements: Intestinal absorption of ethyl 
esters 
In previous studies on the effects of EPA on lipolysis and cancer cachexia, EPA 
was provided as triacylglycerols45,230 or as fi'ee acids l7 but not as ethyl esters. However, 
the use of triacylglycerols has the disadvantage that the concentration of a specific fatty 
acid is relatively low, and tllat only a mixture of futty acids can be administered. On the 
other baud, fi'ee fatty acids have been reported to induce gastrointestinal complaints.23 For 
this reason, it was proposed to use EPA as eUlyl esters in the present intelvention studies 
on the effects of EPA on lipolysis. The use of etllyl esters allows administration of specific 
fatty acids in high concentrations, without interference by other substances. However, a 
review of the literature revealed some controversy conceming tile absorption of ethyl 
esters: some studies showed tlrat plasma incOIporation of EPA aud docosahexaenoic acid 
(DHA; 22:6n-3) was similar between etllyl esters and triacylglycerol supplements,92,156 
but otller studies suggested Ulat the absorption of etllyl esters may be impaired.23,57,122 
Furthelmore, EPA ethyl ester supplementation was fmUld to be ineffective in reversing 
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host body weight loss and inhibiting tmnour growdl in mice, preslUnably due to the 
inability to reach effective plasma and tumour concentrations of EPA over dIe initial time 
period in dlis tmnour model. 
Therefore, in order to assess whether it was justifmble to use EPA edlyl esters 
instead of EPA triacylglycerols in the intervention studies, we decided to per/blm a 
separate study to measure dIe incorporation pattern of EPA into plasllm lipids during 
administration as edlyl esters in healtllY subjects. This study, which is described in Chapter 
5, showed dlat EPA ethyl esters were highly incorpomted into bodl plasma phospholipids 
and cholestelyl esters within one week of supplementation. It was dlerefore concluded that 
n-3 fatty acid ethyl esters were sufticiently well incOlporated into plasma lipids to allow 
the use of n-3 futty acid edlyl esters in fill'dler metabolic and clinical studies. 
An lUlexpected finding in dris study was the observation dlat the incorporation 
patterns of EPA and DHA were quite different: EPA was mainly incorporated into plasllm 
phospholipids, whereas DHA was mainly incorporated into TAG. This finding is 
consistent with resnlts from adler studies on dIe incorporation of n-3 fdtty acids supplied as 
triacylglycerols92,156 as well as studies using ethyl esters.74,123,207 Only Blank et al.,27 
who used a supplement of n-3 futty acid edlyl esters, did not find any difference in 
incorporation between EPA arKl DHA into plasnm phospholipids after 12 weeks of 
supplementation. The difference in incorporation between EPA and DHA may he related 
with dIe fuct that EPA and DHA are competitors for the enzymatic transfer of fatty acids 
from phospholipids to cholesteryl esters.207 Since tile affinity of lecidlin-cholesterol 
acyltransfemse is Iligher for EPA than for DHA, dIe conversion of EPA from 
phospholipids to cholestelyl esters may be relatively higher than dmt of DHA. This would 
explain why, in dtis study, incorporation of EPA into cholesteryl eslers was ltigb, wbereas 
the inCOlporation of DHA in cholesteryl esters was negligible. 
Effects of EPA ethyl esters on lipolysis 
Results in C/wpters 6 alld 7 showed dmt short-telm supplementation of EPA does 
not inhibit whole-body lipolysis hI healtllY subjects or weight-Ioshlg cancer patients when 
using oleic acid edlyl esters as a placebo supplement. However, several questions remahl 
to be solved in order to integrate t1ris result with findings from previous studies. The first 
question is whedler a study period of one week was long enough to be able to detect any 
potential effects of EPA ethyl esters on lipolysis. ArlOdler question is whether the type of 
EPA supplement, pm'e EPA esterified as etllyl esters, could Imve affected stlKly outcome. 
A third question is whedler the choice of oleic acid edlyl esters for use as a placebo 
supplement was justified. Below, the potential hIfluence of dlese fuctors on study outcome 
are discussed. 
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Study period 
The first question concems dIe duration of dIe study. The obselvation of Dagnelie 
et al45 that plasma FFA levels were significantly reduced widlin one day of fish oil 
supplementation in healthy subjects, suggested that dIe eftect of EPA on lipid metabolism 
would be rapid. Flll'dlennOre, the study described in Chapter 5 showed that EPA ethyl 
esters were rapidly incorporated into plasma lipids, especially into plasma phospbolipids, 
witllin fOlU' days of supplementation. AWlOUgh, based on these previous findings, it is 
lutlikely dlat the effect of EPA on lipid metabolism takes more tllan seven days, the 
possibility cannot be excluded that a longer study period in the present studies would have 
resulted in different findings. 
Ethyl esters t'erSliS friacylg~vcerols 
The second question addresses dIe use of EPA ethyl esters in the present study. 
Tllis question was raised by the fuct dlat in our studies mentioned above (Chapter 6 & 7), 
tile rapid decrease of plasma FFA as reponed by Dagnelie et al. 45 was not observed. In 
the latter study, a supplement containing botll EPA and DHA esterified as TAG was used, 
wbereas in the present studies, a supplement containing purified EPA esterified as EE was 
admitlistered. It was suggested dlat tile use of these difterent n-3 futty acid supplements 
migbt have affected study outcome. Theretore, an additiollal study was performed in order 
to detennine whedler the various n-3 fatty acid supplements have differential effects on 
plasma lipid concentrations (Chapter 8). Even thougb all EPA supplements did reduce 
senun TAG concentrations sigllificantly, dIe degree of reduction was significantly greater 
in the group receiving batll EPA and DHA as u'iacylglycerols (EPAlDHA-TAG) than in 
the group receiving pure EPA as edlyl esters (EPA-EE). In addition, plaSlIla fi'ee fatty acid 
concenu'ations were only reduced in dIe EPAlDHA-TAG group but not in the groups 
receiving EPAIDHA-EE or EPA-EE. Difterential effects of the different supplements on 
plasma lipoprotein concentmtions were also detected (Chapter 8). 
Although little is known about mectl1nislllS underlying the obselved differences in 
effect between tile triacylglycerol- and eUlyl ester-containing supplements, dIe route of 
intestinal absorption of 11-3 fatty acid etllyl esters and u'iacylglycerols l11ay differ in several 
aspects.2 Fit'stly, dIe rate of bydrolysis by pancreatic lipase may be lower for etllyl esters 
than for triacylglycerols. 120,236 Secondly, the rate of absorption nl1y be reduced 105,237 
due to an additiollal metabolic step via the phospllatidic acid padlway.235,238 Thirdly, futty 
acids fi'ol11 etlwl esters nlaY be transported from dIe enterocyte as fiee acids bOlmd to 
albumin instead of being I~esterified and released itltO the circulation as triacylglycerols.2 
Especially dIe latter situation lnight induce interactiOll> Witll receptors and I or bormones 
that could difter fi'om tllDse of fatty acids esterified as U·iacylglycerols. 
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Besides tile type of esterification of EPA, the presence of DHA also appears to 
influence the effect of EPA on serum lipid concentratiO!" (Chapter 8). Although some 
authors suggested that EPA and not DHA is responsible for the senun triacylglycerol 
reducing effect of fish oil,7l,72,175 others reported tlrat bOtll EPA and DHA lrave 
triacylglycerol-Iowering effects in healtllY subjects. 8l ,92 
In reu'ospect, the results of this study suggest that EPA as etllyl esters may not have 
been tile most appropriate supplement for studying tile effects of EPA on lipolysis. When 
intelpreting the resl"ts of tile ctU'rent study, it should therefore be taken into accOlUlt that 
the metabolic eftects of supplements containing EPA ethyl esters as described in tllis tllesis 
might differ ft'om the effects of a 1l1ixture of EPA and DHA as u·iacylglycerols. 
Use of oleic acid ethyl esters as a placebo 
The third question addressed the question whetller oleic acid ethyl esters are 
suitable as a placebo supplement. Oleic acid was chosen as a placebo tor being one of tile 
most COllllllon monotU"atlll'ated futty acids present in daily food, especially in olive oil. 
Also, olive oil7,95,201,206,223 and oleic acid 144,188 had been used as a placebo supplement 
in many otller studies. In tile study on tile effects of EPA on lipolysis, it was concluded 
that EPA ethyl esters did not afiect whole-body lipolysis in comparison Witll tile placebo 
group which received oleic acid ethyl esters. However, it was renrarkable that botll whole-
body lipolysis, palmitic acid release and palmitate oxidation tended to decrease in the EPA 
as well as tile placebo group. If oleic acid ethyl esters are asstUned to be a valid placebo 
supplement which did not affect lipolysis, the observed clranges should lrave been caused 
by factors other than tatty acid supplementation. However, it was not possible to identity 
such tactors. This raises the question whether oleic acid etllyl esters could also have 
affected lipolysis. In the study described in Chapter 8, two different oleic acid supplements 
containing either triacylglycerols or etllyl esters were included. This study showed tlrat 
neitller oleic acid etllyl esters nor oleic acid triacylglycerols affected selUm triacylglycerol, 
ft'ee fatty acid or lipoprotein concentrations. These results would suggest tllat oleic acid 
ethyl esters do not specifically affect lipid metabolism and are therefore a valid placebo 
supplement. It should be noted, however, that tlle effects on absolute senlln lipid 
concenu'ations do not necessarily reflect lipid fluxes witlrin tlle body. 
Recellt filldillgs regardillg the ~ffects of EPA ill callcer 
The research described in tllis tllesis was based on various studies perfonned in the 
early 1990's wlrich showed tlrat EPA inhibited bOtll weight loss in !tUllar-bearing mice aud 
lipolysis ill vitro. 
However, since 1996, several s!tKlies have been published on tile eftects of EPA on 
body weight aud inflamnratory response in patients Witll pancreatic cancer. l+17,230 These 
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lmcontroUed clinical tlials l6,17 suggested that supplementation of EPA attenuates the loss 
of body weight, especially that of fut-free mass. In our long-term supplementation study in 
cancer patients (Chapter 9), this beneficial effect of EPA on body weight and CRP was 
confnmed, but no beneficial effects of EPA on fat-free mass were obselved. It should be 
taken into aCCotUlt, however, titat the study was Imderpowered and that selective dropout 
of patients in the EPA-group might have affected tile resldts of this long-telm study. 
The present resldts do show a preservation of fut mass during long-tenn 
supplementation of EPA, which may suggest titat EPA does inhibit lipolysis 011 long tenn. 
This is consistent with a recent study reporting that stimulation of lipolysis ill vitro was 
effectively attenuated by EPA. 170 Nevertheless, hased on tile findings reported in Chapters 
6 & 7, we suppose tilat inhibition of lipolysis ill vivo may not be the key mecltanism 
lmderlying tile obselved etrects of EPA in cancer cachexia.212-214 Instead, other 
mecltanisms are likely to contribute to tile apparent anti-cachectic etrects ofEPA. 
In recent years, it ltas become apparent that tile presence of an inflammatOlY 
response is related Widl tile OCCIUTence of weight loss in cancer,I3,64,145,157,189,196,222 
and titat resting energy expenditure is elevated during intlammation.203 Furtilennore, it is 
now known titat supplementation of EPA can modulate the intlammatOlY response in 
cancer patients I5 ,174,229 and in non-cancer patients.26,33,59 DIU' long-tenn 
supplementation study (Chapter 9) also showed that plasma CRP concentrations were 
lower in the group receiving EPA than in tile placebo group. Based on these findings, it is 
speculated titat tile beneficial effects of EPA in cancer cachexia cOldd be related with 
modulation of the acute-phase I~sponse rather titan Widl direct inhibition of lipolysis by 
EPA. 
Anotiler mecltanism which may possibly playa role in tile anti-cachectic effect of 
EPA is tile inhibition of proteolysis. Recent studies showed that tile proteolytic effects of a 
newly identified,131,217 !lUnor-derived proteolysis-inducing fuctor were effectively 
attenuated by EPA ill vitro. 102, 130 
Conclusions 
Based on tile resldts of tilis tilesis, tile following conclusiolLs can be drawn: 
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Whole-body lipolysis, pahnitate release and palmitate oxidation are significantly 
elevated in weight-losing cancer patients in comparison with healthy control 
subjects. These differences remain significant after correction for energy intake, 
and are not affected by cltanges in body composition. 
Plasnta n-3 fatty acid concentratiolL~ are reduced in pancreatic cancer and tend to be 
reduced in hmg cancer, but are Imchanged in esopltageal cancer when compared 
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with healthy subjects. Total n-3 fatty acids are lower in patients with an 
inflammatOlY response (CRP > 10 mg/L) dum in patients without inflannnation. 
Whole-body lipolysis and lipid oxidation are not inhibited by supplementation of 
EPA ethyl esters in weight-losing cancer patients nor in healtllY subjects during 
short tenn supplementation when compared Witll oleic acid ethyl esters as a placebo 
supplement. 
The effects of EPA administered as edlyl esters on lipid metabolism may differ 
substantially from die effects of a mixture of EPA and DHA administered as 
triacylglycerols. Therefore, die conclusion dmt supplementation of EPA ethyl esters 
do not inhibit lipolysis should not be extrapolated to EPA administration in general, 
since the metabolic effects of EPA might be different when using another type of 
esterification 01' when supplying EPA in combination widl DHA. 
Our findings during long-term supplementation of EPA suggest dmt body weight, 
fat mass and skinfold thickness are higher in cancer patients receiving EPA dUUl in 
patients receiving the placebo supplement. Fm·thermore, EPA supplementation 
ap~ars to reduce senun eRP concentrations. 
Future studies 
Future studies are needed to elucidate the mechanisms Ullderlying cancer cachexia. 
Since recent studies suggest that die infiammatOlY response may play an important role in 
cancer cachexia, lhrdler research should focus on ille clinical effects of inhibition of ille 
acute-plmse response in cancer. Furthennore, the recent identification of a lipid-mobilizing 
factor and a proteolysis-inducing tactOI' snggests timt specific stimulation of lipolysis and 
proteolysis by a tmnour-derived factor may also playa role in ille occmTence of weight 
loss. However, the precise role of lipolysis and proteolysis in cancer cachexia remain~ to 
be clarified. 
Although studies in literature suggest dlat supplementation of n-3 fatty acids may be 
beneficial in cancer patients, it is not kllOwn wheiller illis potential effect is related Witll 
baseline plasma n-3 fatty acid status in dlese patients. Also, it remains lUlcertain whedler 
the futty acid concentrations in plasma reflect dIe fatty acid status in tissues. The present 
study has shown ilmt plasnm n-3 tatty acids levels are reduced in pancreatic cancer and 
appear to be reduced in hUlg cancer, but ille meclmnism underlying these alterations is not 
known. Therefore, fill'iller studies are needed to c1ariry whedler ille fatty acid status in 
plasma and in tissues are related, and whether any reductions in n-3 fatty acid levels in 
plasma and/or adipose tissue are related with reduced intake, with reduced availability or 
with elevated metabolic demands. Clarification of the lUlderlying mechanisms may 
contribute to the identification of patient groups at risk foJ' developing n-3 fatty acid 
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deficiencies, which may lead to Ule designation of specific target groups of patients who 
may benefit fi'om n-3 futty acid supplementation. 
FurUlermore, before perfolllling additional studies on the clinical effects of n-3 
fatty acids in cancer or in otller diseases, the mechanisms llllderlying tile observed 
differences in physiological effects of various n-3 fatty acid supplements will have to be 
clarified. These studies will have to address whether to use triacylglycerols, eUlYl esters or 
supplements with some oUler type of esterification, and wheUler pme EPA, pme DHA or a 
mixtme of Fatty acids should be used to obtain desired clinical effects. Possibly, the type of 
supplement will vary Witll Ule nature of tile etrect to be achieved. 
Once tile problems regarding lipid metabolism in cancer and the use of different n-3 
tatty acid supplements have been solved, double-blind, randomized, long-tenll clinical 
trials on the effects of EPA should be perfonlled. These studies should include sufficient 
numbers of patients to detect whether long-telm supplementation of EPA does inhibit loss 
of weight, fut mass and tat-fi'ee mass in cancer patients. Such studies should concenO'ate 
especially on patients with those types of cancer in which weight loss fi'equently occurs, 
and fuctors such as inflammation and n-3 fatty acid deficiency should be taken into 
account. Obviously, quality-oF-lire and survival will have to be important additional 
outcome meastrres in such trials. 
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Cachexia is a frequent problem in cancer patients which is characterized by weight 
loss, impaired perfonnance and tatigue. In general, administration of nutritional support 
does not improve tlle condition nor is any other ade(~mte treabllent available. The 
mechanisms lmderlying cancer cachexia are poorly mKlerstood, but tactors such as 
increased lipolysis and proteolysis may playa role. Weight loss in twllor-bearing mice has 
been found to be attenuated by n-3 fatty acids derived from fish oil, Witll eicosapentaenoic 
acid (EPA; 20:5n-3) being tlle active component. EPA was shown to inhibit lipolysis and 
proteolysis ill vitro, and recent lUlcontrolled clinical studies suggested tlmt EPA 
supplementation may reverse weight loss in patients Witll pancreatic cancer (Chapter 1). 
The aims of the studies reported in tlus thesis were to assess whetller lipolysis and 
plasma lipid composition are altered in cancer patients and whether supplementation of 
EPA reduces lipolysis and lipid oxidation in healthy subjects and in weight-losing cancer 
patients. Furthennore, we aimed to obtain pilot intormation on the long-term effects of 
EPA supplementation in these cancer patients. 
In order to develop new treatment strategies for cancer cachexia, better knowledge 
of lipid metabolism is needed. Since studies in healthy subjects have demonstrated that 
lipolytic rate depends on energy intake and the size of fat-free mass, the aim of tlle first 
study within tltis tllesis (Chapter 2) was to assess whether whole-body lipolysis, pabrtitic 
acid release and pahrtitate oxidation were increased in weight-losing cancer patients when 
taking differences in food intake and body composition into account. Measurements were 
perfOlmed in 18 weight-losing cancer patients witll different tumor types and in sixteen 
heaWlY subjects after an ovenugbt fdst, and food intake was recorded for four days. Body 
comfXJsition was measured by bioelectrical impedance analysis. After adjustment for 
energy intake, whole-body lipolysis was sigluficantly higher in cancer patients tllan ill 
heaWlY subjects. The difference in palmitic acid release did not reach statistical 
sigluficance. The rate of pabnitate oxidation was also sigluficantly lugher in patients than 
in beaWw subjects. No differences in body composition were observed between groups. It 
is concluded that whole-body lipolysis and palnutate oxidation are elevated in weight-
losing cancel' patients wben differeuces in food intake and body composition are taken into 
account. 
Recently, a lipid-mobilizing tactor hlls been identified in the mine of weigbt-losing 
cancer patients, which was shown to stimulate lipolysis ill vitro as well as in vivo. To 
assess whetller wbole-body lipolysis ill vivo and lipolytic activity ill vitro are correlated, 
lipolytic activity was measmed in plasma samples of weigbt-losing cancer patients alKI 
bealtllY control subjects (Chapter 3). Til vitro lipolytic activity towards isolated fat cells 
was significantly higher in plasma of weight-losing cancer patients than in plasma of 
bealtlly subjects (P < 0.01). However, no sigluficant correlation was detected between 
lipolytic activity ill vitro and whole-body lipolysis ill vivo in tile total study group, nor in 
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heally subjects or cancer patients separately. Tltis suggests that factors otller tlUUl the 
presence of tile lipid-mobilizing tactor probably also contribute to whole-body lipolysis in 
cancer patients. 
The risk of developing essential fatty acid deficiency is increased in cancer patients 
due to reduced food intake, impaired intestinal absorption or increased metabolic demands. 
In the study described in Chapter 4, we investigated whether plasma n-3 fatty acid 
concentrations were reduced in difrerent groups of cancer patients in comparison with 
healOlY subjects. In pancreatic cancer, plasma n-3 futty acids showed a substantial 
reduction in boUI plasma phospholipids and cholesteryl esters. Allough total n-3 tatty 
acids in IIUlg cancer also tended to be reduced, tltis ditference tailed to reach statistical 
significance. In esophageal cancer, however, total n-3 fatty acid concentrations were 
comparable with or even higher tllan those in healthy subjects. n-3 Fatty acid levels were 
lower in weight-losing dIan in weight-stable patients Widl IlUlg cancel'. Pancreatic cancer 
patients Witll diabetes had significantly higher levels ofn-3 fatty acids than those pancreatic 
cancer patients without diabetes. For all Imuor types combined, total n-3 tatty acids were 
significantly reduced in patients Witll plasnIa C-reactive protein concentrations > 10 mg/L. 
Beneficial heall efrects of n-3 fatty acid supplementation have been described in 
several diseases such as cancer cachexia, atherosclerosis and inflammatOlY diseases. Since 
natmal fish oil contains a relatively low concentration of n-3 latty acids, it ntight be 
advantageous to use purified n-3 fatty acid edlyl esters. However, studies investigating the 
intestinal absorption of eicosapentaenoic acid (EPA; 20:5n-3) and docosahexaenoic acid 
(DHA; 22:6n-3) ethyl esters are controversial. In Chapter 5, dIe level of incOlporation of 
EPA and DHA in different plasma lipid fi"actiol1~ of healthy subjects during 
supplementation Witll n-3 fatty acid etllyl esters is described. Within 7 days of 
supplementation, dIe proportion of EPA in plasnIa phospholipids showed a IS-laid increase 
(P < 0.001). The proportion of DHA only showed a two-fold increase. In cholestetyl 
esters, EPA also increased significantly (P < 0.05), whereas DHA did not increase at all. 
In contrast, incorporation of DHA into triacylglycerols was even higher than tlmt of EPA. 
These results showed tllat EPA is rapidly and substantially incOlporated into plasnIa lipids 
when provided as edlyl esters. 
In Chapter 6, the efiects of short-term EPA ethyl ester supplementation on whole-
body lipolysis and lipid oxidation in healthy subjects are reported. In sixteen healthy 
subjects, whole-botly lipolysis, palmitic acid release and palmitate oxidation were measmed 
using stable isotopes. Subjects were randomized to receive EPA ethyl ester (6 g/d) or 
placebo (oleic acid ethyl esters; 6 g/d) for seven days in a double-blind design. After 2 and 
7 days of supplementation, tlll'nover measurements were repeated. Whole-hotly lipolysis, 
pahltitate oxidation, or pahnitic acid release were not significantly different between tile 
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treatment groups, despite substantial reductions in palmitic acid release and palmitate 
oxidation in both treatment groups when compared widl baseline values. 
A similar study on the effects of EPA on lipolysis in weight·losing cancer patients 
is described in Chapter 7. Seventeen weight·losing cancer patients of different tumor types 
were randomized to receive EPA ethyl esters or placebo for seven days, and whole·body 
lipolysis, palmitic acid release and palmitate oxidation were mea,ured at baseline, and after 2 
and 7 days of supplementation. Again, no significant differences in whole·body lipolysis, 
palmitate oxidation, or pahnitic acid release were detected between dle groups receiving EPA 
edryl ester and oleic acid edlyl ester supplementation. Furdlennore, no significant treatment 
effects on resting energy expendiull'e and plasma CRP concentratiolls were detected. Also in 
patients, whole-body lipolysis tended to decrease in the placebo group. 
Results of both studies reported above (Chapters 6 and 7) differed from an earlier 
study fi'om our group in that a rapid decrease in plasma FFA concentrations was not 
observed during n·3 fatty acid supplementation. This raised the suspicion that different 
types of n·3 frltty acid sllPplements could have varied effects on lipid metabolism. We 
therefore perfonned an additional sUldy, described in Chapter 8, in which forty-nine 
healthy subjects were randomized over five treatment groups. Group I received bodl EPA 
and DHA as triacylglycerols, group II received EPA and DHA as ethyl esters, and group 
1Il received pure EPA as edlyl esters for a period of seven days. Groups IV and V 
received placebo supplements containing oleic acid. Ovelllight·fasted blood samples were 
taken at baseline and after 2 and 7 days of supplementation. Senun triacylglycerol 
concentratiolls decreased significantly in all groups receiving EPA (P < 0.05), but 
notably, the triacylglycerol reduction in the group receiving EPA edlyl esters (17%) was 
significantly less tIlan in tile group receiving tile mixture of EPA and DBA as 
triacylglycerols (42 %) (P < 0.05). Furthellllore, altIlOugh both supplements containing 
EPA plus DHA reduced the totaVHDL·choiesterol ratio, tIris was caused by a reduction in 
total cholesterol concentrations in the EPA plus DBA triacylglycerol group, but by an 
increase in HDL-cholesterol in tile EPA plus DHA ethyl ester group (P < 0.05). The 
eftects of n-3 fatty acid supplements on senUll lipid concentratiolLs are tIms aftected bOtIl 
by the presence of DHA and by the type of esterification. 
Besides measuring the effects of shOli-tenll EPA ethyl ester supplementation on 
lipolysis, we also obtained pilot intollnation on the long·tenn cliIrical effects of EPA 
supplementation. In Chapter 9, we explored whedler supplementation of EPA influences 
loss of body weight, body composition and biochemical blood parameters. For this study, 
cancer patients were asked to continue supplementation for anotIler II weeks after 
completion of tile one·week sUldy of metaholic meaSlll'ements (described iIl Owpter 7). 
AutIu'opometric measures and blood samples were taken at baseline and after I, 4, 8 and 
12 weeks, mrd dietalY intake was recorded tor 4·7 days preceding tile measurements. Due 
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to deatll, progressive disease and surgely, only II out of 19 randomized patients (EPA, 
n=4; placebo, n=7) were assessable tor statistical analyses afier fuur weeks of 
supplementation. Body weight, fat mass and SlUn of four skinfolds were significantly 
higher in the EPA group than in tlle placebo group (P = 0.03, P = 0.001 alKI P = 0.002, 
respectively). C-reactive protein (CRP) levels were significantly lower in the group 
receiving EPA tharl in the placebo group (P = 0.01). Although selective patient dropout in 
tlle EPA group may have atrected study outcome, our resl~ts are cOl1~istent with literature 
reports suggesting tlrat body weight, filt mass and blood CRP levels appear to improve 
during long-term EPA supplementation. 
In conclusion, whole-body lipolysis is significantly elevated in weight-losing cancer 
patients when compared witll healthy control subjects. Plasma n-3 tatty acids are reduced 
in pancreatic cancer and tend to be reduced in IUllg CallCer, but are [Ulciranged in 
esophageal cancer in comparison WiOl healtllY subjects. ShOlt-tellll supplementation of 
EPA etllyl esters does not reduce whole-body lipolysis or lipid oxidation in weight-losing 
cancer patients or in healtllY subjects in comparison widl oleic acid etllyl esters as a 
placebo supplement. Furtllennore, tlle metabolic effects of EPA administered as ethyl 
esters ditrer subStalltially from the efiects of a mixture of EPA and DHA administered as 
triacylglycerols. Long-term EPA supplementation nray improve body weight, filt mass, 
skin fold tlrickness and senun CRP concentrations, altllough dlese results nray have been 
afiected by selective patient dropout. 
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Samenvatting 
Veel kankerpatienten lijden aan gewicbtsverlies, wat meestal gepaard gaat met een 
slecbte conditie, vennoeidheid, een slechte weerstand en een kortere leveru;duur. Over het 
algemeen verbetert het geven van bijvoeding de situatie niet of nauwelijks. Ouk bestaat er 
geen geneesntiddel tegen bet optreden van gewicbtsverlies bij kanker. De oorzaak van dit 
gewichtsverlies is niet bekend. Vee! patienten hebben een venninderde eetlust, maar 
daamaast lijkt bet er ook op dat vetweefsel en spieren versneld worden afgebroken. Uit 
dierstudies is gebleken dat bet geven van n-3 vetzuren uit visolie bet gewichtsverlies zou 
kmmen tegengaan. Het vetzuw' eicosapentaeenzulll' (EPA; 20:5n-3) was hierbij het actieve 
bestanddeel. Oak was EPA in staat am de vet- en eiwitafbraak in gelsoleerde cellen te 
wnmen. Docosahexaeenzuur (DHA; 22:6n-3) had daarentegen geen remmend effect in 
deze studies. Recent is gebleken dat EPA waarschijnlijk ook bij patienten met 
pancreaskanker het gewichtsverlies laUl remmen, maar omdat in dat onderzoek geen 
controlegroep aanwezig was, moeten de resuHaten met enige voorzichtigheid worden 
bekeken (Hoofdstuk 1). 
In de studies die beschreven staan in dit proefscbrift, werd onderzocht: 
I. of de vetafbraak bij kankerpatienten met gewicbtsverlies boger is dan bij gezonde 
mensen; 
2. of de vetzUlu'sarnenstelling in bet bloed anders is bij kankerpatienten dan bij 
gezonde memien; 
3. of de afbraak van vet bij kankerpatienten en bij gezonde vrijwilligers geremd wordt 
door bet geven van EPA; 
4. of het geven van EPA gedlll'ende lange tijd invloed beeft op bet gewicbtsverloop bij 
kankerpatienten. 
Men vennoedt dat de afbraak van vetweefsel bij kankerpatienten hoger is dan bij 
gezonde meru;en. Het is ecbter bekend dat de afbraaksnelheid van vet in het lichaam mede 
bepaald wordt door de energie-innarne en de lichaarnssameru;telling. Doordat deze factoren 
zouden kmmen verschillen tussen kankerpatienten en gezonde meru;en, is bet mogelijk dat 
de uitkomsten van eerdere studies hierdoor vertekend zijn. Het doel van onze eerste studie 
(Hoofdsluk 2) was na te gaan of de vetafbraak bij kankerpatienten met gewichtsverlies 
hoger is dan bij gezonde mensen nlt coneetie voor voedselinname en 
lichaarnssamenstelling. Achttien patienten met verschillende soorten kanker en met meer 
dan 5 % gewichtsverlies en zestien gezonde vrijwilligers namen deel aan het onderzoek. 
Eerst schreven zij gedurende vier dagen op wat zij eten en dranken. Na een ""cht vasten 
werd de lichaamssamenstelling bepaald (bioelectrische impedantie analyse) en werd de 
snellieid van de vetafbraak gemeten met behulp van een continu infuus met een gelabeld 
vetzuur. Na come tie voor energie-innarne was de snellieid van de vetafbraak significant 
boger bij kankerpatienten dan bij gezonde mensen. Oak de verbranding van vet was 
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significant hager bij patienten dan hij de controlepersonen. Het verschil in vetafuraak 
tussen kankerpatienten en gewnde vrijwilligers werd niet verkIaard door verschinen in 
lichaamssamenstelling, aangezien deze vergelijkbaar was tussen de twee groepen. 
Recent hebben onderzoekers in de urine van kankerpatienten met gewichtsverlies 
een stof gelsoleerd die de vetafuraak in vetcellen stimuleert en die bij muizen 
gewichtsverlies veroorzaakt. Of deze stof aanwezig is in het bloed van mensen kan bepaald 
worden door het meten van de zogenaamde 'lipolytische activiteit' van het bloed. Hiervoor 
worden vetcellen van proefdieren gedmende twee uur gelncubeerd met het bloed van de 
patient, waarna gemeten wordt hoeveel glycerol (een bestanddeel van vet) er uit de cellen 
is vrijgekomen. Omdat niet bekend is in hoevene deze ill vilro bepating van de vetafuraak 
dezelfde UitkOlllSt geeft als de bepaling van de vetafuraak bij patienten met kanker, is in de 
studie van Hoojdsluk 3 onderzocht in hoevene deze twee maten met elkaar geconeieerd 
zijn. De vetcellen werden hiervoor gelncubeerd met het hloed van de kankerpatienten en 
gelOnde vrijwilligers uit Hoojdsluk 2. De afbraak van vet in de cellen was significant 
hoger bij het bloed van kankerpatienten dan van gelOnde mensen. De mate van vetafumak 
in deze cellen was eclUer niet gecorreleerd met de mate van vetafbraak in het totale 
lichaam, ook niet na opsplitsing van de groep in patienten en gelOnde controlepersonen. 
Dit wijst erop dat ook andere factoren lOals honnonale veranderingen invloed hebben op 
de snelheid van de vetafbraak bij kankerpatienten. 
Omdat kankerpatienten vaak minder eten, de opname in de darm venninderd kan 
zijn en bij veel patienten de stofwisseling verhoogd is, lopen zij een verhoogd risico op het 
ontwikkelen van tekorten aan bepaalde vetzuren in het lichaam. In het onderzoek 
beschreven in Hoofdslllk 4 is nagegaan of de concentraties van n-3 vetzuren (de vetzuren 
uit vette vis) in het bloed lager zijn bij kankerpatienten dan bij gelOnde meriSen. De 
cOllcentraties van n-3 vetzuren in bet bloed waren aanzienlijk verlaagd bij patienten met 
pancreaskanker, met name bij die patienten die geen suikerziekte hadden. Bij de patienten 
Illet longkanker was de concentratie van n-3 vetzuren eveneerl~ verlaagd, hoewel het 
verschil ten opzichte van gezonde personen niet statistisch significant was. Deze verlaging 
werd met name gevonden bij de longkankerpatienten met gewichtsverlies. Bij patienten 
Illet slokdannkanker waren de concentraties van n-3 vetzuren niet al\vijkend van die van 
gelOnde mensen. Verder bleek dat de n-3 vetzmen in het bloed significant lager waren bij 
kankelpatienten bij wie sprake was van een ontstekingsreactie dan bij kanke'lJatienten 
zander ontstekingsreactie. 
Wanneer n-3 vetzuren gegeven worden in de vorm van capsules, heeft men de 
kenze nit verschillende visolie-sllpplementen. In 'natnllrlijke visolie' komen n-3 vetzuren 
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voor als veUen (oftwel triglyceriden), waarbij echter de concenttatie van n-3 vetzuren 
relatief laag is. Daarom wordt vaak gekozen voor het gebruilc van etlwl-esters, een 
klmstmatige vonn van visolie. Wanneer etllyl-esters gebmikt worden, is het mogelijk am 
n-3 vetzuren in zuivere vonn en in hoge concentratie aan te bieden. Het is ecllter niet 
duidetijk of de opname van ethyl-esters door de dann wei goed is. In Hoofds/uk 5 wordt 
beschreven in welke mate de concentraties van EPA en DHA in het bloed omhoog gaan 
wanneer gezonde mell5en zeven dagenlang visolie in de vonn van etlwl-esters slikken. Vi! 
deze studie bleek dat de stijging van EPA in het bloed relatief groot was en SlIel vertiep, 
terwijl de stijging VillI DHA aanmerketijk kleiner en langzamer was. Oak waren er 
duidetijke verschillen tussen de diverse vetftacties in het bloe<:l. De belangrijkste conclusie 
uit dit onderzoek was dat de opname van EPA in het lichailln goed is wanneer n-3 vetzmen 
in de vonn van ethyl-esters gegeven worden. 
Hoojds/uk 6 beschrijft het effect Vatl EPA ethyl-esters op de afuraak VillI vet en de 
vetverbratlding bij gezollde mensen. Zestien gezonde vrijwilligers werden door middel van 
loting verdeeld over twee groepen. De eerste groep kreeg EPA ethyl-esters (6 g/dag) en de 
tweede groep kreeg een placebosupplement (oliezmu' etllyl-esters; 6 g/dag) gedurende 
zevell dagen. De proetjJersonen wisten zelf uiet in welke groep zij ingedeeld waren. Bij 
aatlVang Vatl de sltKlie en na twee en zeven dagen wenl de vetafuraak gemeten met behtdp 
Vatl eell infims met een gelabeld vellum. De afuraak van vet en de vetverbranding 
verschilden uiet siguificant Itlssen de twee behandelingsgroepen. Het was echter wei 
opvallend dat zowel de vetafuraak als de vetverbranding in beide behatldelingsgroepen, dus 
oak in de placebogroep, leek te dalen. 
In Hoojlis/uk 7 wordt het effect van EPA etllyl-esters op de vetafuraak en de 
vetverbratlding bij katlkerpatienten met gewichtsverlies beschreven. Zeventien patienten 
met verschillende soorten kanker werden door middel van loting verdeeld over een EPA 
ethyl-ester groep en een placebogroep. Bij aanvatlg van het onderzoek en na twee en zeven 
dagen slikken Vatl de capsules wenl de snellieid van de vetafuraak gemeten. Oak hier 
waren de vetalbraak eu de vetverbranding uiet siguificant verschillend tussen de twee 
behandelingsgroepen. Oak het energieverbmik tijden5 mst en de lnate van ontsteking in het 
lichaatn verschilden niet significatlt tU5sen de twee groepen. Net als bij de gezonde 
vrijwilligers leek de vetalbraak in beide behandelingsgroepen te dalen. 
In eerder onderzoek leidde het geven VillI visolie aan gezonde mell5en tot een daling 
van de concentraties van vrije vetzmen in het bloed. In bovenstaande studies 
(Hoojds/ukkell 6 ell 7) wenl deze daling echter niet gevonden. Dit heeft mogelijk te maken 
met het gebmik van verschillende soorten visolie in de diverse sltldies. Daat'om is 
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onderzoeht in hoeverre de etreeten van de diverse soorten visolie op de veteoneentraties in 
het bloed verschillen (Hoo/ds/uk 8). Negenenveertig gezonde vrijwilligers werden door 
middel Vall loting verdeeld over vijf behruldelingsgroepen: drie groepen met visolie en 
twee groepen met olijfolie. Groep I kreeg een supplement met zowel EPA als DHA in de 
varm van triglyceriden, groep II kreeg EPA en DHA in de vonn Vall eUlyl-esters en groep 
III kreeg zuivere EPA in de vonn van ethyl-esters. De groepen IV en V kregen 
placebosupplementen in de vonn Vall olijfolie. De personen slikten deze supplementen 
gedurende zeven dagen. Bij aalIVallg van de studie en na twee en zeven dagen werd er 's 
morgens nuchter bloed algenomen. De concentratie triglyeeriden in het bloed daalde 
significant bij aile visoliegroepen. Echter, de mate van daling was significallt groter bij de 
mensen die EPA en DHA in de vonn van triglyceriden kregen dan bij de personen die 
zuivere EPA in de vmill van eUlyl-esters kregen. De coneentratie Vall totaal cholesterol in 
het bloed daalde significant in de groep (lie EPA plus DHA in de vonn van triglyceriden 
kreeg, maal' niet in de andere groepen met visolie of olijlblie. Het HDL-eholesterol gehalte 
steeg daarentegen aileen in de groep die EPA plus DRA in de vmill van eUlyl-esters. 
Hierdoor daalde de mtio van totaal en RDL-cholesterol in de twee groepen die een 
mengsel Vall EPA en DHA kregen, terwijl deze mtio niet veralKierde in de groep lllet 
aileen EPA. Deze resultatenlaten zien dat er duidelijke verschillen in effect bestaan tussen 
de verschillende soorten visolie. 
Tot slot is in een pilotstudie geprobeerd een indmk te krijgen Vall de klinisehe 
effecten van EPA op lange tennijn (HooftMuk 9). In dit mKierzoek werd onderzocht in 
hoeverre het geven Vall EPA het gewichtsverloop, de lichaallLlsamenstelling en de enkele 
bloedpal'ameters krul beluvloeden bij kallkerpati~nten met gewichtsverlies. Daartoe weld 
aall de patienten uit ons onderzoek (beschreven in Hoo/tls/uk 7) gevraagd om, na de eerste 
week Vall metingen Vall de vetalbraak, door te gaan met het slikken Vall de capsules 
gedurende maximaal twaalf weken. Bij aallvang Vall de studie en na 1,4, 8 en 12 weken 
werden de patienten gewogen, werd de lichaanlSsalnenstellhlg bepaald (huidplooimetingen) 
en werd bloed afgenomen. VoorafgaalKi aall elke meting schreven de pationten gedmende 
zeven dagen op wat zij aten en dronken. Als gevolg van overlijden, voortschrijding Vall de 
ziekte of operaties Wal'en er na vier weken nag slechts 11 Vall de 19 patienten beschikbaar 
voor de efiecUnetingen (4 patii~nten in de EPA groep; 7 patienten in de placebogroep). Van 
de overgebleven panenten waren het lichaanL~gewicht en de hoeveelheid vetweefsel 
significant hager bij de pationten met EPA dall bij de patienten met het placebosupplemellt. 
Daamaast was de ontstekhlgsreactie significant lager in de EPA groep dall in de 
conU'olegroep. Hoewel het mogelijk is dat deze resultaten belnvloed zijn door de relatief 
hoge uitval van patienten in de eerste vier wekell, komen deze resultaten Qvereen met 
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gegevell5 in de literannu' dat EPA een positief effect heeft op het Iichaamsgewicht, de 
hoeveellieid vetweefsel en de ontstekingsreactie. 
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De conclusies van het huidige onderzoek zijn: 
De afbraak van vet is hoger bij kankerpatienten met gewichtsverlies dan bij 
gezonde mensen. 
De concentraties van n-3 vetzuren (vetzuren uit visolie) in het bloed zijn verJaagd 
bij patienten met pancreaskanker en waarschijnlijk ook bij patienten met 
longkanker, maar zijn niet veranderd bij patienten met slokdalmkanker ten opzichte 
van gezonde vrijwilligers. 
Toediening van EPA gedlll'ende zeven dagen heeft geen effect op de vetafbraak of 
de vetverbranding bij kankerpatienten met gewichtsverlies of bij gezonde 
vrijwilligers, in vergelijking met olijtolie als een placebosupplement. 
Verschillende soorten visolie hebben verschillende effecten op de vetconcentraties 
in bloed. 
Het geven van EPA gedurende langere lijd Iijkt een positief effect te hebben op het 
licbaamsgewicht, de hoeveelheid vetweefsel en de ontstekingsreactie. 
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Tot slot ... 
Het mOlllellt is llU dan toch daar: mijn hoekje is al1 Ik moet zeggell dat dat een zeer 
prettig gevoel geeft. Maar. .. het feit dat mijn uaam luag prijken op de kaft betekent 
uatuurlijk uiet dat ik dit boekje in tuijn eentje geruaakt heb. Zonder de hulp van vele 
mellSen om tuij heen had ik di! ollderlOek namelijk nooi! tot een goed einde kunnell 
brellgell. Ik Illaak dan ook graag van deze gelegenheid gebmik om iedereen te bedanken 
die tuij in de afgelopen vier jaar met tuijll onderzoek geholpen heeft. 
Mijn begeleider en copromotor Pieter Dagnelie heeft zich in de afgelopen vier jaren 
volledig ingezet voor het onderzoek. Pieter, jouw entllOlIsiasme, je grote betrokkenheid 
(zells vanui! het verre Maastricht) en jOllw snelheid wat betreft lezen zullell weinig mensen 
klUlIlen evenaren. 
Professor Wilson was meestal het grote brein op het gebied van de goede ideeen ell 
geschikte oplossingen. Zijn positieve kijk en grote vertrouwen hebben luij tijdens de, soms 
moeizame, uilvoering van het onderloek vaak een hart onder de riem gestoken. 
Billllen het laboratorilUll van de lnwendige Geneeskwlde II was Winl van den Berg 
op vele gebieden ol1misbaar. WilD, ik bewaar zeer goede herinneringen aan OBze talloze 
hesprekingen over de stofwisseling ell de laboratorimlltechniekell, aan jouw gezelligheid ell 
vomal oak aan jOllw oppeppende woorden walllleer ik even in een dipje zat. 
Roel Swart was als clinicus en hootiJ VaIl de sectie 'Voeding ell Metabolisme' aUijd 
bereid tot het voeren VaIl interessante discllssies over het onderzoek en de klinische 
voeding in het algemeen. Roel, jOllw klinische inbreng en kritische opmerkingen hielden 
luij scherp en hebben tuij veel geleerd over de klinische praktijk. 
De vele laboratorimllaIralyses hadden niet ui!gevoerd kllUllen worden zander de 
grote inzet vall Trine! Rietveld ell Darcos Wattimeua. Trinet, uaast de vele dingen die je 
tuij geleerd hebt over het werken in een laboratorilUll, was jouw gezelsclrap op het lab erg 
aangelraam. DaI"cos, het is misschien maaI' goed dat ik geen idee heb hoe vaak jij 's 
avonds, 's nachts en in het weekelld op het lab gewee,t bent om de analyses van onze 
monsters op de massaspectrometer tot eell goed eiude te brellgen. 
De gezelligheid in OllS knusse krunertje lrad ik te daIlken aan mijn kamergenoten 
Erik Agteresch en AIllle Marie Petersen-Westemran. Erik, als arts heb jij voor luij talloze 
illfullsuaalden geprikt en vele patienten beoordeeld op InUl geschiktheid voor deehlalne aan 
het onderzoek. Amle Marie, je had altijd belallgstelliug voor tuijn onderzoek en ome 
gezellige 'klets-lIurljes' waren een aaIlgename afleiding. 
De congressen kregell een extra kleurtje door de altijd vrolijke Susanne Leij-
HalfWerk. SlISaIme, ik heb er buitengewooll vee! zin in om samen met jou aaII de slag te 
gaan bij Nllmico Research in Wageningell. 
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Ook aHe andere coHega's Vall het Iahoratorillln Inwendige Geneeskllllde II hebben 
bijgedragen aall de prettige werksfeer op het lab. De gezellige koffiepauzes, de vele 
helpende handen en de nooit aflatende belaIIgstelling voor lOweI werk- als priv6-
aangelegenheden zal ik zeker niet vergeten. 
Manon Vall Seters, Michiel Vall der Heijden en David Dezentje hebben als 
studenten een belangrijke steen bijgedragen aall de praktische uitvoering van het 
onderzoek. MallOn, ik vertrouwde de proe1jJersonen en pati~nten tijdens de metingen graag 
aalljouw zorg toe. MichieI, je gedrevenheid, sociale vaardigheden en kritische blik hebben 
een belangrijke rol gespeeld bij het slagen Vall jldlie onderzoek. David, zells na het 
voltooien Vall jouw verplichte stageperiode hleef je OIL~ helpen, waardoor we veel extra 
patienten in het onderloek bebben kUllllen insluiten. 
Voor de uitvoering voor mijn ouderzoek was de salnenwerking met de afdeling 
Interne Oncologie zeer belangrijk. Dokter Splinter, Ate van der Gaast, Tjebbe Kok, Andre 
Vos en Leon Kerkbofs hebben zich twee jaar lang ingezet bij de welving Vall patienten. 
Daamaast was de medewerking van Oea, Mildred, Annie, Marian, Rosa, Elma en aile 
andere assistentes Vall de afdeling Oncologie / Hematologie zeer prettig bij het lOeken naar 
patienten, het gebmik van kalners voor de metingen en het prikken Vall infusen. 
Ook de artsen Vall de afdeling Radiotberapie hebben enige tijd meegewerkt aan de 
patientenwerving. Bij Yvonne en Astrid als assistentes van de afdeling Radiotllerapie kon 
ik altijd terecht voor hulp en een gezellig kletspraatje. 
Naast de bovengenoemde afrlelingen hebben ook vele artsen, verpleegkrmdigen en 
assistentes Vall de at\lelingen Longziekten, Heelkunde en het Thoraxcentmm zich ingezet 
bij onze patientenwerving en het verzalnelen van patientelllnateriaal. 
De verpleging Vall de afdeling 4-Midden was altijd bereid tol assislenlie bij bel 
prikken van infuusnaalden en tot het tel' heschikking steUen van de onderzoekskamer. 
Yvolllle, door jouw vrolijklleid verga ten de patienten dat het afilemen Vall bloed eigerdijk 
iets verve lends is. 
De dagelijkse bel-eiding Vall de innmsvloeistof en het uitvuHen Vall capSldes kwam 
voor rekening Vall de medewerkers Vall de apotheek Vall het Dijkzigt Ziekenhills. De inzet 
van Lidwien Hanff, Marien Pluim en Frederike Engels hebben er mede voor gelOrgd dal 
de praktische uitvoering van het onderzoek goed kon verlopen. 
De raJldomizatie en registratie Vall de patienten en vrijwilligers inmijn ondelzoek is 
velzorgd door de medewerkers Vall het Trialbureau Vall de Daniel den Hoed Klilliek onder 
leiding Vall Dr. P. Schmitz. 
Voor adviezen omlrent de ingewikkelde 'repeated measures' metllOde ill het 
statislische programma SAS kon ik terecht bij Professor Th. Stijnell Vall de afdeling 
Epidelrllologie en Biostatistiek. 
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De hulp van Alies van Lier bij het uitrekenen van aile voedingsdagboekjes heeft mij 
zeer veel tijd uitgespaard. 
I would like to thank professor M.J. Tisdale, Allison Whitehouse and William 
Field from the CRe NuU'itional Biochemislty Research Group, Aston University, 
Binningham, United Kingdom, for dlere willingness to cooperate in a study to detennine 
the correlation between ill vitro lipolytic activity of our plasma samples and whole-body 
lipolysis in our study. 
Dit onderzoek is financieel mogelijk gemaakt door Nmnico Research B. V. te 
Wageningen. De medewerking en het niet allatende verU"onwen van Dr. J.G. Bindels van 
Nmnico Research in een goede afronding vatl het onderzoek waren een essenti~le factor bij 
de sueeesvolle voltooiing van dit project. 
Natuurlijk bad dit onderzoek nooit uitgevoerd kunoen worden zander de 
medewerking van vele, veelal emstig zieke kankerpati~nten, hun fumilieleden en de vele 
gezonde vrijwilligers die aan dit onderzoek meegewerkt hebben. De meeste patienten 
kunnell de afronding van di( onderzoek helaas niet meer meemaken, maar ik hoop dat htll1 
grote inzet mag bijdragen aatl de ontwikkeling vatl nieuwe behandehnethoden van 
kankelpatienten in de toekomst. 
Tot slot is ook aile stem} en belangstelling voor mijn onderzoek van fdmilie en 
vrienden in de afgelopen vier jaren zeer belangrijk voor mij geweest. Maar Vatl al die 
mensen was jij, Remeo, toch echt de belangrijkste. Naar gelang de situatie bood jij mij een 
luisterend oar, een kritisch oog, een brede schouder of een helpende hand. Daamaast heb 
je lnij laten zien hoe lenk het verbouwen van eenlmis kan zijn. Ons llllis in Delft is nu af, 
dus wat daeht je van eenlllooi oud luris in de regia Wageningen? 
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